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ABSTRACT 
 
 
The importance of sphingolipids in lung pathophysiology is becoming more and 
more evident over years. Despite the findings that they have such numerous 
activities on cells, the mechanisms by which sphingolipids elicit their effects are not 
fully understood. Furthermore, the role of other recently-identified mediators such 
as gasotransmitters in pulmonary district has started to be investigated. 
My project aimed at clarifying the cellular/molecular pathways underlying the 
beneficial/detrimental effects of these mediators in lungs in animal experimental 
models by means of in vivo and in vitro approaches. 
The results obtained showed that systemic administration of S1P could induce an 
asthma-like condition in mice and such condition involved the cooperation and 
activation of different cells of the immune system, i.e. mast cells and T cells. The 
effects of S1P were counteracted by B cells. Conversely to the negative effects of 
S1P, we showed that H2S inhalation proved to be beneficial in reducing allergen-
induced airway hyperreactivity via a mast cell- and fibroblast-mediated 
mechanisms, without affecting lung inflammation. However, in an experimental 
model of pulmonary hypertension, we observed that H2S acted as an 
antiinflammatory agent. 
In conclusion, a new experimental asthma-like model useful for defining the role of 
S1P in the mechanism of action of currently-used drugs as well as in the 
development of new therapeutic approaches has been characterised. In addition, 
the protective properties of H2S have been further clarified, evidencing its 
involvement in modulating remodeling processes in inflammatory lung diseases. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
1.1 INFLAMMATORY LUNG DISEASES 
 
Respiratory diseases are considered ones of the major causes of mortality and 
morbidity worldwide: it is believed that they provoke the death of 4 million people 
every year1. The dramatic incidence of the number of cases of asthma in the last 
decades is very important for the public world health: currently, the patients 
affected by asthma are approximately 300 million and those numbers are thought 
to increase further. Furthermore, chronic obstructive pulmonary disease (COPD) 
will be the fourth principal cause of death in the next years2. Asthma and COPD 
are chronic inflammatory conditions but their aetiology and pathogenenesis 
sensibly differ. It is considered that asthma and COPD are caused by the exposition 
to environmental agents (particularly aeroallergens and cigarette smoke, 
respectively) in patients with a sensible background. The typical clinical evolution 
of these conditions is marked by times of acute exacerbations of their symptoms. 
Exacerbations are believed to be significant events of the progression of the 
disease and have huge implications for patients and physicians: exacerbations 
accelerate the progression of the disease, worsen the quality of life, and represent 
the principal cause of mortality. 
Pulmonary hypertension was first identified by Ernst von Romberg in 1891 and is a 
haemodynamic and pathological state that can be found in multiple clinical 
conditions. It is defined as an increase of blood pressure in lung vasculature, 
leading to shortness of breath, dizziness, fainting, leg swelling and other 
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symptoms. Pulmonary hypertension can be a severe disease with a markedly 
decreased exercise tolerance and heart failure. 
 
 
1.1.1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
 
The chronic obstructive pulmonary disease (COPD) is the most common chronic 
respiratory condition among adult populations. The GOLD (Global Initiative for 
Obstructive Lung disease), a collaboration between the World Health Organization 
and the National Heart Lung and Blood Institute, defines the COPD as “a common 
preventable and treatable disease, characterised by persistent airflow limitation 
that is usually progressive, not completely reversible, and associated with an 
enhanced chronic inflammatory response in the airways and the lung to noxious 
particles or gases. Exacerbations and co-morbidities contribute to the overall 
severity in individual patients”. The main etiological agent linked with BPCO is 
cigarette smoke. The inflammatory response consists in an activation of 
neutrophils, mast cells, and T lymphocytes CD8+ and differs significantly from the 
response observed in asthma. The lung inflammation is even more amplified by 
oxidative stress and an excess of proteases released by inflammatory cells 
recruited in lungs. Similarly in asthma, in COPD as well episodes of acute 
exacerbations are more and more frequent as the pathology evolves3. 
Exacerbations are the main cause of morbidity and mortality and accelerate the 
decline of pulmonary functionality4 and quality of life5. 
 
 
1.1.2 ASTHMA 
 
Asthma is the most common chronic respiratory disease and affects up to 10% of 
the adult population and the 30% of infants in the developed countries2. The GINA 
(Global Initiative for Asthma) states that asthma is defined as “a chronic 
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inflammatory disease of airways in which many cell types and cellular elements 
play a role. The chronic inflammation is associated with airway hyperresponsitivity 
that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and 
coughing, in particular during night-time and the early hours of the day. These 
episodes are often associated to a diffuse but variable obstruction of airflow, which 
is reversible spontaneously or after pharmacological treatment”. This definition 
responds to the key physiopathological hallmarks of the pathology: reversible 
obstruction of airflow and airway inflammation. The characteristic profile of the 
inflammation involves eosinophils, mast cells, and Th2 lymphocytes and a wide 
range of mediators. The exacerbations are episodes characterised by coughing, 
wheezing, shortness of breath, and airflow obstruction, which appears with 
reduction of lung functional parameters such as the peak expiratory flow. Acute 
exacerbations are very common and their social and economic burden is 
considerable, due to both direct costs for the use of the national health system 
and indirect costs associated with the lack of productivity. Current 
pharmacological therapies for asthma consist in bronchodilators and 
antiflammatory drugs such as β2-agonists and corticosteroids. These are very 
efficient in alleviating the symptoms and reducing exacerbations down to 50%, as 
clinical trials reveal6. Even though asthma is characterised by a reversible 
obstruction of the airflow, the pharmacological treatment is often not effective in 
alleviating the airflow limitation. This lack of response is associated with 
remodelling of the bronchial wall, a term used to describe the structural 
modifications that happen through the matrix7. 
 
Pathophysiology 
The model of the allergic asthma is the most understood and studied one. The 
allergic (atopic) subject has an increased production of CD4+ T cells, also known as 
Th2 cells, compared to healthy individuals. Such lymphocytes, morphologically 
identical to Th1, mostly produce IL-4, IL-5, and IL-138. These cytokines help the 
allergic inflammation to set up. IL-4 is partly responsible of the isotypic switch of B 
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cells towards the production of IgE9. When an inhaled allergen comes in contact to 
IgE-bearing cells, which selectively recognise the allergen, airway resident mast 
cells10,11 and macrophages12,13 rapidly activate through the FCεRI, the “high-
affinity” receptor for IgE. The activated cells rapidly release proinflammatory 
mediators such as histamine14, eicosanoids15 (in particular leukotrienes), and ROS 
that induce contraction of smooth muscle, mucus production, and vasodilation. 
Bronchial microcirculation plays an important role in this process16: indeed, 
released mediators induce capillary leakage with subsequent formation of 
exudate17,18. Plasma proteins leakage induces a thickening of bronchial walls with 
airways obstruction. Exudate can compromise epithelial integrity and its presence 
in the bronchial lumen can reduce the clearance of mucus19. All these effects 
contribute to airflow obstruction. The early inflammatory phase follows a late 
inflammatory phase that involves the recruitment and activation of eosinophils20, 
CD4+ T cells21, basophils22, neutrophils23,24, and macrophages25. There is a 
selective retention of T cells26, expression of adhesion molecules27,28,29, and the 
release of proinflammatory mediators and Th2-type cytokines involved in the 
recruitment and activation of inflammatory cells30,31,32 that will be important in 
the chronic phase of inflammation. 
The recruitment of peripheral blood cells including eosinophils, lymphocytes, and 
monocytes into inflamed airways is the result of adhesive interactions between 
circulating inflammatory and microvascular endothelial cells via the production of 
proinflammatory mediators, cytokines and chemokines, and the expression of cell 
surface adhesion molecules. Up-regulation of distinct adhesion molecules such as 
CD11a, CD11b, CD18, or VLA-4 on blood cells and ICAM-1 or VCAM-1 on 
endothelial cells is a critical step for the induction of the inflammatory 
response28,33,34. The ligand VLA-4 is not present on neutrophils35, which in part 
may explain the selective recruitment of eosinophils in asthma36. An increase of 
such airway vascular adhesion molecules has been observed in asthma37. 
Recruitment of cells into the airways wall is associated with their priming and 
activation38 and is also dependent on cytokines such as IL-539 and GM-CSF acting 
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to enhance eosinophil recruitment, terminal maturation40, and expression of their 
adhesion molecules35,41. Chemokines such as RANTES42,43 and eotaxin44,45 also act 
on eosinophils and T cells46 to markedly enhance their recruitment and possibly 
their activation. RANTES47, IL-16 (a lymphocyte chemoattractant factor), and MIP-
1α are found in BAL fluid of antigen-challenged asthmatics48 and may participate 
in the process. 
The survival of inflammatory cells in airway tissues depends on survival factors. 
Apoptosis, a dynamic process involved in the control of the “tissue load” of cells at 
inflamed sites, tends to limit inflammatory tissue injury and promote resolution 
rather than progression of inflammation49. Because apoptosis attempts to 
terminate the inflammatory process by reducing the number of viable 
inflammatory cells within the bronchial mucosa, the persistence of inflammation 
may be due to alterations in the regulation of cell apoptosis leading to a chronic 
and self-perpetuating inflammatory cell survival and accumulation. Once at the 
site of airway inflammation, their survival as activated cells is increased50 as a 
consequence of reduced apoptosis51,52 and possibly by increased expression of 
adhesion molecules on epithelial cells53,54. Increased eosinophil survival in asthma 
is associated with reduced apoptosis51,55. Several cytokines and chemokines may 
also promote cell survival, among them GM-CSF, IL-3, IL-5, and RANTES, which are 
overexpressed in asthmatic airways56,57,58,59,60,61. 
Inflammation in chronic asthma appears to be far more complex than a simple 
eosinophilic inflammation alone62. All cells of the airways, including T cells, 
eosinophils, mast cells, macrophages, epithelial cells, fibroblasts, and even 
bronchial smooth muscle cells, are involved in asthma and become activated. 
Nonetheless, eosinophils play an effector role by release of proinflammatory 
mediators63,64,65,66, cytotoxic mediators67, and cytokines68,69,70,71,72,73, resulting in 
vascular leakage, hypersecretion of mucus, smooth muscle contraction, epithelial 
shedding, and bronchial hyperresponsiveness. These cells are also involved in the 
regulation of the airway inflammation and initiate the process of remodelling by 
the release of cytokines68,69,70,71,72 and growth factors. For many years, bronchial 
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epithelial cells were considered to act mainly as a mere barrier participating in 
mucociliary clearance and removal of noxious agents. More recently, epithelial 
cells have been found to participate in inflammatory reactions by the release of 
eicosanoids, peptidases, matrix proteins, cytokines, and NO, as well as performing 
an immune function by their capacity to express HLA-DR and present antigen. 
In asthma, epithelium is partly shed, ciliated cells appear swollen and vacuolised, 
and there is often loss of cilia74,75. When epithelium is reconstituted, there are 
greater numbers of goblet cells than normal. In fatal asthma, extensive epithelial 
shedding is commonly observed. Epithelial cells of asthmatics are also significantly 
less viable than those of normal subjects76. The mechanisms underlying epithelial 
shedding in asthma are still a matter of debate77. Epithelial shedding can be 
caused by plasma exudation78, toxic inflammatory mediators such as eosinophil 
granule proteins79,80, oxygen free radicals, TNF-α81, mast cell proteolytic enzymes82 
or metalloproteases from epithelial cells83, or macrophages84. Furthermore, the 
increased epithelial fragility and shedding may also be caused by a weakened 
attachment of superficial epithelial cells to basal cells or to their basement 
membrane; this probably reflecting a disturbance in cell-cell adhesion85. 
The functional consequences of epithelial shedding are still unclear. Epithelial 
damage may lead to heightened airway responsiveness86,87, a failure to metabolise 
agonists88, the destruction of a diffusion barrier altering permeability of the airway 
mucosa89, the depletion of epithelial-derived relaxant factors90, and loss of 
enzymes (neutral endoproteases) responsible for degrading proinflammatory 
neuropeptides including substance P91. The integrity of airway epithelium may 
influence the sensitivity of the airways to provocative stimuli by liberating a 
variety of bronchoactive mediators, e.g. lipoxygenase and cyclooxygenase 
products76,92 and NO93. Activated epithelial cells release a wide array of mediators 
including 15-HETE76, cytokines94, eotaxin95, growth factors96,97, ECM proteins76,98, 
and metalloproteases99, which may induce bronchial obstruction, inflammation, 
and airway remodelling100. In asthma, epithelial cells are activated and release 
great amounts of 15-HETE, PGE2, fibronectin, cytokines, growth factors, and 
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endothelin spontaneously or after stimulation76,101. There is an increased 
expression of membrane markers such as adhesion molecules102,103, endothelin104, 
NO synthase93, cytokines105,106, or chemokines107. Epithelial cells can be activated 
by IgE-dependent mechanisms108, viruses, pollutants109, or proinflammatory 
mediators such as histamine110. In asthma, epithelial cells are likely to be 
important in repair processes. They release ECM proteins76 including 
fibronectin98,111, which appears to be of importance in cell regeneration. Bronchial 
epithelial cell-derived cytokines may amplify ongoing inflammatory processes via 
the recruitment and activation of specific subsets of inflammatory cells, as well as 
by prolonging their survival in the airway microenvironment112. Bronchial 
epithelial cells represent targets for paracrine acting cytokines and growth factors, 
which may then modulate bronchial epithelial cell functions. They may be 
important in the regulation of airway remodelling and fibrosis as they release 
fibrogenic growth factors such as IGF96,113 and TGF-β114, regulate fibroblast 
proliferation115, and release metalloproteases116. 
Other cells play a role in the slow and complex process of remodelling. 
Eosinophils, through the release of growth factor117,118, elastases119, and 
metalloproteases120, are involved. Alveolar macrophages as well are able to 
release cytokines and growth factor such as PDGF and bFGF or TGF-β121. They 
represent the cellular types that are mostly found in the BAL of asthmatic patients 
and several studies shows their extensive activation122,123,124,125,126. Fibroblasts 
show some characteristics of inflammatory cells after their activation by IL-4 and 
IL-13, which induce them to differentiate and proliferate127, and they can be the 
precursors of various cells, including smooth muscle cells128; furthermore, in 
asthma, myofibroblasts are numerous and are concentrated in the basal reticular 
membrane. The high number of fibroblasts well correlates with the high levels of 
TGF-β found in the BAL and a slight overexpression observed in some works129. 
Finally, airway smooth muscle cells have the capacity of contraction, proliferation, 
and production of mediators, such as chemokines and growth factors. Chemokines 
and their receptors are involved in a large number of pathological processes, 
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which contribute to bronchial hyperresponsiveness, including recruitment of 
inflammatory cells and collagen deposition130. For example, RANTES is a potent 
chemiotactic substance for eosinophils, T cells, and monocytes and seems to 
worsen asthma131. One of the characteristics of these cells is their capacity to 
migrate, which could likely link to remodelling132 and hyperplasia of smooth 
muscle, feature observed only in asthma and not in COPD. 
 
 
1.1.3 PULMONARY ARTERIAL HYPERTENSION 
 
Pulmonary hypertension (PH) is a rare but devastating disease with very low 
therapeutic options. It is a progressive and fatal disease if untreated. 
The World Health Organization (WHO) formulated a clinical classification of the 
various manifestations of PH, according to similarities in pathophysiologic 
mechanisms, clinical presentation, and therapeutic approaches. This classification 
system was initially adopted in 1998 and was re-examined in 2003 and 2008. The 
WHO pulmonary hypertension groups consist in the following133: 
 
Group 1: pulmonary arterial hypertension 
Group 2: pulmonary hypertension with left heart disease 
Group 3: pulmonary hypertension associated with lung disease and/or hypoxemia 
Group 4: pulmonary hypertension due to chronic thrombotic and/or embolic 
disease 
Group 5: miscellaneous (sarcoidosis, histiocytosis X, lymphangiomatosis, 
compression of pulmonary vessels [adenopathy, tumor, fibrosing mediastinitis]) 
 
Patients can also be classified according to the severity of their symptoms and 
functional abilities. The WHO functional class is determined from patient’s own 
subjective impression of ability and symptom severity134: 
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Table 1. WHO functional classification for patients with PAH. 
Class  Description 
I Patients with pulmonary hypertension but without resulting limitation of 
physical activity; ordinary physical activity does not cause undue dyspnea 
or fatigue, chest pain, or near syncope 
II Patients with pulmonary hypertension resulting in slight limitation of 
physical activity; they are comfortable at rest; ordinary physical activity 
causes undue dyspnea or fatigue, chest pain, or near syncope 
III Patients with pulmonary hypertension resulting in marked limitation of 
physical activity; they are comfortable at rest; less-thanordinary physical 
activity causes undue dyspnea or fatigue, chest pain, or near syncope 
IV Patients with pulmonary hypertension with an inability to carry out any 
physical activity without symptoms; these patients manifest signs of right 
heart failure; dyspnea and/or fatigue can even be present at rest; 
discomfort is increased by any physical activity 
 
Pulmonary arterial hypertension (PAH), which is a subgroup of PH, is a group of 
diseases having in common vascular remodelling of the small pulmonary arteries 
with associated elevated pulmonary arterial pressure and right ventricular failure. 
Table 2 reports a classification of PAH, according to the cause. 
 
Table 2. Revised (2009) WHO classification of group 1 PAH. 
1. Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic (iPAH) 
1.2 Familial (fPAH) 
1.3 Associated with (aPAH) 
1.3.1 Connective tissue disorder 
1.3.2 Congenital systemic-to-pulmonary shunts 
1.3.3 Portal hypertension 
1.3.4 Human immunodeficiency virus infection 
1.3.5 Drugs and toxins 
1.3.6 Other (thyroid disorders, glycogen storage disease, Gaucher’s disease, 
hereditary hemorrhagic telangiectasia, hemoglobinopathies, chronic 
myeloproliferative disorders, splenectomy) 
1.4 Associated with significant venous or capillary involvement 
1.4.1 Pulmonary veno-occlusive disease (PVOD) 
1.4.2 Pulmonary capillary hemangiomatosis (PCH) 
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1.5 Persistent pulmonary hypertension of the newborn 
(Data from Simonneau G. et al., 2009) 
 
The primary pathophysiology is remodelling of the small pulmonary arteries and 
increased pulmonary vascular resistance. Symptoms begin as shortness of breath 
on exertion and progress to dyspnea with normal activities and, finally, dyspnea at 
rest. In advanced PAH, patients are unable to perform any activity without 
shortness of breath or chest pain135. 
Estimates of the incidence of PAH have varied from 5 to 52 cases/million 
population136,137. The incidence of PAH associated with scleroderma is estimated 
at 30 to 286 cases/million population138. PAH occurs in both genders and in all age 
groups, although after puberty PAH is seen approximately twice as often in 
females139. Untreated patients with PAH face an estimated mean survival of 2.8 
years, with a 1-, 3-, and 5-year survival rate of 68%, 48%, and 34% respectively140. 
Treated, the survival rates improve to 91% to 97% after 1 year and 84% to 91% 
after 2 years141. Patients with PAH associated with the scleroderma spectrum of 
diseases have a poorer prognosis142. 
The diagnosis of PAH consists of three hemodynamic assessments142: mean 
pulmonary artery pressure >25 mmHg; left atrial pressure or left ventricular end-
diastolic pressure ≤15 mmHg; pulmonary vascular resistance >3 Wood units. 
Patients suspected of PAH should undergo a thorough evaluation (history and 
physical examination), electrocardiogram, chest X-ray, and echocardiogram. The 
symptoms of PAH are non-specific and include breathlessness, fatigue, weakness, 
angina, syncope, and abdominal distension. Symptoms at rest are reported only in 
very advanced cases. The physical signs of PAH include a right parasternal lift and 
an accentuated pulmonary component of second heart sound. Rare findings 
include a pansystolic murmur of tricuspid regurgitation, a diastolic murmur of 
pulmonary insufficiency, and a right ventricular third sound. The 
electrocardiogram might suggest PAH by demonstrating a right axis deviation and 
right ventricular hypertrophy and strain and right atrial enlargement. Many 
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patients with idiopathic PAH will have abnormal chest X-ray findings with central 
pulmonary arterial dilation and right atrial and right ventricular enlargement in 
more advanced cases. Echocardiography will help to evaluate the right heart 
structure and function and estimate the hemodynamic alterations143. 
The diagnosis of PAH must be confirmed by right heart catheterization142. After 
the diagnosis, the patient response to therapy and disease progression is generally 
assessed using non-invasive tests, including transthoracic echocardiography, WHO 
functional class, and the 6-minute walk test. Two biomarkers, brain natriuretic 
peptide and N-terminal fragment of pro-brain natriuretic peptide, are used to 
assess disease severity, with the serum levels of brain natriuretic peptide 
increasing as right ventricular function fails142. Patients with a plasma brain 
natriuretic peptide <180 pg/ml, and especially patients whose brain natriuretic 
peptide levels decrease within 6 months of starting treatment, have a better 
prognosis144. 
 
Pathophysiology 
The pathophysiology of PAH is a complex interplay of vasoconstriction, vascular 
wall hypertrophy, fibrosis, and thrombosis145,146,147,148. Pathologic findings show 
intimal hyperplasia and fibrosis, medial hypertrophy, and in situ thrombi of the 
small pulmonary arteries and arterioles148. Until recently, the underlying causes of 
symptoms were thought to mainly be vasoconstriction and vasodilation pathology; 
however, it is now believed that the processes that contribute to PAH involve 
abnormal proliferation of the vascular smooth muscle and endothelial cells, 
infiltration of the inflammatory cells, and fibrosis of vascular elements (see Figure 
1.1). These changes are associated with increased ET-1 levels, decreased NO 
levels, and decreased PGI2 levels. These factors influence vasodilation, 
vasoconstriction, and cell proliferation, among other processes. 
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Figure 1.1. Cellular and molecular mechanisms of PAH induction (from Schermuly 
et al., 2011). 
 
It is well established that ET-1 is a key mediator of PAH, driving pathological 
changes in the lung that lead to pulmonary vascular remodelling149,150. The effects 
of ET-1 are mediated via two ET receptor subtypes, ETA and ETB, to which ET-1 
binds with high affinity151,152. ETA receptors are found in smooth muscle cells 
whereas ETB receptors are located in both endothelial cells and smooth muscle 
cells. Endothelial cell dysfunction results in overexpression of ET-1. Released from 
the endothelium, it acts primarily on the underlying smooth muscle cells to cause 
vasoconstriction and proliferation. In addition, ET-1 acts on fibroblasts to induce 
contraction, proliferation, and fibrosis and on the endothelium itself to cause 
proliferation, vasodilation (via NO and PGI2), and vasoconstriction (via TXA2). All 
three of these ET-driven processes play an important role in lung vascular and 
structural remodelling153. A greater understanding of the ET system has elucidated 
a role for autocrine/paracrine signalling in the ET system and PAH pathway. The 
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evidence to support this hypothesis is reinforced by a large number of 
observations. For instance, cleavage of big ET-1 to form mature ET-1 is known to 
occur in situ152,154,155 and circulating plasma levels of ET-1 are below the 
pharmacological threshold levels required to elicit vasoconstriction. This is 
suggestive of a local site of action151. Additional support for the importance of 
autocrine/paracrine signalling includes the polarised secretion of ET-1, whereby 
80% of the ET-1 produced by the endothelial cells is released basolaterally towards 
the vessel wall, and hence the tissue, while only 20% is released into the 
bloodstream156. Furthermore, Davie et al.157 reported an increased number and 
density of ET receptors in the small pulmonary arteries of patients with iPAH and 
PAH associated with congenital heart disease. Not only does there seem to be a 
high concentration of ET receptors, there also seems to be continuous occupancy 
of these receptors by their agonist158,159. 
PAH is associated with impaired production of the endothelium-derived 
vasodilator NO160. In healthy individuals, NO acts on smooth muscle cells to induce 
vasodilation and to inhibit proliferation by increasing production of the secondary 
messenger cGMP via the activation of soluble guanylyl cyclase (sGC)161,162. 
Treatment of pulmonary hypertension with NO-releasing agents such as nitrates 
has failed to produce beneficial long-term effects as, in most cases, negligible 
pulmonary vasodilation was counterbalanced by significant peripheral reduction in 
vascular resistance and reflex tachycardia163, both of which are poorly tolerated by 
patients with severe PAH. An alternative therapeutic strategy targets downstream 
components of the NO signalling pathway by inhibiting PDE-5, the enzyme that 
catalyses the conversion of cGMP to GMP164. Sildenafil and tadalafil have been the 
lead substances in this group of agents, showing both acute and long-term 
beneficial effects in patients with PAH165,166,167. However, PDE-5 inhibition is not 
effective in all patients with PAH168; therefore, the full therapeutic potential of 
inducing the NO signalling pathway remains to be exploited. 
The PGI2 pathway has an established role in the pathogenesis of PAH169. This 
pathway is activated when PGI2 stimulates the IP receptor, leading to increased 
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cyclic adenosine monophosphate and resulting in vasodilatory and 
antiproliferative effects169. PAH patients have reduced levels of endogenous PGI2 
and reduced expression of PGI2 synthase in the lung170,171. Several PAH-specific 
therapies that target the PGI2 pathway have been developed169. However, there 
are significant limitations associated with currently approved therapies, including 
inconvenient modes of administration (by continuous intravenous or 
subcutaneous injection or inhalation), short half-life and non-specific receptor 
interactions172,173. Currently, there are no licensed oral PGI2 or PGI2 analogues 
available in Europe or the USA. Parenteral prostanoids are available but their 
uptake has been poor, presumably because of difficulties with administration. 
Finally, iPAH patients exhibit elevated levels of 5-HT which persist post heart-lung 
transplantation. This finding indicates a causal role for 5-HT in the pathogenesis of 
PAH174. 5-HT, stored primarily in the platelets, is a potent vasoconstricting agent 
and mitogen, which promotes smooth muscle cell proliferation. The mitogenic 
effects of 5-HT are mediated by the serotonin transporter, 5-HTT175. Indeed, 
chemical inhibition of 5-HTT results in a loss of 5-HT induced cell proliferation. 5-
HTT is expressed at high levels on pulmonary artery smooth muscle cells (PASMCs) 
and increased production of 5-HTT in PASMCs is capable of triggering spontaneous 
PAH176. 
An interesting observation is that calcium levels in PAH smooth muscle cells have 
been shown to be elevated likely as a direct consequence of the observed 
reduction in transcript for potassium channels and low current in patients by 
comparison to controls. Intracellular calcium levels are regulated by voltage-gated 
potassium channels, which act by regulating membrane potential and controlling 
the release of calcium. Intracellular calcium is integral in driving contraction of 
PASMCs and promoting hypertrophy. The paucity of potassium channels has been 
posited as a potential explanation for the vasoconstriction and uncontrolled 
proliferation observed in patients177. 
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Inflammation in PH 
In recent years, great attention has been paid to PAH associated with systemic 
autoimmune diseases178,179,180,181. In these patients, important evidence of 
perivascular inflammation has been observed. Thus, there is a strong rationale to 
determine how immune-mediated vascular injury initiates and propagates 
alterations in metabolic function and in the phenotype of PAH vascular cells. 
Based on clinical and animal studies, there is now reason to suggest that advanced 
vascular remodelling may be reversed by approaches that address specific 
inflammatory and immune processes. 
Pulmonary vascular lesions occurring in patients with PAH as well as in animal 
models of PH are characterised by varying degrees of perivascular inflammatory 
infiltrates, comprising T and B lymphocytes, macrophages, dendritic cells, and 
mast cells. Recently, correlations of the average perivascular inflammation score 
with intima plus media and adventitia thickness, respectively, and with mean 
pulmonary arterial pressure have been reported; these associations support a role 
for perivascular inflammation in the processes of pulmonary vascular 
remodelling182. 
The fact that inflammation precedes vascular remodelling in experimental PH 
suggests that altered immunity is a cause rather than a consequence of vascular 
disease183. Beyond increased perivascular immune cells accumulation and 
intravascular infiltration, circulating levels of certain cytokines and chemokines are 
abnormally elevated. These include IL-1β, IL-6, IL-8, MCP-1, CCL5/RANTES, and 
TNF-α. Some of these cytokines and chemokines correlate with a worse clinical 
outcome in PAH patients and may serve as biomarkers of disease progression. 
Some, such as IL-1β and TNF-α, have been related to an accumulation of 
extracellular matrix proteins such as fibronectin184, observed in PAH lesions185, and 
others, such as IL-6, have been related to the proliferation of smooth muscle 
cells186. Of particular relevance to my work and to autoimmune types of PAH is the 
finding that IFN is associated with the disease187. There are three types of IFNs, 
type I, type II, and type III, which operate via discreet signalling pathways and 
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specific receptors, all linked to STAT networks188. IFNs activate pulmonary vascular 
cells to release ET-1 and elevated levels of IFN correlated with other biomarkers 
and indicators of the disease, as does the ubiquitous surrogate of IFN signalling, 
IP10187. IP10 is released by all IFNs and has recently been implicated as a potential 
marker or mediator of PAH in its own right187. 
Recent investigations provide evidence that both pulmonary vascular cells and 
inflammatory cells are important local sources of chemokines and cytokines that 
can lead to pulmonary vascular remodelling in PAH. Indeed, the increased 
expression of cytokines and chemokines contribute to exaggerated contractility 
and proliferation of vascular cells. IL-1 can induce FGF2189 and both FGF2 and IL-6 
play an integral role in mediating the proliferative response in the smooth muscle-
like cells and fibroblasts of the pulmonary vasculature190,191,192,193,194,195 and 
contribute to the increased pericyte coverage in PAH. Several cytokines can 
directly control cell proliferation, migration, and differentiation of pulmonary 
vascular cells. IL-6 is prominent among these multifunctional proinflammatory 
cytokines and has been linked to the pathogenesis of PAH. Delivery of 
recombinant IL-6 protein in rodents is sufficient to cause pulmonary vascular 
remodelling and to exaggerate the pulmonary hypertensive response to chronic 
hypoxia196,197. Furthermore, IL-6-overexpressing mice spontaneously develop PH 
and pulmonary vascular remodelling and an obliterative form of remodelling in 
hypoxia resembling human disease, whereas IL-6-knockout mice are more 
resistant to the development of PH induced by chronic hypoxia192,193. IL-6 also 
induces pulmonary artery smooth muscle cell proliferation via induction of FGF2 
by the transcription factor KLF-5186. TNF-related apoptosis-inducing ligand has 
recently been identified as playing a key role in apoptosis of endothelial cells and 
proliferation of smooth muscle cells in many PH experimental models and its 
inhibition is related to prevention of disease pathology198. In addition, 
osteoprotegerin, a protein regulated by serotonin and IL-1 signalling, is highly 
expressed in smooth muscle cells and serum of patients with PH199 and can 
stimulate their migration and proliferation200. Recent data have demonstrated 
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that increased production of macrophage migration inhibitory factor plays a 
pivotal role in the pathogenesis of PAH201. Migration inhibitory factor is a critical 
upstream inflammatory mediator with pleiotropic actions partly explained by its 
binding to the extracellular domain of CD74. In endothelial cells, a migration 
inhibitory factor-CD74 interaction can lead to the activation of Src-family kinase, 
MAPK/ERK, PI3K/Akt, and NF-κB pathways, and to apoptotic resistance via 
repressed p53202,203,204,205,206,207. In addition, migration inhibitory factor can bind to 
CXCR2 and CXCR4 and lead to the proliferation of pulmonary artery smooth 
muscle cells and contribute to hypoxic PH208,209,210,211. In addition to elevated 
production of cytokines and chemokines, phenotypic alterations and functional 
defects in cytotoxic T and natural killer cells are linked to human PAH and 
experimental PH, as well as pulmonary veno-occlusive disease212,213. Recent data 
show deposition of complement C3 in idiopathic PAH patients and the protective 
effect of complement depletion in experimental models of PH214, emphasizing the 
relevance of exploring complement-mediated vascular injury in the pathobiology 
of PAH. 
Additional analyses of immunity in PAH support the notion that maladaptation of 
the immune response exists and may explain both the accumulation of 
perivascular inflammatory cells and the overabundance of cytokines and 
chemokines. Indeed, a delicate balance between immunity and tolerance exists 
and any disturbance may result in chronic inflammation or autoimmunity. Several 
types of autoantibodies directed against antinuclear antigens, endothelial cells, 
and fibroblasts have been found in idiopathic and systemic sclerosis-associated 
PAH215,216,217,218. These autoantibodies may play an important role in endothelial 
cell apoptosis and in the expression of cell adhesion molecules219,220,221. The role 
of T cells and more specifically of Treg cells in the control of self-tolerance is well-
established222,223,224 and altered Treg function has been demonstrated in patients 
with PAH225. Tregs not only control other T cells but also regulate 
monocytes,macrophages, dendritic cells, natural killer cells, and B cells; decreased 
Treg function may predispose individuals to PAH, as it does in animals. For 
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example, conditions associated with PAH, such as HIV, systemic sclerosis, systemic 
lupus erythematosus, Hashimoto thyroiditis, Sjögren syndrome, and the 
antiphospholipid syndrome, are characterised by abnormal CD4+ T cell number 
and function226,227,228,229,230. In animals with a congenital absence of T cells 
(athymic nude rats), vascular injury causes the lungs to become infiltrated with 
macrophages, mast cells, and B cells, similar to human PAH lesions, and disease is 
prevented with Treg reconstitution183,196. In experimental PH and clinical PAH, 
accumulation of immature dendritic cells in remodelled pulmonary arteries has 
been demonstrated, suggesting that they may contribute to PAH 
immunopathology231. Moreover, several autoimmune and infectious diseases such 
as systemic sclerosis, systemic lupus erythematous, HIV, herpes, and 
schistosomiasis infection are recognised causes of PAH. In many of these 
conditions, PAH is not reversible with the treatment of the causal disease232,233,234. 
The sequence of events from initiation or recurrence of inflammation to 
pulmonary vascular disease development remains unknown in idiopathic and even 
in autoimmune and infectious forms of PAH. 
Recent attention has focused on the role of perivascular macrophages infiltrating 
pulmonary arterioles. The role of the macrophages in processes as diverse as limb 
or cardiac regeneration and pathogen defense indicates that it is important to 
comprehend the behavior of this cell in the context of the vascular milieu. CD68+ 
macrophages are prominent in advanced obliterative plexiform lesions observed 
in experimental and clinical PAH235,236,237,238,239,240 and macrophage depletion or 
inactivation prevents PAH in several model systems, including experimentally 
induced hypoxic PH and portopulmonary hypertension237,241. Activation of 
macrophages is also closely linked to epigenetic changes that stimulate and induce 
proliferation of vascular fibroblasts in patients and in experimental models of 
PH242. These features involve HDAC1-mediated activation of a host of 
proinflammatory cytokines. 
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1.2 RELEVANCE OF SPHINGOLIPIDS TO RESPIRATORY 
DISEASES 
 
1.2.1. METABOLIC AND CATABOLIC PATHWAYS 
 
In origin, sphingolipids have been considered simple structural elements of the 
plasmatic membranes, but now it is clear that they participate in the regulation of 
various cellular functions243. Like glicerofosfolipids, sphingolipids are ubiquitous 
components of the mammalian cellular membranes and they can be metabolised 
to active molecules. One of the most important metabolites is represented by 
sfingosine 1-phosphate (S1P). 
 
Ceramide, considered the scaffold of all the more complex sphyngolipids, can be 
either generated de novo at the cytosolic face of the ER or released from 
sphingomyelin by sphingomyelinases. Ceramide is further deacylated by 
ceramidase to sphingosine244. S1P is then generated from the phosphorilation of 
the sphingosine by two isoforms of the same kinase, the sphingosine kinase 1 and 
2 (SphK1 and SphK2)245 (see Figure 1.2). SphK1 is found in the cytosol of eukaryotic 
cells, while the SphK2 is mainly localised to the nucleus. SphK1 can be stimulated 
by a wide variety of growth factors, including EGF246, VEGF247, and other factors, 
such as TNF-α248, estradiol249, lysophosphatidic acid250, and S1P itself251. These 
stimuli induce an activation ERK-dependent on the residues Ser225, Thr54, and 
Asn89 of SphK1 that leads to enhance the membrane affinity, selectively bind 
phosphatidylserine, and target the membrane, where its substrate is252. The 
regulation of SphK2 results in enzymatic activity and nuclear export. Recent 
reported evidence that EGF, the PKC activator, and phorbol ester253 can 
phosphorylate SphK2 on Ser351 and Thr578254. PKD activates SphK2 leading to its 
nuclear export subsequent cellular signal255. SphK2 is thought to be involved in 
epigenetic regulation: indeed, in nucleus, SphK2 interacts with histone H3256. S1P 
regulates activity of HDAC1 and HDAC2; therefore, HDACs are direct intracellular 
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targets of S1P and the activity of SphK can regulate gene expression by S1P, such 
as cyclin-dependent kinase inhibitor p21 or the transcriptional regulator c-Fos. 
The mechanisms for termination of S1P signalling are various: it can be either 
irreversibile metabolised by S1P lyase, leading to the formation of hexadecenal 
and phosphatidylethanolamine (see Figure 1.2), or dephosphorilated by one or 
more integral membrane lipid phosphohydrolases, including two specific S1P 
phosphatates (SPP1 and SPP2) and/or members of the LPP (lipid phosphate 
phosphohydrolases) family, back to sphingosine and recycled. 
 
Figure 1.2. Catabolic and methabolic pathway of sphigolipids. 
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Because of the interconvertibility of ceramide, sphingosine, and S1P and the 
opposing effects on cell fate of ceramide and sphingosine (anti-growth, pro-
apoptotic) compared to S1P (pro-growth, anti-apoptotic), the dynamic balance 
between S1P and ceramide/sphingosine has been proposed to form a ‘‘cellular 
rheostat’’ that determines cell survival or death257. 
 
S1P levels are finely regulated by the two specific kinases, by the enzymes that 
generate its substrate, the sphingosin, and by other enzymes, which have the role 
to degrade the phospholipid: thus, the levels of S1P in plasma are showed to be 
between 0.1 and 0.6 mM. Conversely, the amounts of S1P in tissues are very low. 
This concentration gradient plays an important role in driving S1P function: the 
S1P gradient at the tissue-vascular interface regulates the trafficking of immune 
cells from lymphoid organs into the circulation258. Since S1P is produced 
intracellularly, it is noting that it needs a transporter system to realise this 
concentration gradient. Several transporters have now been identified: these 
include the ABC transporters ABCA1259, ABCC1260, and ACG2261, as well as the 
Spinster2262. This process is called “inside-out signalling” of S1P. 
Once outside of the cell, S1P can bind to two known carriers, albumin or 
ApoM263,264. Approximately 35% of plasmatic S1P is bound to albumin and 65% to 
lipoproteins LDL, VLDL, and HDL. The bulk of lipoprotein-associated S1P is bound 
to HDL. This ApoM+HDL-bound S1P has been proposed as a primary contributor to 
the vasoprotective properties of HDLs265. How albumin or ApoM deliver S1P to 
specific S1PRs has yet to be characterised. 
 
S1P acts through five different membrane receptors, belonging to the GCPRs, 
named S1P1-5 (formerly known as EDG receptors), all with low nM Kd values, widely 
expressed in the whole organism. These receptors are associated to various 
subunits of heterotrimeric G proteins: Gi, Gq, G12/13. This coupling results in the 
activation of small GTPases such as Rho, Rac, and Ras266,267. Further downstream 
effectors of S1P receptors include adenylate cylase, PI3K, PLC, PKC, and 
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intracellular calcium. By binding to its receptors, S1P triggers different actions, 
such as regulation of cellular growth268 and suppression of apoptosis269, suggesting 
a potential role in cancer. Through the activation of S1P1, it can also regulate the 
trafficking of immune cells270 and the development of blood vessels271; 
furthermore, S1P/S1P1 axis is important in controlling the vascular tone and 
permeability, by regulating basal and inflammation-induced vascular leak272. S1P2 
and S1P3 activate PLC and Rho273. Finally, T-bet-dependent S1P5 expression is 
required for natural killer T cell egress from lymph organs274, whereas S1P4 plays a 
role in neutrophil trafficking275. 
Early studies demonstrated that S1P could induce calcium release from the ER, 
although no target has been conclusively identified276. Recently, this changed with 
the demonstration that S1P binds and alters the function of disparate intracellular 
proteins. Besides the effects of S1P on HDAC, which I have already introduced to 
you (see above), S1P binds the PHB2277, modulates the activity of BACE1 in 
neurons278, and is considered to be a cofactor of TRAF2279. 
 
 
1.2.2 S1P AND ASTHMA 
 
Airway smooth muscle (ASM) cells function as the primary effector cells that 
modulate bronchomotor tone. However, beyond their contractile functions, ASM 
cells also contribute to the pathogenesis of asthma in various ways. Airway 
instillation of bacterial LPS into rat lungs enhances ICAM-1 expression in ASM 
cells280. Also, TNF-α induces ICAM-1 and VCAM-1 expression and may play a role in 
cell-cell interactions with other inflammatory cells, such as T cells281, 
eosinophils282, and mast cells283. Under the influence of inflammatory cytokines 
such as IL-6, ASM cells may be induced to undergo hyperplasia and hypertrophy 
and contribute ultimately to airway obstruction284. ASM cells can also secrete 
various inflammatory mediators such as GM-CSF and IL-5, which contribute to the 
proliferation and survival of eosinophils285,286. ASM cells play a prominent role in 
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the recruitment of inflammatory cells, as they have also been demonstrated to be 
a source of various chemokines such as eotaxin287, MCP-1288, and RANTES289. The 
initial clue that S1P plays a role in asthma came from the finding that S1P levels 
were elevated in the BAL fluid of asthmatics, but not healthy controls, after 
antigen challenge290. Indeed, the levels of S1P in the lavage fluid directly 
correlated with eosinophil numbers, another hallmark of asthma. This initial 
finding suggested that S1P might play a role in both acute bronchoconstriction and 
airway remodelling through its direct action on ASM cells290. Indeed muscarine-
induced peripheral airway constriction was reduced by inhibition of SphK using 
DHS (ᴅ,ʟ-threo-dihydrosphingosine) and DMS (N,N-dimethylsphingosine), 
suggesting that the SphK/S1P signalling pathway contributes to cholinergic 
constriction of murine peripheral airways291. Based on a model of human ASM 
cells embedded in collagen matrices, Rosenfeldt et al.292 demonstrated that S1P 
induced the formation of stress fibers and the contraction of individual ASM cells 
and stimulated myosin light chain phosphorylation in a Rho-kinase-dependent 
manner. In another study using guinea pig tracheal smooth muscle strips, 
pretreatment with S1P markedly enhanced methacholine-induced contraction293. 
This effect was inhibited in the presence of a Rho-kinase inhibitor. Exogenous 
addition of S1P to human bronchial smooth muscle cells increased the level of 
active RhoA (GTP-RhoA) and phosphorylation of MYPT1. These findings 
demonstrate that exposure of ASM cells to S1P results in airway hyperreactivity 
mediated via RhoA and inactivation of myosin phosphatase293. In addition, 
Roviezzo et al.294 evaluated the effects of exogenous S1P administration on 
isolated bronchi and whole lungs harvested from BALBC/c mice sensitised to 
ovalbumin (OVA) by measuring bronchial reactivity and lung resistance. They 
found that, in OVA-sensitised mice, S1P caused a dose-dependent contraction of 
isolated bronchi and increased airway resistance in the whole lung system. This 
was accompanied with an enhanced expression of SphK1, SphK2, S1P2, and 
S1P3294. 
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Another important hallmark of chronic asthma is airway remodelling, 
characterised in part by increased smooth muscle mass, extracellular matrix 
deposition, and vasculogenesis. S1P is likely involved in all these processes. First, 
S1P promotes the growth of both human ASM cells and fibroblasts295,296. 
Moreover, S1P produced by SphK1 has recently been shown to be involved in 
fibroblast differentiation into myofibroblasts297, cells thought to be responsible for 
thickening of the lamina reticularis. TGF-β and S1P, which are both increased in 
asthmatic lung, can induce α-SMA expression in lung fibroblasts, a hallmark of 
their differentiation into myofibroblasts297. Subsequently, it was shown that TGF-β 
stimulates SphK1, which in turn releases S1P that activates S1P2 and S1P3 in an 
autocrine manner, leading to α-SMA expression298. 
Mast cells (MCs) are tissue resident effector cells best known for their role in 
atopic diseases. However, these cells can alter both innate and acquired immune 
responses to various stimuli, by releasing a plethora of vasoactive mediators, 
proteases, chemokines, and cytokines that collectively enhance vascular 
permeability, elicit bronchoconstriction, and incite recruitment and function of 
leukocytes. The end effects range from local to systemic inflammation299. MCs 
develop in peripheral tissues from bone marrow-derived circulating committed 
progenitors, with two subpopulations that vary in the composition of their 
intragranular proteases: those expressing tryptase only are designated MCT and 
predominate in lung, while those that also contain chymase, carboxypeptidase, 
and cathepsin G are termed MCTC and predominate in skin. The concentration of 
MCTC cells in ASM in asthmatics increases dramatically and correlates with 
bronchial hyperreactivity283. The presence of IgE antibodies to innocuous antigens 
causes dysregulation of this normally protective response, resulting in allergic 
inflammatory disease. Crosslinking of FcεRI on MC activates many downstream 
signalling molecules, including Src family tyrosine kinases, the Syk tyrosine kinase, 
calcium flux, PKC, and the Ras-MAPK pathway. The result is a biphasic response 
characterised by degranulation with release of histamine and other preformed 
mediators and the subsequent de novo synthesis and secretion of cytokines and 
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chemokines as well as the arachidonic acid metabolites, leukotrienes and 
prostaglandins. Crosslinking of the FcεRI also induces activation of SphK1, 
production of S1P, and subsequent activation of the S1P1 and S1P2 receptors300. 
Activation of S1P2 is required for mast cell degranulation, while S1P1 activation is 
important for their migration to the sites of inflammation. At least in mast cells, 
S1P does not appear to be released by degranulation of stored mediators, rather 
de novo formed S1P is secreted, at least in part, through ABCC1, a member of the 
ATP-binding cassette transporter family260. 
It has been suggested that the decisive balance between sphingosine and S1P is a 
determinant of the allergic responsiveness of MCs301. Whereas sphingosine 
inhibits antigen-mediated leukotriene synthesis and cytokine production by 
preventing activation of ERK1/2, S1P activates ERK1/2, stimulating degranulation 
and cytokine production301. Thus, SphK plays a pivotal role in MC activation by 
modulating the balance of these counterregulatory sphingolipid signalling 
molecules. Moreover, expression of MCP-1, MIP1-α, MIP1-β, MIP2 (belonging to 
the CC-chemokine family), and MIF, all important modulators of monocyte and 
eosinophil recruitment and inflammation, was significantly increased by S1P in 
MCs300. Thus, secretion of S1P by MCs can also promote inflammation by 
activating and recruiting other immune cells involved in allergic and inflammatory 
responses, including eosinophils302 and Th2 lymphocytes303. Controversy 
surrounding the role of SphK1 and SphK2 in MCs has also been documented. 
Olivera et al. reported that SphK2 regulated mast cell activation, whereas SphK1 
enhanced susceptibility to antigen challenge in vivo in knockout mouse models304. 
Taken together, these data suggest a key role for SphK and/or its product S1P in 
the responses triggered by activated mast cells. 
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1.2.3 PEPDUCINS 
 
GPCRs are ones of the most important targets on which the basic pharmacological 
research is based: GPCRs are membrane receptors that are central in almost every 
signalling pathway in the human body, such as inflammation, neurotransmission, 
and hormone signalling. Nearly one in three commercialised compounds are 
designed to modulate GPCR functions. However, as researchers become more and 
more aware of the additional properties of this receptor superfamily, they also 
realise how much is not yet understood about receptor function and potential 
unexploited properties that could reveal new pharmacological approaches to the 
design of the drugs of the future. 
Pepducins were developed in the late 1990s by scientists at the Tufts Medical 
Center: at that time, they started to look at ways to target the receptors from the 
inside and not from the outside surface of the cells. As pepducins can theoretically 
act as either agonists or antagonists, they considered interesting tools for studying 
receptor signalling and mechanisms in cell-based systems, as well as basis for 
developing new attractive drugs supporting a new mechanism of action. 
Pepducins are molecules characterised by a lipid tag attached to the N-terminal of 
a sequence of peptides designed over the sequence of the third intracellular loop 
(i3) of the 7-transmembrane receptor. Although mutagenesis studies have 
demonstrated that the i3 loop of GPCRs largely mediates coupling between the 
receptor and G protein305, further studies have showed that certain pepducins 
based on the i1, i2, or i4 loops could also act as agonists or antagonists of 
receptors, suggesting that all intracellular domains may be important for 
intracellular signal transduction. The four intracellular loops of GPCRs all directly 
interact with heterotrimeric G proteins that are composed of α, β, and γ 
subunits306. 
The lipid tag is essential to the proper operation of the pepducins: the lipid, 
usually a palmitoyl or mirystoyl residue, acts as an anchor to the outer surface of 
the plasmatic membrane. Biochemical and pharmacologic studies indicate that the 
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lipid moiety of pepducins facilitates translocation across the lipid bilayer and 
serves to tether the pepducin in the cytosolic face of the plasma membrane in the 
vicinity of the target receptor, thereby increasing the effective molarity307. Once 
flipped across the membrane, the pepducin can interact with its cognate receptor 
and either block or stimulate signalling to associated G proteins308. Figure 1.3 is a 
schematic example how pepducins work. 
 
Figure 1.3. Schematic mechanism of function of a pepducin. 
 
However, it is well recognised that GPCRs assume heterogeneous conformations 
from resting state to full activation and that the ionic lock between TM3 and TM6 
is destabilised to selectively activate G protein. Therefore, it is highly possible that 
pepducins may act also by stabilizing the GPCR/G protein complex in specific on- 
or off-conformation, possibly by mimicking a receptor dimer309. 
Classically, GPCRs are activated by extracellular ligands. Intracellular pepducin 
agonists have been generated against more than a dozen receptors, including 
PAR1308, PAR2308,309, MC4R308, CXCR4310, S1P3311, and FPR2312. After the initial 
development of agonist pepducins, antagonist pepducins were subsequently 
described for the thrombin receptors PAR1 and PAR4 and most recently for the 
tryptase/trypsin PAR2 receptor. 
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1.3 GASOTRANSMITTERS AND LUNG PATHOPHYSIOLOGY 
 
Nitric oxide, carbon monoxide, and hydrogen sulphide are the major and the most 
studied representatives of the class of gaseous transmitters. It is demonstrated 
that they have effects on lungs and airways, in both pathological and physiological 
conditions. A short introduction to carbon monoxide and nitric oxide follows, in 
order to clarify their characteristics and possible interactions with the hydrogen 
sulphide. 
 
Carbon monoxide 
Carbon monoxide (CO) is a colourless and odourless gas, generally produced 
during incomplete combustion of compounds containing carbon. It is a poisonous 
gas and exerts its noxious effects mostly because it can disrupt normal 
mitochondrial respiratory functions313. 
Synthesis of CO in living organisms is run by heme oxygenase (HO) and is linked to 
heme catabolism. In the initial stage, the heme is oxidised to alpha-
metahydroxyheme. In the next stage, it reacts with a molecule of oxygen leading 
to generation of verdoheme and CO. Verdoheme is finally converted to biliverdin, 
which by the action of biliverdin reductase produces bilirubin (a highly effective 
antioxidant)314. There are three isoforms of HO: HO-1 (inducible isoform, also 
known as Hsp32), HO-2 (constitutive isoform), and HO-3 (constitutive isoform). 
They are the products of the expression of three different genes. HO-1 is a 32 kDa 
protein, one of the thermal shock proteins. HO-1 is cytoprotective against 
oxidative stress. The oxidative stress and a low level of glutathione lead to 
increased expression of the HO-1 gene. In addition, the expression of HO-1 also 
may be induced by a high level of heme, hypoxia or elevated body temperature, 
heavy metals, and ultraviolet radiation314. HO-2 is a constitutive enzyme with a 
mass of 36 kDa. The highest activity of the enzyme is detected in brain. It 
catabolises hemoproteins and generates CO, which functions as a signalling 
molecule in the nervous system, as well as in the circulatory system. 
Depolarization of neurons leads to increased activity of HO-2 and synthesis of 
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CO314. HO-3 (33 kDa) has a significant homology to HO-2, but its activity is low. In 
cells, HO-3 is a heme-binding protein and regulates production of free 
radicals314,315. 
CO has the ability to bind heme groups: it has about 245 times greater affinity for 
hemoglobin and myoglobin than oxygen. However, it should be noted that CO 
interference with oxygen transport in blood due to its binding to heme iron 
centres in hemoglobin is not a major contributor to CO toxicity, but rather the 
increase in CO tissue concentration leading to disruption of mitochondrial 
function313. For this capacity, one of the targets of CO is guanylyl cyclase (GC): CO 
can activate GC and lead to production of cGMP, even though to a lesser extent 
with that observed with nitric oxide. CO may be associated with other 
hemoproteins and inhibit their activity, i.e. cytochrome P450. This inhibition 
induces reduction of the synthesis of 12-HETE, which significantly narrows the 
lumen of blood vessels. CO also activates cyclooxygenase and increases PGE2 
synthesis314. Other targets of CO include nuclear hormone receptors316. The 
activity of various ion channels, i.e. BKC, TREK-1, P2XR2, or P2XR4, may be 
modulated by CO application, but the mechanisms by which CO regulates these 
channels are still unknown. Some experiments suggest that a limited range of 
amino acid residues confers CO sensitivity, either directly or indirectly, to 
particular ion channels and that cellular redox state appears to be important to 
the final response317. 
Similarly to other gasotransmitter, CO is a regulatory molecule, which impacts on 
physiological and pathological functions. CO exerts its principal effects on 
cardiovascular system: indeed, CO induces relaxation of smooth muscle in blood 
vessels, which increase their lumen. In addition, CO regulates blood pressure318,319. 
It has a positive influence in atherosclerosis, in which CO synthesis is increased. 
This is the effect of the increase of HO-1 expression in endothelial cells and foam 
cells of atherosclerotic lesion. Furthermore, an increase in the expression of HO-1 
may be induced by oxidised LDL, peroxynitrite (ONOO-), PDGF, TGF-β, and 
angiotensin II, as well as by heme from damaged cells. CO has an antiapoptotic 
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activity via a number of cellular mechanisms and this activity results in its 
protective role in atherosclerosis. CO inhibits apoptosis of blood vessel smooth 
muscle cells by activation of the sGC. Moreover, CO inhibits the expression of p53 
that regulates transcription of many proteins, i.e. Bax. Activation of Bax by p53 
makes the mitochondrial membrane permeable for cytochrome c, which flows 
from the mitochondria to the cytoplasm and activates a signalling cascade that 
leads to cell death320. Antiapoptotic activity of CO is also associated with increased 
activity of HO-1. HO-1 reduces the bioavailability of iron ions with pro-oxidative 
action engaged in the ROS production. ROS play an important role in the signal 
cascade leading to programmed cell death321. Moreover, CO maintains high levels 
of expression of antiapoptotic proteins such as Bcl-2 or Bcl-xL322. It is known that 
CO and HO-1 inhibit cell cycle in the G0/G1 phase. This inhibition is associated with 
a decrease in the cyclin-dependent kinase 2 activity (Cdk2). Cdk2 is responsible for 
transition from G0 to G1 and G1 to S phase, because it is responsible for cyclin A 
and E phosphorylation. Ability of CO to inhibit Cdk2 activity is due to the 
expression of proteins, i.e. activators of Cdk2 and cyclin A and D1. On the other 
hand, CO increases the expression of Cdk2 inhibitor – a protein p21319. The 
antiinflammatory role of CO is based on the inhibition of the expression of LPS-
dependent proinflammatory cytokines. These cytokines include TNF-α, IL-1β, and 
MIP-1β. On the other hand, CO induces expression of the antiinflammatory 
cytokine IL-10. In addition, CO inhibits the release of nitric oxide produced by the 
inducible nitric oxide synthase. Finally, CO inhibits the release of histamine from 
mastocytes and prevents the activation of basophils323. 
 
Nitric oxide 
In 1980 Furchgott and Zawadzki demonstrated that, in response to muscarinic 
agents, the endothelium released a substance that relaxed blood vessels: the 
chemical nature of this substance was unknown and was named with the 
generically term of endothelium-derived relaxing factor (EDRF)324. It was only with 
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the independent work of Ignarro and Moncada that the EDRF could be identified 
as nitric oxide (NO), the first gasotransmitter discovered161,325. 
The NO is a free radical, but relatively stable compared to other radical species: in 
fact, it could diffuse over micron of distance before reacting with other molecules. 
As a small uncharged molecule, it is higly soluble in hydrophobic environment and 
can easily pass across biological membranes. 
The chemical formule of NO is reported: 
 
∙N=O 
 
NO is synthesised intracellularly through the action of nitric oxide synthase (NOS) 
enzymes. NOS enzymes catalyze the NADPH- and O2-dependent oxidation of ʟ-
arginine to ʟ-citrulline and NO. Enzymatic synthesis of NO is complex and depends 
on the availability of prostetic groups and cofactors such as FAD, FMN, 
tetrahydrobiopterin, and heme326. Three distinct isoforms have been identified, all 
of which have different characteristics and generate NO at different rates, but 
they are all sterospecific and active as homodimers327. Endothelial NOS (eNOS or 
NOS3) generates the lowest levels of NO and was originally discovered in the 
vascular endothelium but it is also found in neurons, epithelial cells, and cardiac 
myocites328. Its location within the cell and activity are controlled by Ca2+ ions and 
calmodulin. Regulation of eNOS is also intimately related to the physical forces 
important in vascular function such as shear stress induced by blood flow327,329. 
Neuronal NOS (nNOS or NOS1) is constitutively present in neurons, skeletal 
muscle, and epithelial cells. It is also a Ca2+/calmodulin-dependent isoform327. The 
last major NOS isoform is inducible NOS (iNOS or NOS2), which has the highest 
capacity to generate NO. This isoform is expressed in multiple cell types in 
response to inflammatory stimuli, such as those induced by endotoxin and 
cytokines, e.g. IL-1 and IL-2, TNF-α, and IFN-γ327,330. It has also been shown to be 
constitutively present in some tissues such as lung epithelium. The NOS enzymes 
are regulated by post-translational modifications, controlled localization within 
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the cell, substrate and cofactor availability, and other proteins with which they 
form stable complexes327. 
Once generated, NO has a number of potential biological fates. The intra- and 
extra-vascular half-lives of NO, which have been measured to be in the range of 2 
ms to >2 s, appear to be dependent on the availability of intracellular reactants of 
NO331. The most specific and highest affinity interactions of NO with biological 
targets are those with metalloproteins such as sGC, CcOX, and hemoglobin. 
NO reacts rapidly with other free radicals such as O2- or lipid peroxyl radicals332,333. 
The best studied of these reactions is the very rapid reaction of NO with 
superoxide to form peroxynitrite334. For example, peroxynitrite (or reactive species 
derived from it such as nitrogen dioxide and carbonate anion radical) can mediate 
the oxidation and nitration of proteins, lipids, or DNA, whereas NO cannot directly 
mediate any of these effects. Since the realization that peroxynitrites are 
produced in biological systems, they have been proposed to be the major 
mediators of the pathological effects associated with NO, particularly 
inflammation335. Peroxynitrite reacts directly with sulfur-containing amino acids 
(cysteine and methionine), as well as those with aromatic structure (e.g. 
tryptophan and tyrosine). Furthermore, secondary products of peroxynitrite 
oxidation can also modify proteins. Although the rate constant for reaction of 
peroxynitrite with free cysteine is 5.9×103 m−1·s−1, reaction with protein thiols is 
much slower. This may then contribute to the selectivity in protein targets. 
Additionally, because NO is freely diffusible and O2- is not, one of the factors 
controlling peroxynitrite reactivity may be the location of O2- production. 
Nitrites and nitrates are higher oxidation states of NO that were previously 
believed to be stable oxidation end-products of the redox sequence. However, 
Recent work suggests that these oxidised species can be recycled in vivo in a 
process that involves oral microbiota and foodstuffs. Oral bacteria can reduce 
dietary nitrate to nitrite, which, upon entering the acidic milieu of the stomach, 
undergoes non-enzymatic reductive conversion to NO. In parallel, nitrate and 
nitrite in blood that originates from the diet and from systemic production and 
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oxidation of NO can be taken up actively by the salivary glands, whereupon it 
enters the nitrate reductase-rich bacterial milieu of the oral cavity facilitating the 
cycle336. 
There are essentially two major biochemical mechanisms under current 
investigation through which NO can mediate signal transduction. The first is the 
ability of NO to bind ferrous heme. The reaction of NO with metalloproteins 
involves nitrosylation of ferrous iron (Fe2+). However, ligand discrimination 
between metalloproteins differs widely because of the effects of the protein 
structure. For instance, sGC does not bind O2 but does form 5-coordinate Fe2+·NO 
complexes, which subsequently activate the enzyme and are responsible for the 
cGMP-dependent effects of NO. In contrast, hemoglobin and CcOX have different 
affinities for NO but also bind O2337. The second is correlated to the capacity of NO 
to induce modifications on proteins. Cysteinyl thiols are targets of NO and NO 
from exogenous and endogenous sources has been shown to increase intracellular 
low molecular weight S-nitrosothiols (e.g. S-nitrosoglutathione), promote protein 
glutathiolation (protein S-glutathione), and increase thiol oxidation338. However, 
the different modifications induced by NO appear to be dependent on the RNS, 
the protein itself, and the subcellular localization of the protein. Recently, S-
nitrosothiols have attracted interest because of i) their potential roles as 
intermediates in the transport, storage, and delivery of NO; ii) as post-translational 
protein modifications in cell signalling and inflammation; and iii) as molecular 
markers of RNS. Well over 100 proteins have been shown to be S-nitrosated and, 
as the list of S-nitrosated proteins grows, the potential relevance of this 
modification and other NO-induced protein modifications in redox biology and 
signalling is of increasing interest. 
Besides the well-known activities of NO in inflammation and nervous system, 
Barnes339 first suggested that NO produced by nNOS has beneficial effects in 
asthma, causing bronchodilation by relaxing ASM. However, NO produced by 
eNOS can induce vasodilation in the arterioles, with plasma extravasation and 
edema. High quantities of NO produced by iNOS can result in vasodilation, plasma 
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extravasation, increase in mucus secretion, and indirect activation by Th2 cells 
(mainly due to eosinophilic recruitment) to contribute to asthma physiopathology. 
However, the role of NO in asthma is not as simple as it has been initially 
described because several in vitro and in vivo studies with animal experimental 
models and humans have showed different results. Some authors suggested that 
NOS activation could exert both beneficial and detrimental effects, such as altering 
relevant aspects of asthma pathology and participating in inflammatory cell 
recruitment340, airway responsiveness341, and airway remodeling342. NO was 
detected in the exhaled air in normal humans, but not in animals343. Various 
researchers demonstrated that the exhaled NO (eNO) concentrations were 
increased in asthmatic patients344,345 and in experimental models of chronic 
pulmonary inflammation346,347. Some authors suggested that the increase in eNO 
can be due to an increase in iNOS expression348. The eNO has been proposed as an 
indirect marker of inflammation to be used in clinical practice. However, the 
efficacy of these measurements is still a matter of controversy. 
 
 
1.3.1 HYDROGEN SULPHIDE 
 
Hydrogen sulphide (H2S) has been considered for a long time as a mere toxic 
compound with the characteristic smell of rotten eggs. In the last decades, the 
hypothesis that H2S could act as a transmitter within the body has risen up, 
because of the observation that it was endogenously produced in animal tissues. 
Nowaday, it is widely accepted that H2S belongs to the class of gaseous 
transmitter, along with NO and CO. 
 
Physical and chemical properties 
This inorganic sulphur compound is a colourless flammable gas that is heavier than 
air (d=1.19). H2S is the sulphur analogue of water, but the only similarity with it is 
the molecular structure. The sulphur atom is not as electronegative as oxygen so 
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that molecules of H2S cannot form hydrogen-bounds among them. Because of this, 
its melting and boiling points are much lower than those of H2O. Hydrogen 
sulphide is a very lipophylic compound that can easily pass across biological 
membranes, also due to its very small dimensions. 
H2S is a weak acid and in water and rapidly dissociates in HS- and S2-, according to 
the equilibrium: 
 
H2S <-> HS- + H+ <-> S2- + H+ 
 
The dissociation constants are respectively Ka1=1.3×10-7 M and Ka2=1×10-19 M349 
(20°C) and they are both temperature-sensitive: this can have a significant effect 
on the relative concentrations of H2S and HS- when comparing experiments 
performed at room temperature to those performed at body temperature (37°C). 
Thus, under physiological conditions (pH=7.40), only one-third of H2S is in the 
undissociated form and the amounts of the undissociated form are even lower 
(approximately one-fifth) when experiments are run at 37°C350. 
The amount of S2- is often irrelevant because it is present only at very high pH 
values. 
 
H2S is also relatively unstable in solution. H2S is spontaneously oxidised in the 
presence of oxygen and metal catalysts, such as ferric iron, and the concentration 
of H2S can be halved in as little as 3 hours. Addition of an iron chelator such as 
diethylenetriaminepentaacetic acid (DTPA) can greatly delay spontaneous 
oxidation; however, this can also remove ions that are vital in most biological 
processes. 
The obnoxious smell of H2S, which is familiar to anyone working with sulphide 
salts, hints at an even greater threat to proper experimental design and that is the 
volatility of H2S. Even in the absence of cells, half of a dose of H2S can be lost from 
open tissue culture wells in 5 minutes. This time is further reduced in bubbled 
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tissue baths to around 3 minutes and it is even less in the Langendorff heart 
apparatus that is used to study cardiac function351. 
 
H2S also has reductive properties and in redox reactions with weak oxidizing 
agents it is oxidised to elementar sulphur, as follows: 
 
H2S(g) + 2M3+ S0(s) + 2H+ + 2M2+ + 2e- 
 
Metabolic and catabolic pathways 
H2S is endogenously produced in mammalian tissues from the sulphurated amino 
acid ʟ-cysteine. The reaction is driven by two pyrydoxal 5’-phosphate-dependent 
enzymes: cystathionine γ-lyase (CSE or CTH) and cystathionine β-synthase (CBS)352. 
Recently, a new enzyme involved in H2S synthesis has been discovered, the 3-
mercaptopyruvate sulfurtransferase (3-MST) (see Figure 1.4). CBS and CSE are 
cytosolic enzymes, whereas 3-MST is predominantly localised to the mithocondrial 
matrix. CBS was originally considered to be the predominant enzyme for H2S 
production in the brain, whereas H2S synthesis in the heart and vasculature was 
attributed to CSE353. In some tissues, CSE and CBS are both required for H2S 
synthesis, whereas in others only one of these enzymes is necessary354: indeed, 
recent studies with improved markers have provided a broader picture of enzyme 
distribution. Recently, CBS and CSE were identified in human plasma, where they 
were proposed to reduce circulating H2S. 
 
Hydrogen sulphide is rapidly oxidised, mainly in mitochondria, initially to 
thiosulfate and subsequently to sulfite and sulfate. The former oxidation is not 
enzymatically driven, while thiosulfate conversion to sulfate and/or sulfite is 
catalyzed by thiosulfate cyanide sulfurtransferase (TST). In addition, sulfite 
originating through this reaction is quickly oxidised to sulfate, as sulfate is the 
major end-product of H2S metabolism under physiological conditions. Another 
catabolic pathway is represented by methylation by thiol-S-methyltransferase 
 CHAPTER 1 
 
38 
(TSMT) to methanethiol and dimethyl sulphide. This reaction occurs mainly in 
cytosol. Methemoglobin, considered a “common sink” for endogenous gases 
including CO and NO, also binds H2S as sulfhemoglobin355 (see Figure 1.4). 
 
Figure 1.4. Catabolic and metabolic pathways of H2S. 
 
Toxicity 
Like NO and CO, at higher concentrations H2S is a toxic gas, but its toxicological 
properties are of low interest because intoxication by H2S is restricted to 
infrequent cases of occupational exposure from industrial activities. It is thought 
that H2S may target lots of organs and tissues, primarily brain and respiratory 
system. Table 3 reports the effects of H2S on humans. 
 
Table 3. Toxicity of H2S. 
Concentration of H2S Physiological responses 
ppm mg/m3  
0.003-0.02 0.042-0.028 Odour threshold 
3-10 4-14 Obviously unpleasant odour 
20-30 28-42 Strong offensive odour 
30 42 Sickening sweet odour 
50 70 Conjunctival irritation 
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50-100 70-140 Irritation of respiratory tract 
100-200 140-280 Loss of smell 
150-200 210-280 Olfactory paralysis 
250-500 350-700 Pulmonary oedema 
500 700 Anxiety, headache, ataxia, dizziness, 
stimulation of respiration, amnesia, 
unconsciousness 
500-1000 700-1400 Respiratory paralysis leading to death, 
immediate collapse, neural paralysis, 
cardiac arrhythmias, death 
(adapted from Reiffeinstein et al., 1992) 
 
The toxicity of H2S is not due to the gas itself, but to the capacity of blocking 
cytochrome c oxydase and forming persulphides356. 
Measurement of the concentration of thiosulfate in blood and urine is useful for 
determining hydrogen sulphide poisoning357. 
 
Study of H2S biology 
Researchers have always faced difficult challenges in the study of H2S biology. As a 
toxic and volatile molecule, its use for scientific purposes has always been limited. 
In order to bypass those difficulties, different approaches have been used. 
Currently, the strategies for delivering H2S in biological systems take advantages of 
molecules that release H2S in solution. These include salts of HS- or S2- species 
(especially sodium salts) and synthetic or natural H2S-releasing molecules, such as 
GYY4137 or diallyl disulphide (DADS) and diallyl trisulphide (DATS). The progress in 
the gasotransmitter research field has clarified the pathways leading to H2S 
synthesis and more tools are now available. These are represented by inhibitors of 
the enzymes CBS, CSE, and 3-MST, such as aminooxyacetic acid (AOAA), ᴅ,ʟ-
propalgylglycine (PAG or PGG), or β-cyanoalanine (BCA), but unfortunately they 
are not high-specific and some of them are unstable. The creation of CBS- and CSE-
knockout mice represents a more useful tool for the study of H2S involvement in 
physiologic and pathologic conditions. 
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The last challenge is represented by the methods used for the quantification of 
H2S levels in biological fluids or its production from tissue homogenates. The most 
common is the methylene blue assay, but it has intrinsic limitations. Apparently 
more precise methods include the monobromobimane method and sulphide-
selective electrodes. All these methods are extensively reviewed by Nagy et al.358. 
 
H2S signalling pathway 
Unfortunately, H2S signalling is not completely and fully understood. Unlike NO 
and CO, it does not seem to activate GC, even though it can bind heme groups. 
Therefore, H2S can signal in a similar way to that observed with NO: H2S is able to 
form a covalent bond on cysteine residues of proteins, a mechanism called 
“sulfhydrilation”, parallel to the “nitrosylation” process run by NO. 
Sulfhydration appears to be substantially more prevalent than nitrosylation. 
Whereas nitrosylation typically affects only about 1-5% of most proteins, 10-25% 
of endogenous GAPDH, β-tubulin, and actin are basally sulfhydrated359. Unlike 
nitrosylation that provides a NO “cap” on the reactive nucleofilic group of 
cysteines inactivating proteins, sulfhydrilation puts an -SSH group on it, which has 
a lower pKa than -HS group solely and thus make them more reactive. 
 
Actions of H2S 
Since the discovery that H2S could act as a gaseous transmitter, a large amount of 
papers regarding the H2S involvement in several districts has been published. Here 
are listed the most relevant ones to our interest. 
 
Cardiovascular system 
Like NO and CO, H2S affects cardiovascular system. Its effects are predominantly 
vasorelaxation, but under some conditions, such as high oxygen concentrations, it 
can constrict vessels as well. H2S has the ability to relax the rat thoracic aorta, 
portal vein, and mesenteric artery, which suggests a more fundamental role in the 
regulation of contractility and blood pressure360,361,362. Conversely, other studies 
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have suggested that H2S is a vasoconstrictor at low concentrations with a possible 
mechanism for suppressing NO, which, since NO is a dilator, could partially explain 
the contractility effects of H2S. One of the most important pieces of evidence for 
the involvement of H2S in regulation of vascular tone is the finding that CSE 
knockout mice develop age-dependent hypertension similar to that observed in 
eNOS deficient mice363. H2S seems to activate KATP, at least in the cardiovascular 
system, by sulfhydrating the channel at Cys43 and the subsequent 
hyperpolarisation elicited by opening KATP channels leads to relaxation of smooth 
muscle cells364. Evidence of this hypothesis comes from the observation that 
glibenclamide, a potent and selective inhibitor of the KATP channel, reduces the 
effects of H2S. 
Before endogenous H2S was shown to regulate blood vessel tone, exogenous H2S 
had been shown to exert beneficial cardiovascular actions. Many studies have 
dealt with myocardial ischemia, which is substantially diminished by 
administration of H2S-donors during ischemia/reperfusion of the heart365,366. 
Numerous mechanisms had been proposed for these cardioprotective 
actions367,368. Particularly promising is the evidence that H2S inhibits apoptosis, as 
H2S-donors reproducibly diminish poly(ADP-ribose) polymerase (PARP) cleavage, 
as well as cleavage of caspase-3369. H2S also preserves mitochondrial structure and 
function in response to myocardial ischemia. H2S may also be cardioprotective by 
decreasing the “work” of the heart, analogous to β-blockers, through diminishing 
contractility of cardiac myocytes, largely by inhibiting L-type calcium channels370. 
 
Inflammation 
Literature reports very conflictive effect of H2S on inflammation. Prominent 
proinflammatory effects have been reported in association with increased 
formation of sulphide in neutrophils as well as activation of these cells371. 
Administration of H2S-donors seemed to accentuate inflammatory factors 
associated with burns, while burn injuries were reduced by treatment by the CSE 
inhibitor propargylglycine372. Lung injury elicited by bacterial sepsis can be 
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alleviated by treatment with propargylglycine and worsened with H2S-donors371. 
By contrast, there are numerous reports of antiinflammatory effects for H2S-
donors as described below. A consensus has emerged in recent years that the 
apparently contradictory findings largely reflect variations in dose-response 
relationships for H2S under different experimental conditions. At relatively low 
physiologic concentrations, H2S appears to be antiinflammatory, while high 
concentrations elicit inflammation, a pattern reminiscent of NO, which is 
antiinflammatory in low concentrations and proinflammatory at high levels. CO, 
well known to be lethal in high doses, is also often beneficial when administered in 
low doses. 
What physiologic mechanisms underlie influences of H2S on inflammation? One of 
the best characterised involves the disposition of leukocytes, especially their 
adherence to vascular endothelium as well as their extravasation. H2S-donors and 
sulphide salts diminish lymphocyte and neutrophil infiltration in models of 
inflammation, whereas inhibitors of H2S biosynthesis increase leukocyte 
adherence373. H2S-donors diminish edema, presumably due to inhibition of plasma 
exudation, while CBS and CSE inhibitors increase the formation of edema in 
response to inflammatory stimuli373. A molecular mechanism underlying 
antiinflammatory roles of H2S may include its scavenging peroxynitrite, a toxic 
derivative of NO, as well as other oxidants374. 
H2S has been shown to exert beneficial influences in disorders of joints, including 
resolving synovitis in rodents375 and alleviating the pathology of carageenen-
associated arthritis376. H2S-donors also have been extensively explored in intestinal 
disorders, with beneficial effects in several models of colitis377. 
H2S may participate in some actions of TNF-α. While TNF-α is regarded as 
proinflammatory, it does display antiapoptotic actions mediated via NF-κB. The 
antiapoptotic actions of NF-κB appear to be mediated by H2S generated by CSE378. 
TNF-α treatment triples H2S generation by stimulating the binding of the 
transcription factor SP1 to the CSE promoter. H2S generated by CSE enhances the 
binding of NF-κB to promoters of downstream genes, whose signalling is markedly 
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diminished in CSE knockout mice. H2S acts by sulfhydrating the p65 subunit of NF-
κB, which promotes its binding to the co-activator ribosomal protein S3 (RPS3). 
The antiapoptotic influences of NF-κB are substantially reduced in CSE deleted 
mice378. The antiinflammatory influences of H2S have led to efforts to develop 
therapeutic agents. Classic non-steroidal antiinflammatory drugs (NSAIDs) often 
cause gastric irritation by inhibiting the formation of prostaglandins, which are 
physiologic cytoprotectants of the gastric mucosa; H2S, on the other hand, reduces 
mucosal inflammation, protects the gastrointestinal mucosa from injury, and 
augments tissue repair. One specific example of this is a H2S-form of naproxen 
(ATB-346) developed by the company Antibe Therapeutics 
(www.antibethera.com). In direct comparisons of naproxen and its H2S-linked 
derivative, the latter exerted comparable therapeutic efficacy with reduced gastric 
damage379,380. 
 
Asthma 
Fitzgerald et al. have demonstrated that H2S relaxed isolated airways smooth 
muscle cells and this implicated the role of the sarcolemmal KATP channel381. 
Although it seems that the effect of H2S on smooth muscle is due to an activation 
of KATP, however the relaxation of animal bronchial smooth muscle is due to 
neither the same mechanism nor the activation of sGC, COX-1 or COX-2, or takinin 
receptors382. Nevertheless, H2S relaxes murine bronchial airway smooth muscle 
preparations precontracted with carbachol very strongly, but only a small effect is 
seen on guinea pig bronchial rings382. 
Several studies suggest that H2S metabolism is altered in pulmonary system-
related pathologies: indeed, Wu et al. noted that the serum level of H2S decreased 
from 75.2±13.0 μM in healthy subjects to 55.8±13.6 μM in patients with stable 
asthma and 31.3±2.9 μM in patients with severe acute exacerbation of asthma383. 
Serum H2S levels positively correlated with forced expiratory volume (FEV1) and 
negatively with the count of sputum cells and the percentage of sputum 
neutrophils in patients with acute asthma. Whether the drop of H2S level in 
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asthma patient serum is the cause or the consequence of asthma development 
has not been addressed. It is also not clear whether the lung production of H2S 
was altered in these individuals. In any rate, this clinical study was mirrored by a 
later animal study: Chen et al. found that serum H2S level in OVA-treated (an 
experimental model of allergic asthma) rats decreased by 81% and H2S production 
from the lungs of these rats decreased by 80%384. The CSE expression level and 
CSE activity were decreased significantly in lung tissues from OVA-treated mice, 
which may explain the decreased endogenous levels of H2S in lung tissues and 
serum in these animals. Chen et al. also found that the peak expiratory flow was 
55.4% lower in OVA-treated rats than that of control rats and the proportions of 
eosinophils, lymphocytes, and neutrophils in BAL fluid were significantly 
increased384. Administration of exogenous H2S improved peak expiratory flow and 
alleviated airway inflammation and airway remodelling in this model384. 
Asthma is a condition where there is an imbalance of oxidant/antioxidant 
influences that is at the basis of the increased oxidative stress385. Activated 
inflammatory cells generate more ROS. H2S has reducing properties by allowing 
reduction of disulphide bonds and scavenging of various oxidants such as 
superoxide and peroxynitrite386. H2S does not react readily with hydrogen 
peroxide but it reduces peroxynitrite-mediated toxicity and tyrosine nitration374. In 
a hypoxic pulmonary hypertension model, H2S reduced oxidised glutathione levels 
and increased total antioxidant capacity in lung tissues, associated with a 
reduction in pulmonary artery pressures387. In an OVA-challenged mouse model, 
NaHS inhibited eosinophil and neutrophilic lung inflammation and prevented 
damage by increasing endogenous antioxidant with inhibition of lipid 
peroxidation. NaHS also increased SOD, glutathione peroxidase and glutathione 
reductase activity, together with a reduction in iNOS388. This indicates that H2S 
may be useful as an antioxidant. 
H2S does act as an antioxidant also in mithocondrial milieu: mitochondrial 
dysfunction and oxidative stress are associated with the development and 
progression of asthma389. Antioxidants have been used to prevent and treat 
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mitochondrial abnormality in asthma patients390. Macromolecule antioxidants, 
such as vitamins E and C, cannot enter mitochondria to scavenge ROS. In contrast, 
the gasotransmitter H2S can freely cross the plasma membrane and the 
mitochondrial membrane. Once inside mitochondria, H2S acts as a reducing agent, 
which can help to decrease oxidative stress and enhance endogenous antioxidant 
defences, leading to the preservation of both mitochondrial structure and 
function391. To date, whether H2S can attenuate airway inflammation and 
hyperresponsiveness in asthma by affecting the mitochondrial/oxidative stress 
pathway is not clear. 
ASM cells contribute not only to airway narrowing in asthma, but also to bronchial 
inflammation through the secretion of inflammatory factors and recruitment and 
activation of inflammatory cells392. Perry et al. investigated the regulatory role of 
H2S on the proliferation of human ASM cells. Exogenous H2S delivered from either 
the fast-releasing donor NaHS or the slow-releasing donor GYY4137 suppressed 
airway smooth muscle cell proliferation and IL-8 release due to the inhibited 
phosphorylation of ERK-1/2 and p38 MAPKs. In these cells, the enzyme CBS, and 
not CSE, was mainly involved in the endogenous production of H2S393. In other 
studies, administration of NaHS or the CSE blocker propargylglycine alleviated or 
aggravated, respectively, airway hyperresponsiveness in both the cigarette smoke 
exposure model and the OVA-induced asthma model in rats394,395. 
H2S also has effects on fibrotic processes. It attenuated epithelial-mesenchymal 
transition of human alveolar epithelial cells induced by TGF-β1, through the 
inhibition of Smad2/3 phosphorylation. H2S also suppressed human lung fibroblast 
proliferation induced by fetal bovine serum and PDGF-BB and TGF-β2-induced 
myofibroblast transdifferentiation396. 
Antiinflammatory effects of H2S have already been discussed above. To this 
extent, it is worth noting that H2S prevented particulate air pollution-induced 
endothelial disruption and lung vascular leakage, through scavenging ROS397. In 
terms of resolution of inflammation, H2S could induce neutrophil apoptosis398 and 
shift macrophage function to a pro-resolution phenotype399, with enhancement of 
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bacterial phagocytosis and suppression of endotoxin-induced production of TNF-α. 
These observations indicate a potential antiinflammatory effect of exogenous H2S 
in asthma and COPD. 
 
Pulmonary hypertension 
Scientific literature about the effect of H2S on pulmonary hypertension is not very 
well developed so far and it deals mostly with animal experiments, so it lacks 
human data. 
The first evidence of a possible role of H2S in PAH was the finding that H2S relaxed 
the smooth muscle of ileum, portal vein, and thoracic aorta in vitro, decreased the 
mean arterial pressure in vivo400,401, and inhibited the proliferation of cultured 
aortic vascular smooth muscle cells of rats402 and humans403 via inhibition of MAPK 
activity. Nevertheless, Chunyu et al. conducted the pioneer work in this area: they 
found out that in an animal model of PH the gene expression and the activity of 
CSE enzyme in lung tissues as well as H2S levels in plasma were reduced, and that 
exogenous supply of H2S alleviated the elevation of pulmonary arterial pressure 
and improve vascular remodelling404. Furthermore, inhibition of CSE by 
propalglycine could further worsen the hallmarks of PH405. Xiaohui et al. confirmed 
the same findings of Chunyu et al. by inducing PH in rats with a different 
method406. It is interesting to note that H2S levels were not affected by 
monocrotaline (MCT) in a rat model of PH407, likely because the pathogenesis of 
MCT-induced PH is different from other animal models. 
The improvement of vascular remodelling by H2S was reported to be due to: 1) 
reduction of production of collagen I and III, important component of the ECM, by 
regulating the homeostasis of their synthesis and degradation through the up-
regulation of the MMP-13 and the TIMP1 and the reduction of ET-1 and CTGF gene 
mRNA expression408; 2) apoptosis of pulmonary artery smooth muscle cells via the 
activation of Fas pathway and the inhibition of Bcl-2409; and 3) the attenuation of 
pulmonary smooth muscle cells proliferation410. In particular, the latter effect is 
considered to be a mixture of involvement of both NO and CO: the treatment with 
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exogenous H2S attenuated the activated NO/NOS pathway and increased the 
production of endogenous CO (reported to inhibit vascular smooth muscle cell 
proliferation in hypoxic pulmonary hypertension411) and up-regulated the HO-1 
protein expression in lung tissue in shunted rats, which might be involved in the 
mechanisms by which H2S alleviates pulmonary vascular remodelling410. It seems 
that NO, CO, and H2S might possibly interact under physiological and pathological 
conditions and constitute a regulatory network in the vascular system, in 
particular in the environment caused by PH, as other works by Yanfei et al.412 and 
Zhang et al.413 may suggest. 
The hypoxic conditions used to induce the animal model of PH are widely known 
to generate large amounts of ROS, which can induce the progression of pulmonary 
vascular remodelling. The role of H2S as an antioxidant agent in the disease was 
evidenced by the fact that the gasotransmitter could restore the levels of the total 
antioxidant capacity and lower the content of oxidised gluthatione in favour of 
reduced glutathione, as indicator of intracellular redox buffers; the activity of SOD 
enzymes was not affected by hypoxia neither before nor after administration of 
H2S387. 
H2S has been found useful to attenuate proliferation of human PASMCs treated 
with cobalt chloride (CoCl2), via upergulation of COX-2/PGI2 pathway414. CoCl2 is a 
hypoxia-mimicking agent, which leads to a cellular model of hypoxic PAH; human 
PASMCs treated with this agent show a marked increase in cell proliferation, 
accompanied by a decrease in COX-2 expression, PGI2 secretion, and H2S levels. 
Exogenous NaHS suppressed CoCl2-induced proliferation of the cells through the 
increase in the intracellular content of H2S; importantly, the exposure of the cells 
to NaHS suppressed the CoCl2-induced down-regulation of COX-2 expression and 
PGI2 secretion from the PASMCs. 
Finally yet importantly, H2S has been proved to relax human pulmonary arteries 
precontracted with potassium chloride in a concentration-dependent manner415 
and this effect is independent of the integrity of the endothelium; however, the 
mechanisms by which H2S exerts these effects have not been investigated. In 
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another paper, Sun et al. compared the vasorelaxing effect of exogenous H2S in rat 
aorta and pulmonary artery: NaHS was able to induce a more pronounced 
vasorelaxation in aorta, compared to pulmonary artery416. They postulated that 
H2S could more widely open KATP channels in aorta rather than pulmonary artery 
because of a higher presence of subunit SUR2B of KATP channels in the former; 
furthermore, in pulmonary artery only glibenclamide (a blocker of cellular KATP 
channels) affected the vasorelaxation, compared to aorta, in which both 
glibenclamide and 5-hydroxydecanoate (a blocker of mithocondrial KATP channels) 
could reduce vasorelaxation, thus further supporting their thesis. 
Therefore, the molecular and cellular mechanisms by which H2S/ʟ-cysteine 
pathway affects PH are still not fully understood and needs further exploration. 
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
 
 
 
2.1 REAGENTS 
 
Phenilephrine (PE), NG-nitro-ʟ-arginine methylester (ʟ-NAME), acetylcholine (Ach), 
bovine serum albumin (BSA), ovalbumin (OVA), sodium hydrosulphide (NaHS), ʟ-
cysteine, zinc acetate, N,N-dimethyl-p-phenylendiamine sulphate (DPD), iron(III) 
chloride (FeCl3), collagenase Type XI, DNase I Type IV from bovine pancreas, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), FR180204, 
monoclonal anti-dinitrophenyl (anti-DNP) IgE, thapsigargin, ionomycin, antigen 
dinitrophenyl-human seralbumin (DNP-HSA), triton X-100, 
polyinosinic:polycytidylic acid [Poly(I:C)], lipopolysaccharide (LPS) from E. Coli 
(serotype 0111:B4), and sodium nitroprusside (SNP) were purchased from Sigma-
Aldrich (Italy). Human IFN-α, mouse IFN-α, and TNF-α were purchased from R&D 
systems (UK). U46619 was purchased from Cayman Chemical (UK). SphK1/2 
inhibitor was purchased from Tocris Bioscience (UK). S1P was purchased from 
Enzo Life Sciences (Italy). All salts and buffers used for Krebs solution preparation 
were purchased from Carlo Erba Reagenti (Italy). 
KRX-725 (Compound 1) has been synthesised and kindly provided to us from group 
of Professors V. Santagada and G. Caliendo (Department of Pharmacy, University 
of Naples, Italy). 
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2.2 ANIMAL STUDIES (AIRWAY RESPONSIVENESS 
ASSESSMENT) 
 
2.2.1 MICE 
 
BALBC/c mice, mast cell-deficient KitW-Sh/W-sh mice417,418, and athymic nude 
BALBC/c mice were purchased from Charles River (Italy). They were allowed food 
and water ad libitum and housed in a controlled environment with a 12-hour 
light/dark cycle under specific pathogen-free conditions at the Department of 
Pharmacy (University of Naples, Italy). Mice were sacrificed by bleeding under 
isoflurane anaesthesia for flow cytometry experiments and under 
ketamine/xylazine (10 mg/1 mg·ml-1·kg-1) anaesthesia for bronchial reactivity 
experiments. Animal care was in compliance with Italian regulations on protection 
of animals used for experimental and other scientific purposes (DM. 116/92) as 
well as with the EEC regulations (O. J. of E. C. L. 358/1 12/18/1986). All studies 
were performed in accordance with European Union regulations for the handling 
and use of laboratory animals and were approved by the local committee. 
 
 
2.2.2 EXPERIMENTAL PROTOCOL 
 
Mice received subcutaneous injection of 0.1 ml of S1P (10 ng/mouse) or vehicle on 
day 0 and 7 and sacrificed at different time points: 7, 14, and 21 days after the first 
subcutaneous injection of S1P. The vehicle used in the experimental procedures 
contained 0.001% of BSA. 
In another set of experiments, an anti-CD20 mAb (rat IgG, 250 μg/mouse, i.p.)419 
was used to deplete CD20+ B cells at day 0, 3, 7, 10, and 14. The anti-CD20 mAb 
was injected the same day, but 30 minutes before the subcutaneous injection of 
S1P or vehicle. We already published that the anti-CD20 mAb depleted CD20+ B 
cells by around 90% compared with IgG419. Anti-CD20 mAb was injected every 
three days since the turnover of CD20+ B cells was approximately 4-5 days419. 
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In another set of experiments, mice received the purified rat anti-mouse CD23 
mAb (10 μg/mouse; B3B4 clone, BD Pharmingen, Italy) 30 minutes before S1P 
administration. 
In another set of experiments, mice were injected subcutaneously with 0.4 ml of 
OVA (100 μg/mouse) dissolved in Al(OH)3 gel (13 mg/ml in sterile saline) or vehicle 
(sterile saline) at day 0 and 7. Other mice were injected subcutaneously with 0.4 
ml of OVA (50 μg/mouse solubilised in PBS) or vehicle (PBS only) at day 0, 2, 4, and 
7. From day 7 to day 21 mice were exposed for 7 minutes on a daily basis to an 
H2S-donor (NaHS) through aerosol (100 ppm), by means of the apparatus 
illustrated in Figure 2.1. Mice were sacrificed at day 21. 
To prove the role of S1P-dependent pathway, OVA-sensitised mice were also 
treated with an inhibitor of SphK1/2 (10 μg/mouse), responsible of sphingosine 
phosphorylation. 
 
Figure 2.1. Apparatus used for administration of aerosolised NaHS. 
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2.2.3 TISSUE PREPARATION 
 
Mice were killed and bronchial tissue was rapidly dissected and cleaned from fat 
and connective tissue. Rings of 1 to 2 mm length were cut and placed in organ 
baths (2.5 ml) filled with oxygenated (95% O2/5% CO2) Krebs solution at 37°C, 
mounted to isometric force transducers (type 7006; Ugo Basile, Italy), and 
connected to a Powerlab 800 (ADInstruments, Italy). The composition of the Krebs 
solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, KH2PO4 
0.0012, CaCl2 0.0025, NaHCO3 0.025, and glucose 0.01. 
 
 
2.2.4 AIRWAY RESPONSIVENESS MEASUREMENTS 
 
Rings were initially stretched until a resting tension of 0.5 g was reached and 
allowed to equilibrate for at least 30 minutes, during which tension was adjusted 
to 0.5 g when necessary and bathing solution was periodically changed. In a 
preliminary study, a resting tension of 0.5 g was found to develop the optimal 
tension to stimulation with contracting agents. In each experiment, bronchial rings 
were firstly challenged with Ach (10-6 M) until the responses were reproducible. 
Bronchial reactivity was assessed performing a cumulative concentration–
response curve to carbachol (10-8-3×10-5 M). Data were expressed as contraction 
capacity (dine/mg of tissue) compared to the concentration of carbachol. 
 
 
2.2.5 ISOLATED PERFUSED MOUSE LUNG PREPARATION AND MEASUREMENTS 
 
Lungs were perfused in a non-recirculating fashion through the pulmonary artery 
at a constant flow of 1 ml/minute, resulting in a pulmonary artery pressure of 2 to 
3 cmH2O. The perfusion medium used was RPMI1640 lacking phenol red (37°C). 
The lungs were ventilated by negative pressure (-3 and -9 cmH2O) with 90 
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breaths/min and a tidal volume of approximately 200 ml. Every 5 minutes a 
hyperinflation (-20 cmH2O) was performed. Artificial thorax chamber pressure was 
measured with a differential pressure transducer (Validyne DP 45–24; Validyne 
Engineering, CA) and airflow velocity with pneumotachograph tube connected to a 
differential pressure transducer (Validyne DP 45–15). The lungs respired 
humidified air. The arterial pressure was continuously monitored by means of a 
pressure transducer (Isotec Healthdyne Cardiovascular, PA), which was connected 
with the cannula ending in the pulmonary artery. All data were transmitted to a 
computer and analysed with the Pulmodyn software (Hugo Sachs Elektronik, 
Germany). The data were analysed through the following formula: P = V × C-1 + RL × 
dV∙dt-1, where P is chamber pressure, C pulmonary compliance, V tidal volume, RL 
airway resistance. The airway resistance value registered was corrected for the 
resistance of the pneumotachometer and the tracheal cannula of 0.6 cmH2O s ml-
1. Lungs harvested from mice of each group treated as described before were 
perfused and ventilated for 45 minutes without any treatment to obtain a baseline 
state. Subsequently, lungs were challenged with Ach. Repetitive dose-response 
curves of Ach (10-8-10-5 M) were administered as 50 µl bolus, followed by intervals 
of 15 minutes, in which lungs were perfused with buffer only. 
 
 
 
2.3 ANIMAL STUDIES (PEPDUCIN ACTIVITY ASSESSMENT) 
 
2.3.1 MICE 
 
CD1 mice were purchased from Charles River (Italy). They were allowed food and 
water ad libitum and housed in a controlled environment with a 12-hour light/dark 
cycle under specific pathogen-free conditions at the Department of Pharmacy 
(University of Naples, Italy). Mice were sacrificed by bleeding under isoflurane 
anaesthesia. Animal care was in compliance with Italian regulations on protection 
  
54 CHAPTER 2 
of animals used for experimental and other scientific purposes (DM. 116/92) as 
well as with the EEC regulations (O. J. of E. C. L. 358/1 12/18/1986). All studies 
were performed in accordance with European Union regulations for the handling 
and use of laboratory animals and were approved by the local committee. 
 
 
2.3.2 TISSUE PREPARATION 
 
Mice were killed and thoracic aortha was rapidly removed, dissected, and cleaned 
from fat and connective tissue. Rings of 1 to 2 mm length were cut and placed in 
organ baths (2.5 ml) filled with oxygenated (95% O2/5% CO2) Krebs solution at 
37°C, mounted to isometric force transducers (type 7006; Ugo Basile, Italy), and 
connected to a Powerlab 800 (ADInstruments, Italy). The composition of the Krebs 
solution was as follows (mol/l): NaCl 0.118, KCl 0.0047, MgCl2 0.0012, KH2PO4 
0.0012, CaCl2 0.0025, NaHCO3 0.025, and glucose 0.01. 
 
 
2.3.3 AORTA RESPONSIVENESS MEASUREMENTS 
 
Rings were initially stretched until a resting tension of 1.0 g was reached and 
allowed to equilibrate for at least 30 minutes, during which tension was adjusted 
to 1.0 g when necessary and bathing solution was periodically changed. In a 
preliminary study, a resting tension of 1.0 g was found to develop the optimal 
tension to stimulation with contracting agents and to preserve the endothelial cell 
layer. In each experiment, aorthic rings were firstly challenged with PE (10-6 M) 
until the responses were reproducible. In order to verify the integrity of 
endothelium, Ach cumulative concentration-response curve (10-8-3×10-5 M) was 
performed on the PE-precontracted rings. Vessels that relaxed less than 85% were 
discarded. Aortic rings were contracted with PE (10-6 M), and once plateau was 
reached, a cumulative concentration-response curve to Compound 1 (10-8-3×10-5 
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M) was performed. Relaxations were expressed as the percentage of contraction. 
Relaxations were determined for each concentration-response curve by nonlinear 
regression analysis. S1P-induced relaxation of aorta involves both S1P1 and S1P3 
and is NO-mediated, but the S1P1 and S1P3 receptors are coupled to different 
mechanisms of signalling transduction. In particular, S1P3 is coupled to a Gi-
dependent ERK. In order to assess the contribution of nitric oxide or the ERK 
activation in the Compound 1-induced vasorelaxation, aortic rings were 
preincubated with the NOS inhibitor ʟ-NAME (100 μM) or the ERK inhibitor 
FR180204 (10 μM). In another set of experiments, the ability of myristoyl peptides 
(2–20) to induce vasorelaxation when compared with Compound 1 was tested 
(data not shown). Upon assays, the more active compounds were discarded, and 
the ability of the less active compounds to inhibit the Compound 1-induced 
vasorelaxation was evaluated. For this purpose, aortic rings were incubated for 15 
minutes with the selected compounds and a cumulative concentration-response 
curve to Compound 1 was performed. 
 
 
 
2.4 ANIMAL STUDIES (PULMONARY ARTERY CONTRACTILITY 
ASSESSMENT) 
 
2.4.1 MICE 
Male C57Bl/6J mice (Charles River, UK) were allowed food and water ad libitum 
and housed in a controlled environment with a 12-hour light/dark cycle under 
specific pathogen-free conditions at the Hammersmith Hospital (Imperial College 
of London, UK). All studies were performed in accordance with UK Home Office 
Animals (Scientific Procedures) Act 1986 and institutional guidelines. 
 
2.4.2 EXPERIMENTAL PROTOCOL 
Mice (8 to 10 weeks old; ≈20 g) were housed in normal air or placed in a 
normobaric hypoxic chamber (FiO2 10%) for 14 days. At day 14, animals were 
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weighed and anesthetised (fentanyl/fluanisone 0.25 ml/kg; midazolam 25 mg/kg 
i.p.), and right ventricular systolic pressure (RVSP) was measured via direct cardiac 
puncture using a closed-chest technique in the spontaneously breathing, 
anesthetised animal to verify development of pulmonary hypertension as 
previously described420. 
 
2.4.3 TISSUE PREPARATION 
At day 14, mice were humanely sacrificed by bleeding under anaesthesia and lungs 
carefully removed from thoracic cavity. Secondary pulmonary artery was rapidly 
isolated and cleaned from fat and connective tissue. Rings of 2 mm length were 
cut and mounted in organ baths (5 ml) of an isometric Mulvany-Halpern myograph 
filled with oxygenated (95% O2/5% CO2) physiological saline solution (PSS) at 37°C. 
Force was recorded via a PowerLab/800 (ADInstruments Ltd., UK) and analysed 
using Chart 6.0 acquisition system (ADInstruments Ltd., UK). The composition of 
the PSS was as follows (mmol/L): NaCl 118, KCl 4.7, CaCl2·6H2O 2.5, MgSO4·7H2O 
1.17, NaHCO3 25.0, NaH2PO4·2H2O 1.0, Na2EDTA 0.03, and glucose 5.5. 
 
2.4.4 PULMONARY VESSEL RESPONSIVENESS MEASUREMENTS 
Rings were mounted and allowed to equilibrate for 10 minutes. They were then 
stretched at a resting tension of 3.99 kPa and contracted with the thromboxane 
mimetic U46619 (10-9-10-6 M). After washing, tissues were contracted with an EC80 
concentration of U46619, followed by cumulative concentration-response curves 
to NaHS (10-6-3×10-3 M) and SNP (10-8-10-5 M). Data were expressed as force (mN) 
developed by the contracting agent or as percentage of U46619-induced 
contraction after administration of vasorelaxant compounds. 
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2.5 LUNG MORPHOLOGICAL ANALYSIS 
 
Left lung lobes were fixed in OCT medium (Pella Inc., Italy) and 7 μm cryosections 
were cut. At least five sections were considered for each animal and the mean of 
the positive staining compared with the total area were plotted. 
 
The degree of inflammation was scored by blinded observers by using hematoxylin 
and eosin (H&E) and Periodic Acid-Schiff (PAS) staining (Sigma-Aldrich, Italy). PAS 
staining was performed according to the manufacturer’s instructions to detect 
glycoprotein. PAS+ cryosections were graded with scores 0 to 4 to describe low to 
severe lung inflammation as follows: 0: <5%; 1: 5–25%; 2: 25–50%; 3: 50–75%; 4: 
>75% positive staining/total lung area. 
 
Mast cell activation was evaluated by toluidine blue (Sigma-Aldrich, Italy) positive 
staining by immunohistochemistry. 
 
Immunohistochemical detection of CD23 was performed by using anti-CD23 or rat 
IgG isotype control. The diamino-benzidinic acid system was used to detect 
complexes. Positive staining was quantified by means of Image J software (NIH, 
USA) and expressed as CD23 positive staining compared with the total area of the 
lung section. 
 
Immunohistochemical detection of FGF2 was performed by using anti-FGF2 or IgG 
isotype control (Santa Cruz Biotechnologies, USA). The diamino-benzidinic acid 
system was used to detect complexes. Positive staining was quantified by means 
of Image J software (NIH, USA) and expressed as FGF2 positive staining compared 
with the total area of the lung section. 
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2.6 CELLULAR STUDIES 
 
2.6.1 FLOW CYTOMETRY ANALYSIS 
 
Lungs were isolated and digested with 1 U/ml collagenase. Cell suspensions were 
passed through 70 μm cell strainers and red blood cells were lysed. Cell 
suspensions were used for flow cytometric analysis of different cell subtypes419. 
The composition of lung inflammatory cells was determined by flow cytometry (BD 
FacsCalibur, Italy) using the following antibodies: CD3-PeCy5.5, CD4-PE, CD8-APC, 
CD11c-FITC, CD11b-PeCy5.5, CD19-PeCy5.5, CD20-APC, CD25-PE, B220-PE, cKit-
PeCy5.5 or -PE, FoxP3-PeCy5.5, IgE-FITC, MHC II-PE, and MHC I-FITC (Bioscience, 
USA). 
 
CD4+ T cells were isolated by digesting mediastinic lymph nodes with collagenase 
(0.5 U/ml) and by using immunomagnetic beads for negative selection421, 
according to the manufacturer’s instructions (EasySep, Voden, Italy). The purity of 
CD4+ T cells was around 90%. CD4+ T cells were then marked for 
carboxyfluoresceindiacetate succinimidyl ester (CFSE; 5 μM; Molecular Probes, 
Invitrogen, Italy) to perform proliferation assay by using CD3/CD28 stimulation 
(CD3/CD28 beads, Invitrogen, Italy). CFSE flow cytometry data were analysed by 
means of ModFit software (BD Pharmingen). 
 
In another set of experiments, CD4+ T cells harvested from vehicle-, S1P-, or 
S1P+anti-CD23-treated mice were adoptively transferred into naïve (untreated) 
mice. Then 1×106 CD4+ T cells were injected intravenously as previously 
described421. 
 
Lung B cells (CD19+ cells) were generated by digesting the lung with collagenase 
(5-10 U/ml), DNAse I (20 μg/ml), and antibiotics for 45 minutes. Cell suspensions 
were passed through 70 μm cell strainers and red blood cells were lysed. For some 
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experiments, CD19+ cells were isolated using a negative selection for CD19+ cells 
(EasySep Stem Cell, Voden, Italy). Purity was routinely around 90%, as already 
published419. 
 
 
2.6.2 MIXED LYMPHOCYTE REACTION 
 
Lung CD19+ B cells were harvested, treated with PBS or S1P (0.1-1 μM), and then 
cultured for 24 and 72 hours with splenic CD8+ (ratio 1:10) and CD4+ T cells (ratio 
1:10). Splenic CD8+ and CD4+ T cells were isolated using an EasySep Stem Cell kit 
(Voden, Italy). Purity was checked by flow cytometry by using anti-CD3, anti-CD19, 
anti-CD4, and anti-CD8 antibodies (eBioscience, USA) and was routinely around 
90% (data not shown). Cell-free supernatant was tested for IFN-γ and IL-10 
release. CD4+ and CD8+ T cells were tested for cell proliferation by using CFSE (1 
μM) assay (eBioscience, USA). 
 
 
2.6.3 RBL-2H3 CELL CULTURE AND β-HEXOSAMINIDASE MEASUREMENT 
 
RBL-2H3 (Rat Basophilic Leukemia Mast Cell Line; Japan Health Sciences 
Foundation) were sensitised with the anti-DNP IgE (0.50 µg/ml). The H2S-donor 
NaHS (10-1000 μM; 5 min) or the vehicle were incubated. RBL-2H3 cell 
degranulation was induced by i) the antigen DNP-HSA (10 ng/ml); ii) ionomycin (1 
µM) and iii) thapsigargin (1 µM). Triton X-100 was added to cause exhaustive 
release of β-hexosaminidase. The concentration of p-nitrophenate release of β-
hexosaminidase was measured at 405 nm. 
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2.6.4 SMOOTH MUSCLE CELL CULTURE 
 
Human pulmonary artery specimens were obtained from healthy segments of lung 
from patients undergoing lung resection at the Royal Brompton Hospital, London, 
UK (Research Ethics Committee study number 02-081, sub-amendment 3). Full-
informed written consent was obtained from all participants. Human pulmonary 
artery smooth muscle cells (hPASMCs) were isolated from those arteries, as 
already described422. Cells were serum-deprived for 24 hours and subsequently 
treated with increasing concentrations of NaHS (10-1000 µM) and stimulated with 
IFN-α (10 ng/ml) or TNF-α (10 ng/ml) for 24 hours; after this period, supernatants 
were collected and stored for following analysis. Cell viability was measured using 
the AlamarBlue® method (Life Technologies, UK) according to manufacturer’s 
instructions. 
 
 
2.6.5 ISOLATION OF BLOOD OUTGROWTH ENDOTHELIAL CELLS 
 
Blood was collected from patients with PAH and healthy controls and blood 
outgrowth endothelial cells (BOECs) were isolated as per previously published 
protocols423,424. BOECs were treated with increasing concentrations of NaHS (10-
1000 µM) and stimulated with IFN-α (10 ng/ml) for 24 hours; after this period, 
supernatants were collected and stored for following analysis. Cell viability was 
measured using the AlamarBlue® method (Life Technologies, UK), according to 
manufacturer’s instructions. 
 
 
2.6.6 FIBROBLASTS CULTURE AND PROLIFERATION ASSESSMENT 
 
Murine lung fibroblasts were isolated from lungs of mice treated with OVA and/or 
H2S aerosol by means of enzymatic digestion, according to Baglole et al.425. 
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Fibroblastic phenotype was confirmed by presence of vimentin staining by 
immunocytochemistry (data not shown). 
Cell viability was assessed using the MTT colorimetric assay, considering the ability 
of living cells to oxidise the yellow MTT into water-insoluble purple crystals of 
formazan. Briefly, cells were seeded at a density of 7,500 cells/well in a 96-well 
plate. After 24 hours from the seeding, the medium was discarded and replaced 
with 200 µl of a solution of MTT (0.25 mg/ml) solublised in RPMI1640. After 3.5 
hours of incubation at 37°C, supernatants were removed and the crystals of 
formazan dissolved with 100 µl of DMSO. Absorbances were read at 520 nm with 
the Multiskan GO spectrophotometer (Thermo Scientific, Italy). The number of 
cells was extrapolated from absorbances against a reference curve. 
 
 
2.6.7 IMMUNOCYTOCHEMISTRY 
 
Murine lung fibroblasts were seeded on glass Lab-Tek II chamber slide™ (Thermo 
Scientific, USA) until confluence. They were first washed and then fixed with 
formalin. Fibroblasts differentiation was tested by incubating cells with mouse 
monoclonal antibody against α-SMA (Sigma Aldrich, Italy) or rabbit polyclonal 
antibody against vimentin (Santa Cruz, USA). For detection, fluorescein-labeled 
anti-mouse IgG (ABNOVA, Italy) or Texas-Red-labeled anti-rabbit IgG (ABNOVA, 
Italy) were used. Finally, glass slides were mounted with Fluoroshield™ with DAPI 
histology mounting medium (Sigma-Aldrich, Italy) and analysed by 
immunofluorescence. Myofibroblasts relative presence over fibroblasts was 
assessed as reported by Singh and Hall426. 
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2.7 ELISA MEASUREMENTS 
 
Total serum IgE levels were measured by means of ELISA using matched antibody 
pairs (BD Pharmingen, USA). The amount of serum PGD2 was quantified using an 
EIA Kit (Cayman, USA). 
ET-1, IP10, and IL-8 were measure on cell culture supernatans by using 
commercially available ELISAs (R&D System, UK; Bethyl Laboratories, UK), 
according to manufacturers’ instructions. 
TNF-α, IL-4, IL-6, IL-10, IFN-γ, Granzyme B, TGF-β (R&D Systems, UK), and IL-13 
(eBioscience, USA) were measured in lung homogenates by using commercially 
available ELISAs and expressed as pg/mg of proteins. 
 
 
 
2.8 WESTERN BLOTTING ANALYSIS 
 
Lungs isolated B cells were lysed in RIPA buffer (50 mM Tris/HCl, pH 7.4, 1% Triton-
X-100, 0.25%, sodium deoxycolate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 10 
μg/ml aprotinin, 20 μM leupeptin, and 50 mM sodium fluoride). Lysates were 
centrifuged at 14,000 g in a precoooled centrifuge for 15 minutes. Lysates were 
separated by SDS/PAGE (10% gels) and proteins were transferred onto a PVDF 
membrane. Membranes were blocked by incubation in PBS containing 0.1% 
Tween-20 and 5% (w/v) non-fat dried skimmed milk for 1 hour, followed by 
overnight incubation at 4°C with anti-SphK1 (SantaCruz Biotechnologies, USA) and 
anti-GAPDH (Sigma-Aldrich, Italy) antibodies. The membranes were washed 
extensively in PBS containing 0.1% Tween-20, before incubation for 2 hours with 
HRP-conjugate secondary antibodies. The membranes were then washed and 
developed using ECL (enhanced chemiluminescence substrate) using Image Quant 
F40 Instrument (GE Healthcare Life Sciences, Italy) for acquisition. 
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2.9 H2S LEVELS MEASUREMENT (METHYLEN BLUE ASSAY) 
 
Serum determination of H2S was performed as follows. Briefly, 200 µl of serum 
were added in Eppendorf tubes containing zinc acetate (150 µl; 1% w/v). 
Subsequently, DPD (100µl; 20 mM in 7.2 M HCl) and FeCl3 (133 μl; 30 mM in 1.2 M 
HCl) were added to the reaction mixture. After 20 minutes of incubation in the 
dark, trichloroacetic acid (10%, 300 µl) was added to each sample. After 
centrifugation (10,000 r.p.m. for 10 minutes at 4°C), the optical absorbance of the 
newly generated methylene blue was measured at a wavelength of 667 nm. All 
samples were assayed in duplicate and H2S concentration was calculated against a 
calibration curve of NaHS (3.9-250 µM). 
 
 
 
2.10 STATISTICAL ANALYSIS 
 
Results are expressed as means ± SEM. Changes observed in treated groups 
compared with controls were analysed using one-way analysis of variance 
(ANOVA), followed by Bonferroni’s post-test for multiple comparisons, and/or 
Student’s t-test, by using the GraphPad Prism software (USA). Two-way ANOVA 
was applied where required. p-values less than 0.05 were considered significant. 
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CHAPTER 3 
RESULTS 
 
 
 
 
 
3.1 STUDY OF CELLULAR MECHANISMS OF S1P-INDUCED 
AIRWAY HYPERREACTIVITY AND PULMONARY 
INFLAMMATION 
 
3.1.1 RATIONALE 
 
Allergic asthma is a pulmonary disease characterised by reversible 
bronchoconstriction, lung inflammation, and mucus hyperproduction: all these 
hallmarks are responsible of impaired respiration and lung functionality. 
It is accepted that allergic asthma is an inflammatory condition driven by a 
complex mix of mediators. In line with this, S1P is found in elevated levels in the 
BAL of patients with asthma, after challenge with the antigen. This finding 
suggests that S1P could be induced in allergic asthma. Indeed, Roviezzo et al.294 
have demonstrated that interfering in a specific step of the sphingolipid 
methabolic pathway with ᴅ,ʟ-threo-dihydrosphingosine (DTD), a SphK inhibitor, 
the OVA-induced hyperreactivity is abrogated. Furthermore, S1P has direct effects 
on SMCs. Roviezzo et al.427 have already demonstrated that systemic 
administration of S1P in mice leads to lung inflammation, airway hyperreactivity, 
and goblet cell hyperplasia, associated with an increase in mast cell recruitment in 
lungs, but the molecular/cellular mechanisms of these effects have not been 
investigated. Here, we aim at delucidating the pathways responsible for the S1P-
mediated effects on lungs and airways. 
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Thus, in this chapter, we have addressed the following hypothesis and specific 
aims: 
 
Hypothesis: 
“Systemic administration of S1P in mice contributes to lung inflammation, airway 
remodelling, and bronchoconstriction via immune system activation” 
 
Aims: 
- to investigate the effect of exogenous S1P on airway inflammation and 
markers of allergic asthma in mice; 
- to investigate the role of mast cells in the effects of S1P on airway 
responses and lung inflammation in vivo; 
- to investigate the role of T cells in the effects of S1P on airway responses 
and lung inflammation in vivo; 
- to assess the role of B cells in S1P- and OVA-induced hyperresponsiveness 
in vivo; 
- to assess the effects of S1P on B cells in vitro; 
- to assess the efficacy of a new pepducin-derived S1P3 antagonist. 
 
 
3.1.2 METHODS 
 
The methods relating to experiments performed in this section are described in 
the Chapter 2 (Materials and methods). 
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3.1.3 DATA HANDLING AND STATISTICAL ANALYSIS 
 
The statistical analysis relating to experiments performed in this section are 
described in the Chapter 2 (Materials and methods). The details of each statistical 
test used are reported in the respective figure legends. 
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3.1.4 RESULTS 
 
S1P induces airway smooth muscle hyperreactivity and lung inflammation 
Lungs harvested from mice injected with S1P (Figure 3.1A) displayed a progressive 
alteration in lung morphology. The effect was maximal at 21 days after S1P 
challenge (Figure 3.1B) and was associated with increased mucus production as 
determined by PAS staining (Figure 3.1C). Plasma levels of IgE (Figure 3.1D) were 
significantly increased too. Flow cytometry analyses of lungs showed a significant 
increase in the percentage of mast cells, identified as CD11c+cKit+IgE+ cells (Figure 
3.2A and Figure 3.2B). Mast cells were stained for IgE since they covalently bind to 
its receptor (FcεRI) on these cells428. Plasma levels of PGD2 were significantly 
increased in S1P-treated compared with vehicle-treated mice (Figure 3.2C). 
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Figure 3.1. Systemic S1P administration induces lung inflammation. (A) Mice 
received s.c. S1P (10 ng) or vehicle (BSA 0.001%) on days 0 and 7. (B) Lung sections 
were fixed and stained with H&E. Lung sections were photographed under light 
microscopy at 10× magnification. (C) PAS was performed to detect glycoprotein (* 
p<0.05 vs. vehicle, one-way ANOVA with Bonferroni’s post-test). (D) Sera were 
collected and levels of total IgE were determined by using specific ELISA (** p<0.01 vs. 
vehicle, one-way ANOVA with Bonferroni’s post-test). Data are mean ± SEM, n=6 mice 
in each group. 
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Figure 3.2. S1P increases mast cell infiltration in the lung. (A) Mast cells were 
identified as CD11+cKit+IgE+ cells by flow cytometry as shown in the representative 
dot plot. (B) Mast cell-infiltration was quantified after 7, 14, and 21 days following S1P 
administration (* p<0.05, ** p<0.01 vs. vehicle, one-way ANOVA with Bonferroni’s 
post-test). (C) Sera were collected and PGD2 levels were determined by using specific 
ELISA. (* p<0.05 vs. vehicle, one-way ANOVA with Bonferroni’s post-test). Data are 
mean ± SEM, n=6 mice in each group. 
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S1P-induced hyperreactivity, but not lung inflammation, is attenuated in mast cell-
deficient KitW-sh/W-sh mice 
In mast cell-deficient KitW-sh/W-sh mice, S1P failed to induce bronchial 
hyperresponsiveness (Figure 3.3A). Conversely, lungs harvested from the same 
animals still displayed i) altered alveolar structure (Figure 3.3B) and ii) increased 
mucus production (Figure 3.3C) in comparison with wild type. Basal serum IgE was 
significantly reduced in KitW-sh/W-sh mice when compared with wild-type mice 
(Figure 3.3D). Nevertheless, S1P challenge significantly increased IgE levels in KitW-
sh/W-sh mice when compared with the basal levels of mast cell-deficient mice 
(Figure 3.3D). 
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Figure 3.3. Mast cells are essential for the development of S1P-induced bronchial 
hyperreactivity, but not for lung inflammation. Mast cell-deficient KitW-sh/W-sh or wild-
type mice received s.c. S1P (10 ng) or vehicle (BSA 0.001%) on days 0 and 7. Mice were 
killed on day 21. (A) Assessment of bronchial reactivity to carbachol (*** p<0.001 vs. 
vehicle, two-way ANOVA with Bonferroni’s post-test). (B) Lung sections were fixed and 
stained with PAS (* p<0.05, Student’s t-test). Lung sections were photographed under 
light microscopy at 10× magnification. (C) PAS staining was quantified as described in 
Methods chapter. (D) Sera were collected and levels of IgE were determined by ELISA 
(* p<0.05; ** p<0.01, Student’s t-test). Data are mean ± SEM, n=6 mice in each group. 
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S1P induces lung inflammation and airway smooth muscle hyperreactivity in an 
IgE-dependent manner 
CD23 is an important regulatory receptor for IgE production and its interaction 
with IgE can amplify IgE-associated immune responses429,430,431. 
Immunohistochemical analysis (Figure 3.4A) showed that CD23 expression was 
significantly increased in S1P-treated mice with a maximal effect at 21 days after 
S1P challenge in comparison with vehicle mice (Figure 3.4B). Therefore, in order to 
investigate the role of IgE in S1P-induced airway dysfunction, we used an anti-
CD23 mAb. Administration of anti-CD23 per se did not affect S1P-induced increase 
in pulmonary mast cell infiltration (Figure 3.4C). Conversely, anti-CD23 significantly 
reduced S1P-induced IgE increase (Figure 3.4D) thereby confirming the role of 
CD23 in S1P-induced IgE production. IL-4 and IL-13 are key cytokines for the 
initiation of Th2-mediated responses and for IgE isotype class switching432,433. S1P 
administration induced a significant increase in both IL-4 (Figure 3.4E) and IL-13 
(Figure 3.4F) in the lung. Anti-CD23 inhibited S1P-induced expression of IL-13 
(Figure 3.4F), but not of IL-4 (Figure 3.4E). However, the administration of anti-
CD23 to S1P-treated mice prevented airway smooth muscle hyperresponsiveness 
(Figure 3.5A), lung damage (Figure 3.5B), and mucus production (Figure 3.5C). 
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Figure 3.4. S1P enhances pulmonary CD23 (FcεRII) expression. (A) 
Immunohistochemical detection of CD23 was performed on lung sections harvested 
from mice challenged with vehicle or S1P by using anti-CD23 mAb or rat IgG isotype 
control as shown in the representative lung section staining. Lung sections were 
photographed under light microscopy at 10× magnification. (B) CD23 quantification was 
performed at 7, 14, and 21 days after S1P challenge (* p<0.05 vs. vehicle, Student’s t-
test). In another set of experiments, anti-CD23 (10 μg/mice) was administered i.p. 30 
minutes before S1P or vehicle on days 0 and 7. On day 21, mice were killed. (C) 
Pulmonary mast cells were identified as CD11+cKit+IgE+ cells by flow cytometry (** 
p<0.01, Student’s t-test). (D) Sera were collected to determine IgE levels by ELISA (** 
p<0.01, Student’s t-test). (E) (F) Pulmonary expression of IL-4 and IL-13 (* p<0.05, ** 
p<0.01, Student’s t-test) was determined by ELISA. Data are mean ± SEM, n=6 mice in 
each group. 
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Figure 3.5. Anti-CD23 attenuates S1P-mediated effects on the lung. Anti-CD23 (10 
μg/mice) was administered i.p. 30 minutes before S1P on days 0 and 7. Mice were 
killed on day 21. (A) Bronchial responses to carbachol were evaluated (*** p<0.001 vs. 
vehicle, two-way ANOVA with Bonferroni’s post-test). (B) Representative staining of 
lung sections with H&E. (C) Quantification of PAS staining performed as described in 
Methods chapter (* p<0.05, Student’s t-test). Lung sections were photographed under 
light microscopy at 10× magnification. Data are mean ± SEM, n=6 mice in each group. 
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T cells are involved in S1P-induced effects on lung 
The major control step in IgE synthesis is the regulation of IgE class-switch 
recombination, which is mostly T cell-dependent434,435. Our data define IgE/CD23 
signalling as a key driver for the effects triggered by S1P in the airways. In order to 
extend our observations on the role of CD23 and to further elucidate the role of 
IgE-dependent mechanisms, we evaluated T cell involvement. Nude mice, which 
genetically lack of T cells, injected with S1P did not develop bronchial 
hyperresponsiveness (Figure 3.6A). In addition, alteration of lung structure (Figure 
3.6B), mucus production (Figure 3.6C) and mast cell infiltration (Figure 3.6D) in 
S1P-treated nude mice were significantly lower than wild-type mice. Plasma levels 
of IgE were unaltered by S1P in nude mice compared with wild type (Figure 3.6E). 
Accordingly, we observed neither an increase in CD23 pulmonary expression 
(Figure 3.6F) nor IL-4/IL-13 overexpression in the lung (data not shown). 
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Figure 3.6. T cells play a key role in S1P-mediated effects on lung. Nude athymic mice 
or wild-type mice received s.c. S1P (10 ng) or vehicle (BSA 0.001%) on days 0 and 7. 
Mice were killed on day 21. (A) Assessment of bronchial response to carbachol (*** 
p<0.001, two-way ANOVA with Bonferroni’s post-test). (B) Representative staining of 
lung sections with H&E. (C) Quantification of PAS staining performed as described in 
Methods chapter (* p<0.05, ** p<0.01, Student’s t-test). (D) Pulmonary mast cells 
quantified by flow cytometry (** p<0.01, Student’s t-test). (E) Sera IgE levels 
determined by ELISA (** p<0.01, Student’s t-test). (F) Immunohistochemical detection 
of CD23 (* p<0.05, Student’s t-test) on lung sections by using anti-CD23 mAb. Data are 
mean ± SEM, n=6 mice in each group. 
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Adoptive transfer of S1P-derived CD4+ T cells into naïve mice induces airway 
smooth muscle hyperreactivity and lung inflammation 
In order to gain further insight into the cellular mechanisms, we isolated CD4+ T 
cells. CD4+ T cells were labelled at day 0 with CFSE (parent histogram; Figure 3.7A) 
and then cultured for 3 days in the presence or absence of CD3/CD28 beads. CD4+ 
T cells were isolated from the mediastinic lymph node of vehicle- (Figure 3.7B and 
3.7C), S1P- (Figure 3.7D and 3.7E), IgG- (Figure 3.7F), anti-CD23- (Figure 3.7G and 
3.7H), or S1P+anti-CD23- (Figure 3.7I and 3.7J) treated mice. CD4+ T cells 
harvested from S1P-treated mice (Figure 3.7E) displayed a basal increase in the 
proliferation rate as compared with vehicle-treated mice (Figure 3.7C), even in the 
absence of CD3/CD28 beads (Figure 3.7B and 3.7D). We observed that CFSE+CD4+ 
T cells proliferated for up to seven generations when they were obtained from 
S1P- (Figure 3.7D and 3.7E) but not vehicle-treated mice (Figure 3.7B and 3.7C). 
The proliferation rate of CD4+ T cells induced by S1P was not affected by anti-
CD23 treatment (Figure 3.7I and 3.7J). IgG- (Figure 3.7F), or anti-CD23- (Figure 
3.7G and 3.7H) derived CD4+ T cells did not show any significant increase in the 
proliferation rate. These results imply that the role of CD23 in vivo is to regulate 
negatively IgE production during S1P exposure without a direct significant effect 
on T cell growth or differentiation. These latter data fit well with the lack of effect 
of anti-CD23 in regulating IL-4 expression. To determine whether S1P could 
directly affect the proliferation of CD4+ T cells, we incubated CD4+ T cells obtained 
from vehicle-treated mice with S1P. In these experimental conditions, there was 
no detectable increase in the proliferation index (data not shown). Finally, 
adoptive transfer of CD4+ T cells, harvested from the mediastinic lymph node of 
S1P-treated mice, into naïve mice was performed. S1P-derived CD4+ T cell 
adoptively transferred into naïve mice increased mast cell infiltration (Figure 
3.8A), bronchial reactivity (Figure 3.8B), lung inflammation (Figure 3.8C), IL-4 
(Figure 3.8D), and IL-13 (Figure 3.8E) release. Conversely, adoptive transfer of 
CD4+ T cells, harvested from mice treated with anti-CD23 and S1P reversed airway 
smooth muscle hyperreactivity (Figure 3.8B), lung inflammation (Figure 3.8C), and 
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IL-13 up-regulation (Figure 3.8E). In agreement with previous data (Figure 3.4), 
neither mast cell infiltration (Figure 3.8A) nor IL-4 up-regulation (Figure 3.8D) were 
modified. 
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Figure 3.8. Adoptive transfer of CD4+ T cells from S1P-treated mice into naïve 
(untreated) mice mimics S1P-induced effects in BALB/c mice. Adoptive transfer of 
CD4+ T cells derived from vehicle-, S1P- or anti-CD23+S1P-treated mice into naïve 
BALB/c mice was performed. Mice were killed at 3 and 7 days following adoptive 
transfer. (A) Mast cells were identified as CD11c+cKit+IgE+ cells by flow cytometry 
(*** p<0.001 vs. vehicle, Student’s t-test). (B) Assessment of bronchial response to 
carbachol (*** p<0.001 vs. vehicle, two-way ANOVA with Bonferroni’s post-test). (C) 
PAS staining of lung sections harvested from mice after 7 days of adoptive transfer. 
(D) Pulmonary levels of IL-4 (** p<0.01, Student’s t-test). (E) Pulmonary levels of IL-13 
(*** p<0.001, one-way ANOVA with Bonferroni’s post-test). Data are mean ± SEM, 
n=6 mice in each group. 
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S1P/SphK1/2-dependent signalling is involved in B cell recruitment during OVA-
induced airway hyperreactivity and inflammation 
We already demonstrated that S1P/SphK1/2 signalling is involved in airway 
hyperresponsiveness in OVA-sensitised mice294. Indeed, the injection of a SphK1/2 
inhibitor in OVA-treated mice significantly reduced airway reactivity to carbachol 
(Figure 3.9A). Because allergic airway diseases are well characterised by the high 
levels of immunoglobulins, we went on by evaluating the presence of B cells in the 
lung of OVA-sensitised mice. The percentage of B cells (identified as CD19+B220+ 
cells) in the lung of OVA-sensitised mice was significantly higher than control mice 
(Figure 3.9B) at earlier time points. Interestingly, we observed a significant 
reduction of B cells in the lung of OVA-sensitised mice treated with SphK1/2 
inhibitor (Figure 3.9B), implying that S1P axis is responsible of B cell recruitment 
during allergic airway inflammation. In addition, the injection of a SphK1/2 
inhibitor markedly reduced OVA-induced IL-13 (Figure 3.9C), IL-10 (Figure 3.9D), 
and TGF-β (Figure 3.9E). These data further confirm the role of S1P axis in airway 
allergic Th2-like responses. 
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S1P-mediated hyperresponsiveness is associated to higher presence of B cells in the 
lung 
In order to further clarify the role of S1P signalling in B cells recruitment during 
sensitization, we went on exposing BALBC/c mice to S1P (10 ng/mouse). In our 
previous study, we already demonstrated that S1P exogenous administration, as 
well as OVA, increases airway responsiveness and inflammation in a time- and 
dose-dependent manner427. Similarly, in this study we observed that the 
treatment with S1P induced higher responsiveness to carbachol starting at day 3 
(data not shown) up to 14 days (Figure 3.9F), when statistical differences were 
appreciated. This effect was similar to what happened in OVA-sensitised mice 
(Figure 3.9A). In addition, the release of IL-13, well-known airway allergic 
cytokine436, was significantly increased in lung homogenates of mice treated with 
S1P compared to vehicle mice (Figure 3.9G). Interestingly, B cells significantly 
accumulated into the lung of S1P-treated mice at day 3, 7, and 14, compared to 
vehicle mice (Figure 3.9H), similarly to what happened to OVA-sensitised mice 
(Figure 3.9B). These data imply that S1P axis is involved in lung B cell recruitment 
during allergic airway inflammation. 
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Figure 3.9. S1P-mediated airway inflammation is similar to that observed in OVA-
treated mice. BALB/c mice were s.c treated with OVA (100 μg/mouse) or S1P (10 
ng/mouse) at day 0 and day 7. (A) Bronchi of OVA-treated mice showed higher 
reactivity to cumulative administration of carbachol (10-9-3×10-6 M), expressed as 
contraction ability (dine/mg), compared to vehicle (BSA 0.001%) and SphK1/2 
inhibitor-treated mice (* p<0.05, two-way ANOVA with Bonferroni’s post-test). (B) B 
cell (identified as CD19+B220+ cells) percentage was significantly increased in the lung 
of OVA-treated mice compared to mice treated with SphK 1/2 inhibitor (** p<0.01, 
*** p<0.001, Student’s t-test). Lung homogenates were tested for Th2-like cytokine 
levels such as (C) IL-13, (D) IL-10, and (E) TGF-β (** p<0.01, *** p<0.001, Student’s t-
test). (F) Bronchi of S1P-treated mice showed higher reactivity to cumulative 
administration of carbachol (*** p<0.001 vs. vehicle, two-way ANOVA with 
Bonferroni’s post-test), associated to (G) higher levels of IL-13 (** p<0.01, Student’s t-
test), but also to (H) higher B cell recruitment to the lung (** p<0.01, *** p<0.001, 
Student’s t-test), as reported for OVA-treated mice. B cell recruitment is shown as B 
cell count (1×106/ml). (I) Representative dot plot of lung CD19+B220+ gated cells. Data 
are mean ± SEM, n=9 mice in each group. Experiments were performed in two 
different experimental days. 
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S1P-mediated hyperresponsiveness is associated to an immune-suppressive 
environment 
To further dissect the role of leukocytes in our mouse model, we went on and 
analysed the presence of immune-suppressive cells such as Treg cells. Treg were 
identified by means of flow cytometry analysis and gated as 
CD3+CD4+CD25+FoxP3+ cells. The administration of S1P significantly increased the 
levels of Treg into the lung only after 7 and 14 days post the first administration of 
S1P (Figure 3.10A) when B cell presence was reduced. This effect was also 
observed in OVA-sensitised mice (data not shown). In addition, the levels of IL-10 
(Figure 3.10C) and TGF-β (Figure 3.10D), well-known immune-suppressive 
cytokines, were significantly increased in lung homogenates of S1P-treated mice 
sacrificed at 14 days. These cytokines were not detected at earlier time points (3-7 
days) after S1P treatment. These data imply that S1P treatment can increase Treg 
recruitment, which has already been observed for OVA-sensitised mice437. 
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Figure 3.10. S1P treatment promotes the recruitment of Treg cells. (A) Increase of 
CD4-FITC, CD25-PE and FoxP3-PeCy5.5 positive Treg cells in the lung of vehicle and 
S1P-treated mice (* p<0.05, ** p<0.01, *** p<0.001, Student’s t-test). (B) 
Representative flow cytometry dot plot are reported. (C) IL-10 and (D) TGF-β levels in 
lung homogenates obtained from vehicle and S1P-treated mice sacrificed at 14 days 
(* p<0.05, *** p<0.001, Student’s t-test). Data are mean ± SEM, n=9 mice in each 
group. Experiments were performed in two different experimental days. 
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S1P-pulsed B cells behave as B regulatory cells 
Our previous data demonstrated that S1P increased B cell influx to the lung of 
BALBC/c mice (Figure 3.9H). In order to understand the role of S1P axis, we 
isolated lung B cells after S1P or vehicle treatment. Lung-derived B cells expressed 
sphingosine kinase, SphK1 (Figure 3.11A), as already reported by Pi et al.438. No 
differences were observed in SphK1 expression in B cells obtained from the lung of 
both vehicle and S1P-treated mice isolated at different time points, implying that 
this kinase is physiologically present in these cells. In addition, the levels of the 
most relevant receptor for S1P, the S1P1, was equally expressed on B cells derived 
from vehicle-, S1P-, and OVA-treated mice (Figure 3.11B). 
In order to understand the phenotype of S1P-pulsed B cells, in vitro experiments 
were performed by using lung-derived B cells isolated from vehicle mice. S1P 
treatment (0.1-1 μM) of vehicle mice-derived lung B cells increased the levels of IL-
10 (Figure 3.11C) and TNF-α (Figure 3.11D) in a significant manner. In contrast, the 
addition of S1P on vehicle-derived lung B cells did not increase the release of the 
cytotoxic protease granzyme B (Figure 3.11E) nor IL-13, a Th2-like cytokine (Figure 
3.11F). However, B cells isolated from the lung of S1P-treated mice at 7 and 14 
days showed significant release in vitro of both granzyme B (Figure 3.11D) and IL-
13 (Figure 3.11E), implying that another signal was essential to induce these cells 
to release harmful mediators such as granzyme B and IL-13. Because of the well-
described activity of B cells as antigen-presenting cells (APCs)439, we performed 
flow cytometry analysis for cell surface markers. Again, B cells were isolated from 
vehicle- and S1P-treated mice at different time points. At 3 days post S1P or 
vehicle injection, the stimulation of vehicle-derived B cells with S1P in vitro 
showed higher levels of MHC I (Figure 3.12A) and MHC II (Figure 3.12B). Instead, B 
cells from S1P-treated mice did not show any increase in MHC I (Figure 3.12A) and 
MHC II (Figure 3.12B) after S1P addition. However, the basal levels of MHC I 
(Figure 3.12A) and MHC II (Figure 3.12B) on B cells from S1P-treated mice were 
already significantly higher than those from vehicle mice, implying that B cells 
from S1P-treated mice were already in their active phenotype. 
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Similarly, vehicle-derived B cells obtained at 7 days showed a significant increase 
of MHC I (Figure 3.12C) and MHC II (Figure 3.12D) under S1P stimulation. 
However, at this time point, B cells obtained from the lung of S1P-treated mice 
showed a significant increase in MHC I (Figure 3.12C) and MHC II (Figure 3.12D) 
levels after S1P treatment. However, it is to note that the stimulation in vitro with 
S1P (0.1–1 μM) of B cells obtained from mice treated in vivo with S1P for 3 days, 
had a reduced expression of MHC I (Figure 3.12A) and MHC II (Figure 3.12B), 
compared to the basal conditions. In addition, the different behaviour of B cells 
obtained from the lung of S1P-treated mice at 3 and 7 days may be due to the 
administration of S1P that was performed 7 days before the isolation. 
Interestingly, B cells isolated from the lung of S1P- or vehicle-treated at 14 days 
did not show any differences in both the levels of MHC I (Figure 3.12E) and MHC II 
(Figure 3.12F). In contrast, higher levels of CD80 were detected on S1P-derived B 
cells compared to vehicle at 14 days (Figure 3.12G). These data imply that, 
although B cells do not present antigens via MHC I-II overexpression at day 14, 
they can interact with T cells via CD80. 
To understand the role of lung-derived B cells from mice treated with vehicle or 
S1P on T cells, we performed mixed lymphocyte reaction experiments in vitro. B 
cells obtained from the lung of vehicle mice were first treated with S1P or PBS and 
then added to CD4+ or CD8+ T cells obtained from the spleen of naïve (non-
treated) mice. CFSE-marked CD4+ T cells alone did not show any increase in 
proliferation when S1P was added (Figure 3.13A). Similarly, CD8+ T cells did not 
proliferate (Figure 3.13F). In contrast, B cells obtained from mice exposed to S1P 
and sacrificed at 14 days induced higher proliferation rate of both CD4+ (Figure 
3.13A) and CD8+ T cells (Figure 3.13F), although in the absence of an additional 
(exogenous) stimulus. This effect was associated to the higher release of TGF-β 
(Figure 3.13B) and IL-10 (Figure 3.13C) from B cells harvested from the lung of S1P-
treated mice sacrificed at 14 days when added to naive CD4+ T cells. The levels of 
these immunosuppressive cytokines was higher than that detected in the 
supernatant of B cells alone (Figure 3.13B and 3.13C). In contrast, we did not 
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detect any increase in IFN-γ (data not shown). In addition, to understand the 
phenotype of CD4+ T cells after the co-culture with B cells, we went on by 
analysing the expression levels of FoxP3, a well-known Treg transcription factor. 
Indeed, FoxP3 expression was significantly higher in CD4+ T cells that were co-
cultured with B cells derived from the lung of S1P-treated mice compared to 
vehicle mice (Figure 3.13D and 3.13E). Similar to CD4+ T cells, B cells obtained 
from both vehicle- and S1P-treated mice were added to CD8+ T cells derived from 
naïve mice. Again, we observed higher proliferation rate after the addition of CD8+ 
T cells to B cells from S1P-treated mice (Figure 3.13F), associated to higher release 
of the suppressive cytokine IL-10 (Figure 3.13G). These data suggest the ability of 
S1P to lead B cells toward a regulatory phenotype. Besides their APC activity, B 
cells behave as immunoglobulin-producing cells419,439. 
To evaluate the role of S1P on plasma cell-like B cells, we analysed the levels of the 
surface marker CD20, which is predominantly present on immunoglobulin-
producing cells419. B cells isolated from the lung of mice treated with S1P and 
sacrificed at 3 (Figure 3.14A) and 7 days (Figure 3.14B) did not show any statistical 
difference in CD20 expression either in the presence or not of S1P in vitro. Instead, 
B cells isolated from the lung of S1P-treated mice sacrificed at 14 days had 
significantly higher basal levels of CD20 (Figure 3.14C) compared to vehicle. 
Conversely, the administration of S1P in vitro on B cells derived from vehicle- or 
S1P-treated mice did not alter CD20 levels (Figure 3.14C). In addition, B cells from 
S1P-treated mice and sacrificed at 14 days showed higher levels of IgA (Figure 
3.14D), but not IgG2a (Figure 3.14E) and IgM (Figure 3.14F). Taken altogether, 
these data suggest that S1P can increase MHC I, MHC II, and CD20 expression on B 
cells, which in their regulatory phenotype are associated to the polarization of T 
cells toward IL-10-producing T cells and an immunosuppressive environment, as 
also demonstrated by the higher release of the antiinflammatory activity of IgA-
producing B cells. 
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Figure 3.11. Treatment of B cells with S1P. Lung-derived B cells (0.5×105 cells/well) 
from vehicle and S1P-treated mice were isolated and then treated in vitro with S1P 
(0.1-1 μM) overnight. (A) The expression of SphK1 and (B) S1P1 was equally observed 
on B cells isolated by both vehicle- and S1P-treated mice at different time points. S1P 
stimulation of vehicle-derived lung B cells promoted a significant release of (C) IL-10 
and (D) TNF-α, but not of (E) granzyme B and (F) IL-13; in contrast, lung B cells 
obtained from S1P-treated mice, sacrificed at day 14, were able to release (E) 
granzyme B and (F) IL-13, even in the absence of an external stimulus (* p<0.05, ** 
p<0.01, *** p<0.001, Student’s t-test). Data are mean ± SEM, n=6 mice in each group. 
Experiments were performed in two different experimental days. 
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Figure 3.12. Stimulation of lung-derived B cells with S1P increases MHC I and MHC II 
expression at early time points (3-7 days). (A) Expression of MHC I and (B) MHC II at 3 
days on lung-derived B cells (identified as CD19+B220+) obtained from vehicle- and 
S1P-treated mice (* p<0.05, ** p<0.01, Student’s t-test). (C) Higher expression of MHC I 
and (D) MHC II at 7 days on lung-derived B cells (identified as CD19+B220+) obtained 
from vehicle- and S1P-treated mice (* p<0.05, ** p<0.01, Student’s t-test). No statistical 
differences were observed in MHC I (E) and MHC II (F) on lung-derived B cells obtained 
at 14 days. (G) CD80 expression was higher on B cells obtained from S1P-treated mice 
at day 14 (*** p<0.001, Student’s t-test). Data are mean ± SEM, n=6 mice in each 
group. Experiments were performed in two different experimental days. 
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Figure 3.13. Lung-derived B cells from S1P-treated mice increased T cell proliferation 
and IL-10 release. (A) Lung B cells (identified as CD19+B220+) were harvested from 
both vehicle- and S1P-treated mice and then treated in vitro with PBS or S1P (0.1-1 
μM) and then co-cultured for 24 and 72 hours with splenic naive CD4+ (ratio 1:10) (** 
p<0.01, Student’s t-test). Cell-free supernatant was tested for (B) TGF-β and (C) IL-10 
release by means of ELISA. T cell proliferation (72 hours) was tested by using flow 
cytometry analyses of CFSE (** p<0.01, Student’s t-test). (D) The expression of FoxP3 
was tested by means of flow cytometry after the co-culture of vehicle- or S1P-derived 
lung B cells with naïve (non-treated) CD4+ T cells (** p<0.01, Student’s t-test). (E) 
Representative histograms for FoxP3 expression by means of FACS. (F) Similar to CD4+ 
T cells, CD8+ T cells were co-cultured with B cells obtained from vehicle and S1P-
treated mice (ratio 1:10) in order to evaluate the proliferation rate and the release of 
suppressive cytokine, such as (G) IL-10 (* p<0.05, ** p<0.01, Student’s t-test). Data are 
mean ± SEM, n=6 mice in each group. Experiments were performed in two different 
experimental days. 
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Figure 3.14. Stimulation of lung-derived B cells with S1P increased CD20 expression at 
later time points (14 days). Expression of CD20 after in vitro stimulation with S1P (0.1-1 
μM) of lung-derived B cells obtained from both vehicle- and S1P-treated mice at (A) 3, 
(B) 7, and (C) 14 days (* p<0.05, *** p<0.001, Student’s t-test). S1P treatment in vivo 
increased lung (D) CD19+B220+IgA+ cells, but not (E) CD19+B220+IgG2a+ and (F) 
CD19+B220+IgM+ cells (** p<0.01, Student’s t-test). Data are mean ± SEM, n=6 mice in 
each group. Experiments were performed in two different experimental days. 
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Depletion of CD20+ B cells increases S1P-induced airway hyperresponsiveness and 
inflammation 
Our previous results showed that the exposure of mice to S1P increased the 
surface expression of CD20 on B cells at 14 days (Figure 3.14C). Since CD20 is a 
marker for mature B cells440, we wanted to understand the role of these cells in 
our experimental protocol. Mice were treated with a specific anti-CD20 mAb prior 
S1P or vehicle administration. Anti-CD20 mAb was injected every three days to 
deplete mature B cells419,440. The depletion of CD20+ B cells was approximately of 
90%, as already demonstrated419. The absence of CD20+ B cells increased S1P-
induced airway responsiveness to carbachol (Figure 3.15A), compared to anti-
CD20 mAb alone or vehicle-treated mice. In addition, PAS-stained lung 
cryosections showed that the depletion of CD20+ B cells further increased lung 
inflammation in S1P-treated mice compared to S1P alone and vehicle. Indeed, the 
number of goblet cells was significantly increased in S1P-treated mice depleted of 
CD20+ B cells compared to mice solely treated with S1P (Figure 3.15B). The 
injection of isotype control IgG or anti-CD20 mAb alone did not alter lung 
morphology (Figure 3.15B), as already published419. Importantly, the presence of 
Treg was significantly reduced at all time-points (from 3 up to 14 days) in the lung 
of anti-CD20 mAb+S1P-treated compared to S1P-treated mice (Figure 3.15C). To 
confirm the absence of Treg, we tested the levels of IL-10 and TGF-β. Again, the 
antibody-mediated depletion of CD20+ B cells reduced both IL-10 (Figure 3.15D) 
and TGF-β (Figure 3.15E) in the lung of S1P-treated mice. 
Taken altogether, these results imply that B cells counteract S1P-mediated airway 
hyperresponsiveness and inflammation via the induction of an 
immunosuppressive environment with the attempt to affect asthma-like 
outcomes. 
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Figure 3.15. Depletion of CD20+ B cells increases S1P-induced lung airway 
inflammation. BALB/c mice were s.c treated with S1P (10 ng/mouse) at day 0 and day 7. 
Another group of mice was treated i.p. with anti-CD20 mAb (250 μg/mouse) to deplete 
CD20+ B cells at day 0, 3, 7, 10, and 14, or with isotype control Ab (rat IgG) or isotype 
control Ab+S1P. The anti-CD20 mAb was injected the same day, but 30 minutes before 
the s.c. injection of S1P or vehicle. (A) Bronchi of anti-CD20+S1P-treated mice showed 
higher reactivity to cumulative administration of carbachol (10-9-3×10-6 M), expressed as 
contraction ability (dine/mg), compared to S1P-, anti-CD20-, or vehicle-treated mice (* 
p<0.05, ** p<0.01, two-way ANOVA with Bonferroni’s post-test). (B) Upper panels: 
representative pictures of PAS-stained lung cryosections. Lower panel: goblet cell (PAS+ 
cells) quantitation per square millimeter of the bronchial basement membrane (* 
p<0.05, *** p<0.001, Student’s t-test). (C) Lower influx of CD4+CD25+FoxP3+ T cells in 
the lung of anti-CD20+S1P-treated mice compared to S1P-treated mice (*** p<0.001, 
Student’s t-test). Lung homogenates were tested for (D) IL-10 and (E) TGF-β (* p<0.05, 
*** p<0.001, Student’s t-test). Data are mean ± SEM, n=6 mice in each group. 
Experiments were performed in two different experimental days. 
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Assessment of a new pepducin-derived S1P3 antagonist in vitro 
As an endogenous metabolite, S1P acts as a full agonist on all the S1P1-5 receptors. 
The study of the role of these receptors is limited by the reduced availability of 
specific receptor agonists or antagonists. In this context our interest has been 
focused on S1P3 becasue of its main involvement in airway diseases. 
The well-described pepducin KRX-725 (Compound 1), derived from the second 
intracellular loop of S1P3 receptor, mimics the effect of S1P, triggering specifically 
the S1P3 receptor. In our experimental design, the effectiveness of the peptide to 
modulate the S1P3 receptor activation was assessed by determining its ability to 
affect vascular tone. First, we have characterised the Compound 1-induced 
vasorelaxation. S1P3 induces Gi-dependent ERK activation and a nitric oxide-
mediated relaxation. In order to assess the ability of Compound 1 to induce a 
vasorelaxation with a similar mechanism of signalling transduction, we tested the 
ability of ʟ-NAME (100 μM), a NOS inhibitor, or FR180204 (10 μM), an ERK 
inhibitor, to affect the Compound 1-induced effect on vascular tone. As shown in 
Figure 3.16A, both ʟ-NAME and FR180204 significantly inhibited the Compound 1-
induced vasorelaxation. These data confirmed that, also in our experimental 
conditions, Compound 1 activated the same signalling pathway, although 
triggering S1P3 intracellularly. 
Starting from the native pepducin, the group of Professors V. Santagada and G. 
Caliendo has performed an Ala-scan on KRX-725 to identify new compounds that 
could act as antagonists (Figure 3.16B). Unfortunately, none of these showed such 
activities (data not shown). Despite of these findings, a collection of deleted 
peptides from both the C- and N-terminus of KRX-725 (Figure 3.16C) had more 
promising properties. In particular, the Compound 16 showed S1P3-antagonist 
properties: incubation of increasing concentrations of Compound 16 (1, 10, and 
100 μM) on PE-precontracted aortic rings harvested from naïve mouse and 
relaxed with KRX-725 (10-7-3×10-5 M) showed that Compound 16 reduced in a 
concentration-dependent manner the vasorelaxation provoked by the native 
pepducin (Figure 3.16D). 
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Compound Peptide sequence
1 myristoyl-Gly-Met-Arg-Pro-Tyr-Asp-Ala-Asn-Lys-Arg-NH2
2 myristoyl-Ala-Met-Arg-Pro-Tyr-Asp-Ala-Asn-Lys-Arg-NH2
3 myristoyl-Gly-Ala-Arg-Pro-Tyr-Asp-Ala-Asn-Lys-Arg-NH2
4 myristoyl-Gly-Met-Ala-Pro-Tyr-Asp-Ala-Asn-Lys-Arg-NH2
5 myristoyl-Gly-Met-Arg-Ala-Tyr-Asp-Ala-Asn-Lys-Arg-NH2
6 myristoyl-Gly-Met-Arg-Pro-Ala-Asp-Ala-Asn-Lys-Arg-NH2
7 myristoyl-Gly-Met-Arg-Pro-Tyr-Ala-Ala-Asn-Lys-Arg-NH2
8 myristoyl-Gly-Met-Arg-Pro-Tyr-Asp-Ala-Ala-Lys-Arg-NH2
9 myristoyl-Gly-Met-Arg-Pro-Tyr-Asp-Ala-Asn-Ala-Arg-NH2
10 myristoyl-Gly-Met-Arg-Pro-Tyr-Asp-Ala-Asn-Lys-Ala-NH2
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Figure 3.16. Assessment of a newly-synthesised pepducin acting as a S1P3 antagonist. 
(A) Compound 1-induced vasorelaxation on PE-precontracted aortic rings and 
vasorelaxation inhibitory effects of ʟ-NAME (100 μM) and FR180204 (10 μM) (*** 
p<0.001 vs. vehicle, two-way ANOVA with Bonferroni’s post-test, n=6 mice in each 
group). (B) Chemical structure of Compound 1 (KRX-725) and its Ala-scan derivatives. 
(C) Chemical structure of Compound 1 and its deleted derivatives. (D) Compound 16 
reduces Compound 1-induced vasorelaxation in a concentration-dependent manner (** 
p<0.01, *** p<0.001, two-way ANOVA with Bonferroni’s post-test, n=3 mice in each 
group). Data are mean ± SEM. 
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3.1.5 SUMMARY 
 
Roviezzo et al. have previously showed that in vivo inhibition of SphK, the ezyme 
responsible of phosphorylation of the sphingosine, reduced bronchial contractility 
in allergen-sensitised mice294. They went further and demonstrated that systemic 
administration of S1P in laboratory animals induced asthma-like features 
characterised by bronchial hyperreactivity, lung inflammation, and airway 
remodelling427; in this study, we have extensively cleared the cellular mechanisms 
responsible for S1P-mediated effects in laboratory animals. These morphological 
and functional alterations were associated with an increase in levels of PGD2 and 
IgE as well as IL-4 and IL-13. 
It is now accepted that both IgE and mast cells are key factors in establishing 
pathophysiological changes on airways in chronic asthma condition. Such effects 
include IgE-dependent regulation of mast cells, mast cell-independent IgE-
mediated actions and mast cell activities that do not directly involve IgE. In order 
to assess the role of mast cells in our experimental conditions, we explored the 
effects of administration of S1P in vivo to mast cell-deficient KitW-sh/W-sh mice. Such 
animals did not show bronchial hyperreactivity after treatment with the 
sphigolipid; however, they were still characterised by lung inflammation, high IgE 
levels, and mucus hyperproduction. Thus, the absence of mast cells does not 
affect IgE levels suggesting an alternative target for IgE in our model. 
CD23 is the “low-affinity” receptor for IgE (FcεRII). It has been implicated in a 
number of inflammatory conditions and is considered important in the regulation 
of IgE production. An altered expression of CD23 has been widely associated with 
allergic diseases429,430,441. Based on these observations, we found that CD23 was 
highly expressed in lung of S1P-treated mice compared to vehicle. In order to 
define the role of CD23, we treated mice with a neutralizing antibody (B3B4 
clone), extensively characterised for its high affinity for CD23 and for a reciprocal 
inhibitory pattern with IgE. Indeed, treatment of mice with both anti-CD23 and 
S1P reduced airway smooth muscle hyperresponsiveness, pulmonary hyperplasia, 
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and IL-13 and IgE levels, but pulmonary mast cell infiltration and IL-4 levels were 
not altered. Therefore, these data, taken together with previous evidence, imply 
that S1P/CD23 signalling is not directly involved in mast cell recruitment, but 
rather interferes with their activation, as suggested by the marked reduction in 
production of IgE. This hypothesis is also supported by the observation of reduced 
levels of IL-13 after anti-CD23 treatment. Similarly, we did not observe any change 
in IL-4 release after the treatment with anti-CD23, suggesting a predominant Th2 
bias in S1P-induced asthma-like model in mice. 
In order to look deeply into the cellular mechanisms, our attention focused on T 
cells. Effects of S1P on nude mice, which genetically lack of the adaptive immune 
system, were studied. Our results showed that T cells were crucial in fully 
explaining the effects elicited by S1P in our model, since nude mice injected with 
S1P did not exhibit airway hyperreactivity, mast cell infiltration, and IgE 
production; furthermore, IL-4, IL13, and CD23 were not induced by S1P. 
The idea that all these events are T cell-dependent is further sustained by the 
finding that the CD4+ T lymphocytes, harvested from BALBC/c mice exposed to 
S1P, showed an increased ability to proliferate in vitro. To note, CD4+ T cells 
harvested from S1P-treated mice were able to proliferate even in the absence of 
the in vitro stimulation with CD3/CD28 beads. However, the proliferation rate of 
CD4+ T-cells, obtained from mice pretreated in vivo with the anti-CD23 before S1P 
administration, was not altered. This indicates that the major action of CD23 in 
vivo is to negatively regulate IgE production without a significant effect on T cell 
growth or differentiation. These data fit well with the lack of effect of anti-CD23 in 
regulating IL-4 release, mainly involved in a Th2 skew in the lung of S1P-treated 
mice, together with IL-13, IgE, and PGD2442. That these mechanisms triggered by 
S1P require this in vivo cellular activation is strongly supported by the finding that 
CD4+ T cells, harvested from vehicle-treated mice, were not able to proliferate 
when exposed in vitro to S1P. These latter events occur in an IgE-independent 
manner. 
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The final results confirming S1P could induce a modulation of the adaptive 
immune system came from the adoptive transfer experiments. S1P-derived CD4+ 
T cells adoptively transferred into naïve mice increased mast cell infiltration, 
bronchial reactivity pulmonary inflammation, and IL-4 and IL-13 release. As 
expected, adoptive transfer of CD4+ T cells derived from S1P-treated mice 
receiving anti-CD23 into naïve mice did not promote any effect on the lung. In 
particular, we did not observe any increase in airway smooth muscle reactivity or 
an inflammatory response. Conversely, IL-4 overexpression was still present. These 
data, together with the studies performed in mast cell knockout and nude mice, 
confirm that CD4+ T-cells are the main cells involved in S1P-induced effects. In 
addition, this implies an obligatory role for CD23/IgE signalling to trigger IgE-
mediated immune responses in order to observe functional changes in the lung. 
However, the role of innate immune cells in this context still remains to be 
elucidated. 
 
We then explored the role of B cells in our experimental model. We found that B 
cells counteract S1P-induced allergic inflammation in the lung. 
Similarly to OVA-sensitised mice, the presence of B cells was strictly correlated to 
the recruitment of Treg and to the higher release of IL-10 and TGF-β, well-known 
immuno-suppressive cytokines, in S1P-treated mice compared to the controls. In 
animal models of allergic airway disease, Treg can suppress established airway 
inflammation and airway hyperresponsiveness443. Existing therapies including 
corticosteroids and allergen immunotherapy act on Treg, in part to increase IL-10 
production, while vitamin D3 and long-acting β-agonists enhance IL-10 Treg 
function444. 
Importantly, the inhibition of SphK1/2 reduced B cell recruitment and IL-13 release 
in OVA-sensitised mice, implying that the endogenous presence of S1P can 
participate to the inflammatory patterns observed during the allergic 
inflammation427. 
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The involvement of S1P signalling in B cell migration was already observed for 
marginal zone B cells that require S1P1 receptor activity to egress into the bone 
marrow vascular compartment and into the peripheral blood445. Our study, 
instead, is the first to our knowledge to demonstrate that B cells migrate to the 
inflamed lungs of S1P-treated mice. Additionally, the co-presence of Treg with B 
cells is at the basis of an immuno-suppressive environment characterised by IL-10 
and TGF-β446. It is well-known that during asthmatic conditions, Th2 cells and Treg 
are present in an oscillatory mode in that Treg presence tries to dampen Th2-
derived harmful signals444,447,448,449. In this scenario, B cells, important for the 
humoral immune responses, behave as IL-10-producing B regulatory (B reg) 
cells419,446 and, more importantly, they induce CD4+ and CD8+ T cells to a 
suppressive phenotype associated to the release of suppressive cytokines such as 
TGF-β and IL-10. Upon recognition of specific antigens, B cells can present 
antigen(s), interact with T cells, and differentiate into plasma cells419,440,446. 
However, upon specific allergic conditions, B cells can behave as Breg and 
negatively regulate inflammation and immune responses through IL-10419. The 
stimulation of B cells with S1P increased the levels of IL-10 and TNF-α. The release 
of TNF-α in vitro by S1P-stimulated B cells is in line with the observation that this 
cytokine is overproduced in asthmatic patients and is a potent activator of 
SphK1/2 and subsequent production of S1P450. Indeed, SphK1 activation is 
observed in many cell types relevant to allergic disorders and occurs principally in 
response to inflammatory cytokines, such as TNF-α and IL-1β450. IL-10 is a potent 
immune-modulator and it can inhibit Th1 polarization and also dampen 
proinflammatory activities of Th2 cells451. IL-10-producing B cells have been shown 
to down-regulate inflammation in airway hyperresponsiveness. Regulatory B cells 
were reported to be protective against allergic airway inflammation, especially 
when they express high levels of CD23 and IL-10452. In our mouse model, lung B 
cells also expressed high levels of CD23 after the administration of S1P at all time-
points examined (data not shown). The suppressive activity of Breg underlies the 
recruitment of Treg to the lungs, which mediate the suppression of lung 
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inflammation in an IL-10-dependent manner452. Indeed, we observed that the 
suppressive B cells obtained from the lung of S1P-treated mice were able to both 
induce Treg activity and to promote CD8+ T cells to release IL-10, further 
suggesting the role of regulatory B cells on the adaptive immunity after S1P 
treatment in mice. In support to our data, FTY720, a pro-S1P-mimetic, proved of 
successful activities against multiple sclerosis as an immunomodulator once in its 
phosphorylated form, mimicking S1P453. Moreover, we observed that B cells 
isolated from the lung of S1P-, but not vehicle-treated mice, were able to release 
high levels of granzyme B and IL-13. This effect was not a direct activity of S1P on B 
cells but most probably dependent on the environment these cells encountered. 
Granzyme B is a cytotoxic mediator. B cells were also reported to behave as 
cytotoxic cells and the release of granzyme B may underlie their activity to 
modulate T cells419. In addition, granzyme B was also reported to be functionally 
important for Treg proliferation, further supporting our data on the role of 
Breg/Treg in countering S1P-mediated airway allergic inflammation. The activation 
of B cells has also been described as a mean to induce B cell maturation in plasma 
cells454. Indeed, our in vitro and in vivo experiments showed that the 
administration of S1P increased the expression of CD20 on B cells. CD20 is a 
maturation marker for B cells, which are programmed to produce 
immunoglobulins as plasma cells419. The depletion of the mature CD20+ B cells 
increased airway reactivity and lung inflammation, implying the relevance of the 
immunomodulator activity of Ig-producing B cells. This effect was associated to 
the lower presence of Treg, IL-10, and TGF-β. 
 
The sphingolipid S1P exerts its effects by activating five G protein-coupled 
membrane receptors, namely S1P1-5. S1P, as an endogenous mediator, is a full 
agonist and unspecifically activates its receptors. In particular, activation of S1P3 is 
associated with a pro-angiogenic455 and pro-tumorigenic role456,457. It is now clear 
that the S1P3 receptor is one of the most expressed receptor along the airways 
among S1P receptors. Many works have established that blocking S1P3 could have 
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beneficial effects in animal models of lung injury in terms of controlling and 
pulmonary inflammation458 and reducing airway hyperreactivity459. It is evident 
that the possibility of designing S1P3-specific antagonists could be helpful in 
therapy, but at the moment no specific molecule exists. Furthermore, full S1P3 
agonists have been synthesised neither. 
Our collaboration with the chemistry research group of Professors G. Caliendo and 
V. Santagada (Department of Pharmacy, University of Naples, Italy) cleared the 
way in further advancing the research in this field, pointing out the ability of 
pepducin-derived compound to act as a S1P3 antagonist. However, further 
chemical studies are underway to optimise selective S1P3 receptor antagonists; 
anyway, the unique biological properties of Compound 16 make it a useful and 
handle pharmacological tool for the study of S1P signalling involving the S1P3 
receptor. 
 
 
3.1.6 CONCLUSIONS 
 
In conclusion, systemic administration of S1P triggers a cascade of events that 
sequentially involves T cells, IgE, and mast cells, which leads to the asthma-like 
symptoms in mice. In this context, B cells have protective activities in S1P-induced 
allergic inflammation because they behave as Breg that highly release IL-10. The 
association of Breg to Treg represents a potential cellular mechanism by means 
the host tries to dampen S1P-mediated proinflammatory/allergic patterns. 
 
 
3.1.7 LIMITATIONS 
 
Although we have extensively studied the molecular and cellular mechanisms in 
the S1P model, the results are related to mice. Thus, clinical translational studies 
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to human beings affected by allergic asthma is recommended in order to evaluate 
possible affinities/differences in the activation of the immune system. 
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3.2 STUDY OF H2S EFFECTS IN ANTIGEN-INDUCED AIRWAY 
HYPERRESPONSIVENESS: ROLE OF MAST CELLS 
 
3.2.1 RATIONALE 
 
The precise role and the importance of H2S in lung pathophysiology is still a matter 
of debate. The controversial effects of this gaseous transmitter are far from being 
delucidated. Here, we have further investigated the influence of H2S on lung 
function in a well-established model of allergic asthma. 
In particular, the administration of H2S in vivo was carried out by means of an 
aerosolizing apparatus, in order to exactly mirror the empiric findings that thermal 
waters rich in sulphurs relieve the symptoms of asthma and upper respiratory 
tract conditions. 
 
Thus, in this chapter, we have addressed the following hypothesis and specific 
aims: 
 
Hypothesis: 
“The gaseous mediator H2S can affect lung function” 
 
Aims: 
- to investigate the effects of H2S inhalation in a mouse model of allergic 
asthma; 
- to determine the role of mast cells; 
- to establish an involvement of remodelling processes assessing fibroblast 
activity. 
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3.2.2 METHODS 
 
The methods relating to experiments performed in this section are described in 
the Chapter 2 (Materials and methods). 
 
 
3.2.3 DATA HANDLING AND STATISTICAL ANALYSIS 
 
The statistical analysis relating to experiments performed in this section are 
described in the Chapter 2 (Materials and methods). The details of each statistical 
test used are reported in the respective figure legends. 
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3.2.4 RESULTS 
 
Aerosol administration of hydrogen sulphide abolishes OVA-induced airway 
hyperreactivity 
The effect of hydrogen sulphide aerosol administration on allergen-induced airway 
hyperreactivity was tested using the protocol described in Figure 3.17A. 
We have assessed both bronchial reactivity (Figure 3.17B) and lung resistance 
(Figure 3.17C), after carbachol challenge. Bronchi harvested from OVA-treated 
mice showed an increased reactivity to carbachol in comparison to vehicle-treated 
mice (Figure 3.17B). Conversely, hyperreactivity to carbachol was reverted in 
bronchi harvested from mice treated in vivo with hydrogen sulphide aerosol 
(Figure 3.17B). Similarly, hydrogen sulphide brought back to control level the lung 
resistance in OVA-treated mice (Figure 3.17C). Hydrogen sulphide inhalation did 
not alter OVA-induced hyperplasia (Figure 3.17D), as evaluated by PAS staining 
since mucus production was still visible in pulmonary histology (Figure 3.17E). 
Administration of hydrogen sulphide to control mice had no effects on the 
parameters analysed (data not shown). 
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Figure 3.17. Administration of hydrogen sulphide aerosol abrogates OVA-induced 
airway hyperreactivity. (A) Schematic representation of the protocol used. Mice 
received subcutaneous administration of OVA (100 µg) adsorbed onto alum at day 0 
and 7. Aerosol administration of vehicle or hydrogen sulphide (NaHS, 100 ppm) was 
performed daily from day 7 to day 21. Twenty-four hours after the last administration 
mice were sacrificed. (B) Measurement of bronchial reactivity to carbachol in organ 
bath (*** p<0.001 vs. control, two-way ANOVA with Bonferroni’s post-test). (C) 
Measurement of lung resistance by using isolated perfused lung preparation (*** 
p<0.001 vs. control, two-way ANOVA with Bonferroni’s post-test). (D) Histological 
analysis of pulmonary sections (H&E staining). (E) Goblet cell hyperplasia evaluation 
by PAS staining (** p<0.01 vs. control, one way ANOVA with Bonferroni’s post-test). 
Lung sections have been photographed under light microscopy at 10× magnification. 
Data are mean ± SEM, n=6 mice in each group. 
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Hydrogen sulphide reduces mast cell activation and FGF2 and IL-13 production 
Flow cytometry analysis of lungs harvested from OVA-sensitised mice 
demonstrated a significant increase of mast cell recruitment (Figure 3.18A). 
Treatment of mice with aerosol administration of hydrogen sulphide did not affect 
OVA-induced mast cell infiltration (Figure 3.18A). Conversely, NaHS administration 
significantly prevented mast cell degranulation (Figure 3.18C). Sensitization caused 
also a significant increase in IgE plasma levels (Figure 3.18B) that was not modified 
by hydrogen sulphide. Finally, hydrogen sulphide reverted the OVA-induced up-
regulation of two important fibrogenic cytokines in the lung such as IL-13 (Figure 
3.18D) and FGF2 (Figure 3.18E). Administration of hydrogen sulphide to control 
mice had no effects on the parameters analysed (data not shown). 
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Figure 3.18. Hydrogen sulphide inhibits mast cells infiltration and cytokines 
expression in the lung. (A) Quantification of lung mast cells (** p<0.01 vs. control, 
one-way Bonferroni’s post-test). (B) Sera IgE levels were determined by using specific 
ELISA (* p<0.05 vs. control, one-way ANOVA with Bonferroni’s post-test). (C) Toluidine 
positive staining of lung cryosections. (D) IL-13 concentrations in whole lung 
homogenates have been determined by ELISA (* p<0.05, ** p<0.01, one-way ANOVA 
with Bonferroni’s post-test). (E) Immunohistochemistry of FGF2 expression in lungs (* 
p<0.05 vs. control, one-way ANOVA with Bonferroni’s post-test). Data are mean ± 
SEM, n=6 mice in each group. 
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Hydrogen sulphide reduces the development of mast cell-dependent airway 
hyperreactivity 
The development of airway hyperreactivity can be either mast cell-dependent or -
independent in mouse models of asthma and it is widely suggested that the 
former is due to a sensitization without and the latter with adjuvant460. In order to 
further address the role of mast cells, we treated mice with OVA without alum 
using the protocol reported in Figure 3.19A. This is a chronic allergic asthma model 
mainly mast cell-dependent460. Bronchi harvested from these mice displayed 
bronchial hyperreactivity to carbachol (Figure 3.19B) that was abrogated by 
hydrogen sulphide aerosol (Figure 3.19B). PAS staining evidenced a weak increase 
of goblet cells, suggesting a marginal role of mast cells in the regulation of mucus 
production (Figure 3.19C). Finally hydrogen sulphide did not affect pulmonary 
metaplasia (Figure 3.19D). Administration of NaHS to vehicle-treated mice had no 
effects on the parameters analysed (data not shown). 
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Figure 3.19. Hydrogen sulphide abrogates OVA-induced mast cell-dependent 
hyperreactivity. (A) Schematic representation of the protocol used. Mice received 
subcutaneous administration of OVA (50 µg) without alum at day 0, 2, 4, and 7. Mice 
were treated with either vehicle or NaHS aerosol daily from day 7 to day 21. Twenty-
four hours after the last administration mice were sacrificed. (B) Measurement of 
bronchial reactivity to carbachol in organ bath (*** p<0.001 vs. vehicle, two-way 
ANOVA with Bonferroni’s post-test). (C) Quantification of lung mast cells (* p<0.05 vs. 
vehicle, one-way ANOVA with Bonferroni’s post-test). (D) Goblet cell hyperplasia 
evaluation by PAS staining. Lung sections have been photographed under light 
microscopy at 10× magnification. (E) Histological analysis of pulmonary sections (H&E 
staining). (F) Toluidine positive staining of lung cryosections. Data are mean ± SEM, 
n=6 mice in each group. 
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Mast cell-deficient KitW-sh/W-sh mice fail to develop airway hyperesponsiveness 
The role of mast cells in the development of airway hyperreactivity has been 
investigated by using mast cell-deficient mice in different mouse asthma model. 
The lack of mast cells generally decreased the effect of carbachol both with and 
without allergen challenge compared to wild type. However, in mast cell-deficient 
KitW-sh/W-sh mice bronchial hyperresponsiveness could be induced changing the 
protocol of antigen challenge. Under the different experimental conditions 
employed, it is possible to observe different effects. In particular, frequent 
stimulation could induce airway hyperreactivity also in these mice. To validate the 
data obtained by using the model described in the above paragraph, we tested if 
our sensitization protocol could affect airway responsiveness in mast cell-deficient 
KitW-sh/W-sh mice. These mice exposed to OVA sensitization did not develop 
bronchial hyperreactivity to carbachol (Figure 3.20A). The mucus production was 
increased after OVA exposure (Figure 3.20B), even though sensitization failed to 
induce a significant increase of both IL-13 (Figure 3.20C) and FGF2 (Figure 3.20D) 
expression in lungs. Treatment of control mice with hydrogen sulphide did not 
cause any effect on all parameters considered (Figure 3.20B, 3.20C, and 3.20D). 
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Figure 3.20. Lack of effect of hydrogen sulphide in mast cell-deficient KitW-sh/W-sh mice. 
(A) KitW-sh/W-sh mice received subcutaneous administration of OVA (100 µg) adsorbed 
onto alum at day 0 and 7. Mice were treated with either vehicle or hydrogen sulphide 
aerosol daily from day 7 to day 21. Twenty-four hours after the last administration mice 
were sacrificed. Bronchial reactivity to carbachol was assessed. For this protocol, see 
Figure 17A. (B) Goblet cell hyperplasia evaluation by PAS staining. Lung sections have 
been photographed under light microscopy at 10× magnification (* p<0.05 vs. vehicle, 
one-way ANOVA with Bonferroni’s post-test). (C) Whole lung homogenates IL-13 
concentrations, determined by ELISA. (D) Immunohistochemistry of FGF2 expression in 
lungs. Data are mean ± SEM, n=6 mice in each group. 
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Hydrogen sulphide aerosol reduces fibroblast activation: ex vivo study 
Lung mast cells are found in close proximity to fibroblasts and the number of the 
cells is increased in asthma. Since mast cell-fibroblast interactions contribute to 
increased contractile response in airways, we evaluated the effect of H2S on 
fibroblasts activation in vivo. We isolated primary fibroblasts from mice exposed 
to OVA and tested their proliferation rate and differentiation. Our data show that 
primary fibroblasts harvested from sensitised mice displayed an increased 
proliferation rate (Figure 3.21A) as well as increased expression of α-SMA (Figure 
3.21B and 3.21C). In fibroblasts harvested from mice treated with hydrogen 
sulphide aerosol both the increased proliferation rate and differentiation were 
reverted (Figure 3.21A, 3.21B, and 3.21C). Thus, mice exposed to hydrogen 
sulphide inhalation displayed a significant reduction of fibroblast activation 
beyond reduction of airway hyperreactivity. 
In order to further demonstrate that the fibroblasts contribute to mast cell-
dependent airway hyperreactivity, we evaluated fibroblast activation also in the 
model of mast cell-dependent hyperreactivity using the protocol described in 
Figure 3.19A. Our data show that primary fibroblasts harvested from these mice 
displayed an increased rate of proliferation (Figure 3.22A) as well as an increased 
expression of α-SMA (Figure 3.22B and 3.22C). When mice were treated with 
aerosol of hydrogen sulphide, again both the increased fibroblast proliferation and 
differentiation measured ex vivo were prevented (Figure 3.22A, 3.22B, and 3.22C), 
as well as the airway hyperreactivity. 
Administration of hydrogen sulphide to control mice had no effects on the 
parameters analysed in any of the conditions tested (data not shown). 
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Figure 3.21. Hydrogen sulphide inhibits pulmonary fibroblasts proliferation and 
differentiation. (A) Lung primary fibroblasts were harvested from OVA+alum-
sensitised mice exposed to vehicle or NaHS aerosol. For the in vivo protocol, see 
Figure 17A. The MTT colorimetric assay was used to assess fibroblast proliferation in 
vitro (** p<0.01 vs. control, one-way ANOVA with Bonferroni’s post-test). (B) 
Percentage of myofibroblasts (* p<0.05 vs. control, one-way ANOVA with Bonferroni’s 
post-test). (C) Fibroblasts were labelled with anti-vimentin antibody (red). Nuclei were 
stained with DAPI (blue). Myofibroblast differentiation was determined by detection 
of expression of α-SMA (green). Lowest panels represent the merge of upper and 
central panels. The percentage of myofibroblasts are easily distinguishable since they 
display well-developed, thick and α-SMA-positive stress fibers. Images were taken at 
200× magnification. Data are mean ± SEM, n=3 mice in each group. 
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Figure 3.22. Hydrogen sulphide inhibits fibroblasts proliferation and differentiation 
in the asthma model mast cell-dependent. (A) Lung primary fibroblasts were 
harvested from mice sensitised with OVA without alum and exposed to vehicle or 
NaHS. For protocol, see figure 19A. Proliferation rate and differentiation of fibroblasts 
were evaluated. The MTT colorimetric assay was used to assess fibroblast 
proliferation in vitro (** p<0.01 vs. vehicle, one-way ANOVA with Bonferroni’s post-
test). (B) Percentage of myofibroblasts (* p<0.05 vs. vehicle, one-way ANOVA with 
Bonferroni’s post-test). (C) Fibroblasts were labelled with anti-vimentin antibody 
(red). Nuclei were stained with DAPI (blue). Myofibroblast differentiation was 
determined by detection of expression of α-SMA (green). Lowest panels represent the 
merge of upper and central panels. The percentage of myofibroblasts are easily 
distinguishable since they display well-developed, thick and α-SMA-positive stress 
fibers. Images were taken at 200× magnification. Data are mean ± SEM, n=3 mice in 
each group. 
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Hydrogen sulphide inhibits RBL-2H3 antigen-induced degranulation in vitro 
A direct effect of hydrogen sulphide on mast cell degranulation was investigated in 
vitro by using mast cell-like RBL-2H3 cell line. The addition of the antigen DNP-HSA 
to presensitised RBL-2H3 cells caused an evident degranulation, indicated by a 
massive release of β-hexosaminidase (about 50% of the total content of the 
enzyme; Figure 3.23A). An almost equivalent level of degranulation was induced 
by the non-antigenic stimuli thapsigargin and ionomycin (Figure 3.23A). Hydrogen 
sulphide caused a remarkable concentration-dependent inhibition of the RBL-2H3 
degranulation induced by DNP-HSA (Figure 3.23B). In contrast, hydrogen sulphide 
did not exhibit any significant inhibitory activity on the degranulation induced by 
both thapsigargin and ionomycin (Figure 3.23C). 
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Figure 3.23. Hydrogen sulphide reduces IgE-mediated RBL-H3 cells degranulation. (A) 
RBL-2H3 cell degranulation was pharmacologically induced by i) the antigen DNP-HSA 
(DNP; 10 ng/ml); ii) ionomycin (ION; 1 µM); and iii) thapsigargin (TPS; 1 µM). In 
matched wells, Triton X-100 was added to elicit cell lysis and exhaustive release of β-
hexosaminidase (** p<0.01 vs. vehicle, one-way ANOVA with Bonferroni’s post-test, 
n=9 in each group). (B) Cells were sensitised with DNP and then incubated for 5 
minutes with either the H2S donor NaHS (10, 100, and 1000 μM) or the vehicle. Cell 
degranulation was induced by DNP (*** p<0.001 vs. vehicle, one-way ANOVA with 
Bonferroni’s post-test, n=3 in each group). (C) Cells were incubated with either NaHS 
(1 mM) or vehicle for 5 minutes and cell degranulation induced by ION or TPS (n=6 in 
each group). Data are mean ± SEM. 
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3.2.5 SUMMARY 
 
Once confirmed the role of S1P and its mechanisms in inducing an asthma-like 
condition in mouse, we then investigated the effects of protective mediator in the 
pulmonary district in a well-described and recognised animal model of allergic 
asthma induced by OVA. Intraperitoneal treatment with H2S have already been 
proved to be effective in reducing the OVA-induced effects in animals461 and the 
administration of inhibitors of the enzymes deputed to its synthesis even 
worsened the symptoms384. Here, we evaluated the effect of an administration of 
H2S through aerosol. H2S, given as NaHS, reversed the OVA-induced bronchial 
hyperreactivity to carbachol and total lung resistance. Conversely, H2S did not 
affect either cell infiltration or mucus hypersecretion as determined by histological 
analysis of lungs. Since goblet cell metaplasia and mucus hypersecretion are two 
parameters indicative of lung inflammation462,463, these data imply that hydrogen 
sulphide regulatory action is not strictly dependent upon reduction of the 
inflammatory response in our experimental conditions. 
Airway hyperresponsiveness is an important pathophysiological characteristic of 
asthma. It is linked to both inflammation and remodelling of the airways and is 
partially reversible with therapy. The mouse model used mimics the prominent 
features of allergic asthma associated with airway hyperreactivity such as the 
infiltration of mast cells into the airway smooth muscle layer and the increase in 
plasmatic levels of IgE460,464. It is now accepted that both IgE and mast cells are key 
factors in establishing pathophysiological changes on airways in chronic asthma 
condition, but the mechanisms by which H2S affects bronchial tone are not fully 
understood and not deeply explored yet. Aerosol administration of hydrogen 
sulphide prevented mast cell activation but did not modify IgE plasma levels. 
These data suggest that aerosol administration of hydrogen sulphide, rather than 
modified systemic immunologic reactivity, had a local immunosuppressive role. 
Indeed, hydrogen sulphide aerosol prevented OVA-induced increase of IL-13 and 
FGF2 in the lung. 
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In order to further assess the role of mast cells, we tested the efficacy of hydrogen 
sulphide aerosol in a chronic allergic asthma model mainly mast cell-dependent460. 
Hydrogen sulphide abrogated airway hyperreactivity, without modulating either 
goblet cell metaplasia or mucus hypersecretion. To further validate these data, we 
performed the same protocol in mast cell-deficient mice. Bronchi harvested from 
these mice failed to develop an increased reactivity following OVA sensitization as 
well as IL-13 and FGF2 up-regulation. Aerosol administration of hydrogen sulphide 
did not further modify these parameters. On the other hand, in mast cell-deficient 
mice, OVA-induced goblet cell metaplasia and mucus hypersecretion were still 
present and were not affected by the hydrogen sulphide aerosol. Thus, our data 
indicate that mast cells are the main responsible of airway hyperreactivity. 
However, we still had to define how this effect is translated into a beneficial effect 
on bronchial hyperreactivity. Mast cells synthesise and secrete a large number of 
proinflammatory cytokines, which regulate both IgE synthesis and the 
development of inflammation, and several pro-fibrogenic cytokines. One possible 
explanation was suggested by the finding that aerosol of hydrogen sulphide 
prevented FGF2 and IL-13 up-regulation, that are known to be fibroblast 
activators. Indeed, these cytokines are known to activate lung fibroblasts in 
asthmatic patients as well as to be up-regulated by sensitization in experimental 
model of asthma465,466. In addition, there is increasing evidence for a strong 
correlation between sub-epithelial fibrosis and airway hyperreactivity as it has 
been demonstrated in human studies467,468. This is suggested by the increased 
number of fibroblasts/myofibroblasts found in the airways of asthmatic 
patients469,470. On the basis of this clinical evidence and our findings, we have 
investigated the possible role played by fibroblasts in hydrogen sulphide inhibitory 
effect on airway hyperreactivity. In order to address this issue, we used both 
models of OVA-sensitised mice with or without alum. Fibroblasts harvested from 
mice sensitised with either OVA plus alum or OVA without alum displayed an 
increased proliferation rate in vitro. Both treatments also caused a significant 
increase in the percentage of fibroblasts converted in myofibroblasts. Treatment 
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of mice with hydrogen sulphide aerosol inhibited both the increased fibroblast 
proliferation rate and their differentiation into myofibroblasts. Thus, aerosolised 
hydrogen sulphide attenuates airway hyperreactivity and causes a selective 
reduction of mast cell and fibroblast activation. These data suggest that the 
hydrogen sulphide might modulate mast cell-mediated fibroblast activation. This 
hypothesis is supported by the finding that, in mast cell-deficient mice, FGF2 and 
IL-13 up-regulation is not induced by OVA sensitization. In clinical studies, it has 
been shown that IL-13+ cells, present within the airway smooth muscle of 
asthmatic patients, are predominantly mast cells471. IL-13 has been shown to elicit 
many of the features of human asthma as well as to regulate production of several 
profibrogenic cytokines including FGF2472. Our data, taken together with this 
clinical evidence, suggest that hydrogen sulphide, by inhibiting mast cell 
activation, modulates fibroblast activation leading to an improvement of bronchial 
hyperreactivity. These data also imply that mast cells are responsible of the direct 
or indirect production of IL-13 in our experimental model and control FGF2 up-
regulation. This is of particular interest on the clinical side since recently it has 
been demonstrated that FGF2 levels in induced sputum significantly correlate with 
pulmonary function and have been proposed to be a possible biomarker of 
asthmatic airway remodelling473. In order to define if hydrogen sulphide can 
directly affect mast cell activation, we tested the effect of hydrogen sulphide on 
mast cell degranulation by using naïve or sensitised RBL-2H3 cells474. The data 
obtained showed a remarkable concentration-dependent inhibition of the RBL-
2H3 degranulation by hydrogen sulphide only in sensitised cells. Indeed, hydrogen 
sulphide did not exhibit any effect on the degranulation induced by different non-
specific stimuli such as thapsigargin and ionomycin. These results confirm that 
hydrogen sulphide, as it happens in vivo, displays an inhibitory action only once 
mast cells are activated. 
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3.2.6 CONCLUSIONS 
 
In conclusion, the treatment of sensitised mice with the aerosol of hydrogen 
sulphide improves lung and bronchial hyperreactivity to carbachol. Our data 
indicate that these effects are due to a modulation of mast cell and 
myofibroblast activation. These results suggest a possible explanation of the 
beneficial effects clinically obtained by the inhalation of sulfurous waters. Finally, 
the data obtained can propose that aerosol treatment with H2S-donors could be 
exploited as therapeutic complementary approach in lung diseases such asthma 
or COPD. 
 
 
3.2.7 LIMITATIONS 
 
Although empiric evidences already suggest that sulphurous thermal waters have 
beneficial properties in upper airway chronic diseases, the mechanism has not 
been investigated. In our model, we observed that the aerosolised H2S ameliorates 
hyperreactivity in an animal model via the inhibition of activation of mast cells and 
fibroblasts. Future traslational studies involving patients suffering from asthma 
and treated with H2S-releasing molecules is recommended in order to observe 
affinities/differences in the mechanism of action. 
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3.3 STUDY OF H2S IN MODELS OF PULMONARY 
HYPERTENSION 
 
3.3.1 RATIONALE 
 
In the previous chapter, we demonstrated that inhaled H2S could prevent the 
airway hyperreactivity associated with OVA sensitization. Since the effect of H2S 
appeared to be independent of inflammation, the observations are consistent 
with a direct effect on airway smooth muscle. This is in line with the well-
established finding that H2S is a direct bronchodilator. 
In the current chapter, we have extended our investigation into the role of H2S 
biology into models of PAH. PAH is a devastating respiratory condition that could 
rapidly lead to death if not treated. Furthermore, the pharmacological therapy is 
limited and is not addressed at re-establishing the physiological conditions in the 
vessels, but only aims at limiting the symptoms. Indeed, current drugs used to 
treat PAH do not cure the disease but merely leads to a very limited delay in 
ultimate death. 
In this part of the study, human and animal models of PH were considered. In 
particular, human models of PAH were established by means of in vitro 
experiments of cultured cells. As PAH affects the pulmonary vessels, only the most 
relevant vascular smooth muscle cell type to use is from pulmonary artery 
(PASMCs). Pulmonary artery endothelial cells were not used; instead, advantage 
was taken of a relatively new endothelial cell model where cells are grown out 
from progenitors in blood, the so-called “blood outgrowth endothelial cells” 
(BOECs). These were used because they can be easily obtained from living donors 
without the need for surgical specimens, allowing cells to be compared from 
healthy donors and from patients with PAH. 
 
Thus, in this chapter, we have addressed the following hypothesis and specific 
aims: 
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Hypothesis: 
“H2S has protective actions in experimental models of PAH” 
 
Aims: 
- to establish the effect of H2S on human pulmonary artery smooth muscle 
cell proliferation and inflammatory responses; 
- to investigate the effects of H2S on proliferation and inflammatory 
responses of endothelial cells grown from the blood of healthy donors and 
from patients with PAH; 
- to determine any combined effect of H2S and clinical drugs used to treat 
PAH on endothelial cell proliferation and inflammatory responses; 
- to investigate the effect of PAH on tissue levels of H2S in the hypoxic 
mouse model; 
- to investigate the effect of PAH on the vascular effects of H2S in pulmonary 
arteries from control and hypoxic mice; 
- to establish the effects of PAH in human patients on plasma levels of H2S 
measured using two established techniques. 
 
 
3.3.2 METHODS 
 
The methods relating to experiments performed in this section are described in 
the Chapter 2 (Materials and methods). 
 
 
3.3.3 DATA HANDLING AND STATISTICAL ANALYSIS 
 
The statistical analysis relating to experiments performed in this section are 
described in the Chapter 2 (Materials and methods). The details of each statistical 
test used are reported in the respective figure legends. 
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3.3.4 RESULTS 
 
H2S release from NaHS donor on in vitro experiments 
We measured the H2S release over time from the classical H2S-donor NaHS to 
assess its relevance to in vitro experiments. We aimed at performing a stability 
experiment that could effectively mirror the conditions used for the following 
experiments. In order to do this, 200 µl of NaHS solution (10, 100, and 1000 µM) 
dissolved in complete DMEM (with 10% FCS) were put in a 96-well plate, in 
absence or presence of cells (hPASMCs, 8,000 cells/well), and incubated in a 
humidified chamber at 37°C/5% CO2. Each condition was run in triplicate and H2S 
generated by NaHS were assessed by means of methylen blue assay. 
The results of our experiments proved that, in absence of cells, H2S released by a 
concentration of NaHS 1000 µM dramatically dropped about 90% after 1 hour of 
incubation and the amount of H2S is so low as to be irrelevant after 4 hours (Figure 
3.24). In presence of cells, H2S released instantly dropped about 15%, likely due to 
metabolic consequences, and after 1 hour an 88% loss was observed. As observed 
previously, after 4 hours the concentrations of H2S are irrelevant. H2S production 
by NaHS 100 µM, in presence and absence of cells, rapidly went down of about 
86% and 92%, respectively, after 1 hour of incubation. NaHS 10 µM generated 
undetectable concentrations of H2S already after 1 hour and still were so after 4 
hours. 
We did not try lower concentration because of the detection limit of the assay (1-2 
µM). 
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Figure 3.24. Stability of NaHS in medium. Production of H2S from different 
concentrations of the H2S-donor NaHS (10, 100, and 1000 μM) was tested, in absence 
and presence of cells (hPASMCs), at different time points (0, 1, and 4 h) by means of 
MB assay. Data are mean ± SEM, n=4 in each group. 
RESULTS 
 
127 
Effect of NaHS on IP10 release from hPASMCs and BOECs 
The research group in which I completed the last part of my doctorate project had 
previously showed that IFN-α-primed hPASMCs released increased levels of 
IP10187, as shown in Figure 3.25A. Here, we demonstrated that NaHS was able to 
significantly reduce IFN-α-induced IP10 release from hPASMCs in a concentration-
dependent manner (Figure 3.25B). Although TNF-α co-administration accentuated 
IFN-induced responses, it is not an absolute prerequisite for IFN sensing in some 
cells. Nevertheless, NaHS showed only a slight and not significant inhibition of IP10 
release after a combination of IFN-α and TNF-α, likely due to the synergistic effect 
of the substances422 (data not shown). 
As already demonstrated187, BOECs cultured from blood of patients affected by 
PAH were more sensitive to IFN-α compared to healthy BOECs in releasing IP10 
(Figure 3.25C). Similarly, NaHS was able to reduce IP10 production also in BOECs 
and this effect was even more marked for iPAH rather than healthy (Figure 3.25D). 
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Figure 3.25. NaHS decreases IP10 levels released from hPASMCs and BOECs. (A) IP10 
release from vehicle- and IFN-α-stimulated hPASMCs (*** p<0.001 vs. control, 
Student’s t-test). (B) Decrease of IP10 release from hPASMCs stimulated with IFN-α 
(10 ng/ml) and treated with increasing concentrations of NaHS (10-5-10-3 M) (*** 
p<0.001 vs. control). (C) IP10 release from vehicle- and IFN-α-stimulated BOECs (from 
PAH patients and healthy individuals) (* p<0.05 IFN-α vs. control, Student’s t-test). (D) 
Decrease of IP10 release from BOECs (from PAH patients and healthy individuals) 
stimulated with IFN-α (10 ng/ml) and treated with increasing concentrations of NaHS 
(10-5-10-3 M) (# p<0.05 PAH vs. healthy, two-way ANOVA with Bonferroni’s post-test). 
Data are mean ± SEM, n=4 in each group. 
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Effect of NaHS on IL-8 release from hPASMCs and BOECs 
We then looked at the effect of NaHS on a more general inflammatory cytokine, 
namely IL-8. We stimulated both hPASMCs and BOECs (healthy and PH) with TNF-
α (Figure 3.26A and 3.26C), as IFN-α does not promote IL-8 production. NaHS was 
able to reduce IL-8 release from hPASMCs (Figure 3.26B), even though this effect 
was less pronounced when compared to that seen on IP10; on BOECs, NaHS 
showed any effect on the production of the cytokine neither in healthy cells nor in 
PAH-affected cells (Figure 3.26D). 
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Figure 3.26. Effect of NaHS on IL-8 release from hPASMCs and BOECs. (A) IL-8 
release from vehicle- and TNF-α-stimulated hPASMCs (*** p<0.001, Student’s t-test, 
n=5 in each group). (B) Decrease of IL-8 release from hPASMCs stimulated with TFN-
α (10 ng/ml) and treated with increasing concentrations of NaHS (10-5-10-3 M) (** 
p<0.01 vs. control, n=5 in each group). (C) IL-8 release from vehicle- and TNF-α-
stimulated BOECs (from PAH patients and healthy individuals) (n=3 in each group). 
(D) No effect is observed on IL-8 release from BOECs (from PAH patients and healthy 
individuals) stimulated with TNF-α (10 ng/ml) and treated with increasing 
concentrations of NaHS (10-5-10-3 M) (n=5 in each group). Data are mean ± SEM. 
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Effect of NaHS on viability of hPASMCs and BOECs 
Others have shown that NaHS was able to reduce proliferation rate in both human 
and animal smooth muscle cells both in vivo409,410 and in vitro414. This is relevant to 
PH since the disease is characterised by hyperplasia of the inner cell layers of the 
vessels. However, under our experimental conditions tested, neither the 
stimulating agents nor the NaHS affected the viability of cells (Figure 3.27A, 3.27B, 
and 3.27C). 
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Figure 3.27. NaHS does not affect proliferation rate of hPASMCs and BOECs. 
Representative graphs of cell viability. (A) No effect has been observed on 
proliferation rate of hPASMCs not-stimulated or stimulated with IFN-α (10 ng/ml) or 
TNF-α (10 ng/ml) and treated with increasing concentrations of NaHS (10-1000 μM). 
(B) No effect has been observed on proliferation rate of BOECs (isolated from PAH-
affected patients) not stimulated or stimulated with IFN-α (10 ng/ml) or TNF-α (10 
ng/ml) and treated with increasing concentrations of NaHS (10-1000 μM). (C) No 
effect has been observed on proliferation rate of BOECs (isolated from healthy 
individuals) not stimulated or stimulated with IFN-α (10 ng/ml) or TNF-α (10 ng/ml) 
and treated with increasing concentrations of NaHS (10-1000 μM). Cell viability has 
been assessed by Alamar Blue® after 24 hours from treatment. Data are mean ± SEM. 
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Effect of NaHS on ET-1 release from hPASMCs and BOECs 
As the group where I worked demonstrated that ET-1 is an IFN-regulated gene, 
then our attention focused on ET-1. ET-1 is a key mediator in PAH: its increased 
levels are responsible for hyperproliferation of SMCs, constriction state of vessels, 
and endothelial dysfunction. My group showed that also hPASMCs released 
increased levels of ET-1 when treated with an appropriate stimulus187. 
Surprisingly, unlike the observations above using IP10 as a read-out, IFN-α-induced 
ET-1 release was not affected in either hPASMCs (Figure 3.28A) or BOECs (healthy 
and PAH) (Figure 3.28B and 3.28C). 
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Figure 3.28. NaHS does not affect ET-1 production from hPASMCs and BOECs. (A) 
Increasing concentration of NaHS (10-1000 μM) showed no effect on ET-1 release 
from unstimulated hPASMCs or cells primed with IFN-α (10 ng/ml) or TNF-α (10 
ng/ml), (n=4 in each group). (B) Increasing concentration of NaHS (10-1000 μM) 
showed no effect on ET-1 release from unstimulated BOECs (from PAH patients) or 
cells primed with IFN-α (10 ng/ml) or TNF-α (10 ng/ml) (n=3 in each group). (C) 
Increasing concentration of NaHS (10-1000 μM) showed no effect on ET-1 release 
from unstimulated BOECs (from healthy individuals) or cells primed with IFN-α (10 
ng/ml) or TNF-α (10 ng/ml) (n=3 in each group). Data are mean ± SEM. 
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Synergistic effect of NaHS and sildenafil, ACT-132577, and treprostinil on IP10 
release 
The current therapy for PAH is based on drugs aiming at controlling the 
vasoconstriction. Thus, PDE type V inhibitors, ET-1 receptor antagonists, and 
prostacyclin (PGI2) analogues have been introduced in therapy. Here, we aimed at 
identifying a potential synergistic effect of NaHS with these substances: therefore, 
we pretreated IFN-α-stimulated healthy BOECs with NaHS (0, 100, and 1000 µM) 
and increasing concentrations of sildenafil (a PDE type V inhibitor), ACT-132577 
(the active metabolite of macitentan, a new ETA receptor antagonist), or 
treprostinil sodium (a synthetic analogue of PGI2). The drugs alone had either no 
effect or tended to reduce the IP10 release from the cells. However, the treatment 
with the drugs and NaHS revealed an inhibitory effect that, where relevant, was 
additive. The effect of NaHS was particurarly pronounced at concentration of 1000 
µM (Figure 3.29A, 3.29B, and 3.29C). 
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Figure 3.29. Additive effect of NaHS and Sildenafil, ACT-132577, and Treprostinil 
sodium on IP10 release from healthy BOECs. (A) IP10 production is decreased after 
co-incubation of NaHS (100 or 1000 μM) with Sildenafil (10-9-10-5 M) (*** p<0.001 
NaHS 1000 μM vs. no NaHS, two-way ANOVA with Bonferroni’s post-test). (B) IP10 
production is decreased after co-incubation of NaHS (100 or 1000 μM) with ACT-
132577 (10-9-10-5 M) (*** p<0.001 NaHS 1000 μM vs. no NaHS, two-way ANOVA with 
Bonferroni’s post-test). (C) IP10 production is decreased after co-incubation of NaHS 
(100 or 1000 μM) with treprostinil sodium (10-10-10-6 M) (*** p<0.001 NaHS 1000 μM 
vs. no NaHS, two-way ANOVA with Bonferroni’s post-test). Data are mean ± SEM, n=3 
in each group. 
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Effect of NaHS on mice undergoing hypoxic/normoxic conditions 
The following experiments aimed at looking into the effects of H2S on an 
experimental model of hypoxia-induced PAH in mice using tissues ex vivo, in order 
to further understand the role of this gasotransmitter in the pathology. 
First of all, we incubated parts of the lung of these mice in DMEM (with 10% FCS) 
and treated with Poly(I:C) (10 µg/ml), mouse IFN-α (10 ng/ml), and LPS (1 µg/ml) 
for 24 hours. After this period, cell-free supernatants were collected and assayed 
for H2S levels by means of methylen blue assay. The data showed that untreated 
lungs from hypoxic mice released higher amount of H2S in medium compared to 
normoxic mice and this difference was significant (Figure 3.30A). These data well 
correlated with the findings that serum H2S levels from human patients affected 
by iPAH were significantly higher than healthy individuals (Figure 3.30B). 
Surprisingly, a very high increase in H2S release was seen in IFN-α-treated tissues 
from normoxic mice compared to hypoxic (Figure 3.30A). No significant 
differences has been observed in Poly(I:C)- and LPS-treated lungs (Figure 3.30A). 
Finally, pulmonary artery reactivity has been assessed as well. Pulmonary arteries 
precontracted with the thromboxane-mimetic U46619 were exposed to 
cumulative concentrations of NaHS. As already shown by others475,476, NaHS 
relaxed vessels. However, the data obtained showed that there was a significant 
difference in relaxation as evidenced by EC50 and maximum effect (Emax) values: in 
arteries harvested from hypoxic mice, a more pronounced response to relaxant 
effects of NaHS was seen (Figure 3.30C). It seemed that this effect was selective to 
NaHS: the same vessels relaxed with SNP, a NO-donor, had only a slight effect 
attributed to hypoxia-induced PAH on EC50, but the differences were not 
significant (Figure 3.30D). However, it is relevant to note that pulmonary arteries 
from hypoxic mice showed a significant increased contractile response to 
cumulative concentrations of U46619 (Figure 3.30E). 
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Figure 3.30. Characterization of murine experimental model of PH. (A) H2S 
production in supernatants of lungs from normoxic/hypoxic mice cultured in DMEM 
10% in absence of stimulus or with Poly(I:C) (10 μg/ml), mouse IFN-α (10 ng/ml), or 
LPS (1 μg/ml) for 24 hours in a temperature-controlled humidified incubator (* 
p<0.05; *** p<0.001, Student’s t-test, n=4 in each group). (B) Serum H2S levels from 
healthy and PAH-affected patients (*** p<0.001, Student’s t-test, n=9 individuals in 
each group). (C) Vasorelaxant effect of NaHS (10-6-3×10-3 M) on U46619-precontracted 
pulmonary artery harvested from normoxic/hypoxic mice (*** p<0.001, two-way 
ANOVA, n=3 mice in each group). (D) Vasorelaxant effect of SNP (10-8-3×10-5 M) on 
U46619-precontracted pulmonary artery harvested from normoxic/hypoxic mice (n=3 
mice in each group). (D) Contractory effect of U46619 (10-9-3×10-7 M) on pulmonary 
artery harvested from normoxic/hypoxic mice (** p<0.01, two-way ANOVA, n=3 mice 
in each group). Data are mean ± SEM. 
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3.3.5 SUMMARY 
 
In this part of the study, we investigated the idea that H2S could be protective in 
PH. This was a relatively new idea and our work is therefore based at a preclinical 
level only. To investigate this, we assessed the effect of H2S in cell and mouse 
tissue models relevant to PH in humans. 
As a toxic gas, H2S itself is neither easy nor recommended for use in experimental 
procedures. Because of this, we used the sodium hydrosulphide (NaHS) as a H2S-
donor because it is inexpensive, soluble in aqueous buffer, and has a very long 
history in use for scientific purposes. Moreover, as a salt, the concentrations of 
H2S levels released by NaHS are very easy to control. First, we performed stability 
experiments in order to establish the correct concentration range of NaHS for our 
experimental procedures. We observed that H2S released from NaHS dropped very 
rapidly (within 1 hr) to undetectable levels under the conditions tested. We can 
conjecture that the time-dependent H2S loss was even shorter, as Martelli et al. 
already reported, although with a different detection method477. 
In addition to the originally accepted view that PH is a disease of remodelled and 
constricted vessels, it is now known that PH is also driven by inflammatory 
cytokines478,479. Previous works from my group had implicated, in particular, 
interferon and interferon-target genes, which include ET-1 and IP10187. IP10 is one 
of the best characterised of all the IFN-stimulated genes. IP10, which is secreted 
by endothelial cells (among other cell types), is the cognate ligand of CXCR3 and is 
an antiviral and chemoattractant that promotes the formation of lymphoid 
infiltrates commonly seen in viral infection and autoimmune disease480; it also 
potentiates the adhesion of T lymphocytes to the endothelium481 and promotes 
the migration of CXCR3+ cells to the lung482. CXCR3 expression, at both the gene 
and protein level, has previously been demonstrated to be up-regulated in 
patients with PAH and IP10 has been shown to mediate endothelial dysfunction by 
disrupting calcium homeostasis483. We evaluated IP10 levels as read-out because it 
is increasingly recognised as a potential mediator of inflammation, including that 
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associated with the lung481,482. Furthermore, my group has shown that IP10 levels 
correlate with disease indicators and biomarkers in PAH187. Our results showed 
that NaHS was able to reduce IP10 levels in IFN-α-primed hPASMCS and BOECs, 
but not IL-8 release from TNF-α-stimulated cells, suggesting a specific role of H2S 
towards lung inflammatory mediators in our experimental model. Since ET-1 is an 
IFN-related gene, our attention then focused on ET-1 release: surprisingly, NaHS 
did not affect ET-1 release from cells. 
Current pharmacological approaches for PAH are not addressed at resolving the 
underlying causes, but only at targeting the symptoms. Here, we showed that the 
one of each most representative class of drugs used in therapy have a synergistic 
effect with H2S in terms of reducing IP10 release and, consequently, lowering the 
inflammation and symptoms. 
We then extendended our observations from experiments performed on human 
cells to ex vivo approaches from an animal model of PH. Even if we did not 
performed systemic administration of NaHS into mice, we showed that lung tissue 
from hypoxic mice produced higher levels of H2S compared to normoxic ones: 
these findings are in line with the human data showing that iPAH-affected patients 
had higher levels of circulating H2S compared to healthy individuals. However, this 
is in contrast with some other reports assuming that serum H2S levels are lower in 
patients affected by the disease compared to control387,404,405,406,412. 
H2S is a well-known vasorelaxant mediator of both capacitance and resistance 
vessels. Its vasorelaxing effects have been shown also in both human and rat 
pulmonary artery475,476. Here, for the first time to our knowledge, we compared 
relaxing effects of NaHS on pulmonary arteries harvested from normoxic (control) 
and hypoxic (with PH) mice: we demonstrated that NaHS relaxed more powerfully 
arteries from hypoxic mice and this effect seemed to be H2S-specific since an NO-
donor did not showed the same differences in terms of relaxation. As endothelial 
dysfunction of pulmonary arteries is a well-characterised hallmarks of PAH, we 
expected and obtained a stronger contraction from PH arteries compared to 
controls. 
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3.3.6 CONCLUSIONS 
 
Work from this chapter shows that H2S, via actions on inflammatory pathways 
associated with IFN and on pulmonary vessels from animals with established PH, 
could be protective in PAH. However, more efforts are necessary to fully explore 
the potential of these observations. 
 
 
3.3.7 LIMITATIONS 
 
The experiments we run represent only preliminary data. It is worth to evaluate 
the effects on inflammatory patterns from human cells by using different H2S-
donors, such as the slow-releasing molecules GYY4137 or DADS., in order to 
further validate the observations. 
The data we collected are related only to human cellular models of pulmonary 
hypertension. Other suggested experiments could involve the effects of 
systemic/localised administration of NaHS in the animal model of pulmonary 
arterial hypertension in order to observe whether H2S could have beneficial 
effects. Furthermore, H2S levels should be measured also in serum from 
hypoxic/normoxic mice and in a larger well-defined cohort of human patients 
affected by PAH, by means of methylen blue assay. However, since this assay does 
not measure free sulphide levels but the whole pool358, another way to measure 
the gasotransmitter is desirable, such as the monobromobimane method 
associated to HPLC. 
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CHAPTER 4 
DISCUSSION 
 
 
 
 
 
Inflammatory pulmonary diseases represent an authentic threat for global 
population since it is estimated that they will be among the first causes of death in 
the next years, because of their complications. Many progresses has been 
achieved since they were described for the fist time, but the biomedical research 
in this field is far from having reached an end-point. Many new drugs (including 
monoclonal antibodies from the area of biotechnologies and long-acting β-
agonists) have been recently introduced in therapy, but they have still some 
limitations. In asthma, for example, an important share of patients does not 
respond to conventional treatments, such as corticosteroids, or suffers a loss of 
efficacy of β-agonists in the long term. Furthermore, in pulmonary hypertension, 
current pharmacological approach only aims at treating the symptoms but does 
not cure the causes at the basis. Here, pharmacological research in discovering 
new pathological pathways that could lead to designing new drugs is capital. 
Our study well integrates in this perspective. Our first objective was to clarify the 
role of the sphingolipid S1P in lung pathophysiology. It is known that S1P affects 
immune system, fibroblasts, and smooth muscle cells, central effector entities in 
the pathophysiology of asthma. We demonstrated that T cells and mast cells are 
essential in mediating the effects of S1P and B cells counteract them. The model 
described and characterised in this study may represent a useful tool to define the 
role of S1P in the mechanism of action of currently used drugs, as well as in the 
development and characterisation of new therapeutic approaches. Furthermore, 
current therapies are designed to treat the symptoms of asthma trying to 
decrease the ongoing inflammation and reducing bronchial constriction. Further 
understanding of the role of IgE has led to new approaches in asthma 
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management that act early on in the allergic cascade of events. Therefore, we 
believe that the understanding of B and T lymphocyte and mast cell implication in 
S1P-induced asthma-like responses has considerable therapeutic implications, 
according to the role of the endogenous S1P in both mice and asthmatic patients. 
The centrality of mast cells in this condition is also supported by our further 
findings. We demonstrated the beneficial properties of an aerosolised 
administration of H2S in a well-described and accepted experimental model of 
airway hyperresponsiveness. We observed that treatment with H2S through 
aerosol to OVA-sensitised mice reduced bronchial hyperresponsiveness but did 
not affect lung inflammation. Mast cell and fibroblast activation accounted for the 
blunt in airway hyperreactivity. However, the beneficial effect of H2S in the OVA 
model needs to be further studied at molecular levels. In particular, the 
interaction of the sphingolipid methabolism with the gasotransmitter by means of 
our S1P-induced asthma-like model needs to be performed. Once these aspects 
have been defined, it will be also possible to assess the possible interaction with 
the other two gasotransmitters, namely CO and NO. 
Finally, the role of H2S was studied in another inflammation-based disease, the 
pulmonary arterial hypertension. Conversely to the previous results, in 
experimental cellular models of PH, H2S acted as an antiinflammatory mediator. 
The difference in terms of effects of H2S in the two experimental conditions could 
be attributable to the finding that in OVA-induced asthma H2S has been 
administered in vivo, whereas in PH models it has been administered in vitro. 
Another possible explanation is that, in different pathologies, the relative role of 
the H2S pathway and its interaction with other mechanism(s) deployed leads to a 
different outcome. In other words, the difference in the pathophysiology between 
PH and the asthma-like model used may account for the different contribute of 
the H2S pathway. 
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